TYK2 inhibitor and application thereof

By developing the selective allosteric TYK2 inhibitor compound 1, the problem of poor effect on TYK2 tyrosine protein kinase inhibitors in the prior art was solved, and effective treatment of psoriasis and psoriatic arthritis was achieved. It reduces inflammatory response and painful symptoms and significantly improves the quality of life of patients.

CN118973583APending Publication Date: 2024-11-15TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029505.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-16
Filing Date
2023-03-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing methods for treating inflammatory conditions such as psoriasis and psoriatic arthritis have not yet effectively inhibited TYK2 tyrosine protein kinase, resulting in poor treatment effects, especially for moderate to severe conditions, and existing JAK inhibition The agent has the risk of target side effects and infection.

Method used

A selective allosteric TYK2 inhibitor was developed, Compound 1, which has high selectivity and is administered through oral routes, which can effectively inhibit TYK2 tyrosine protein kinase, reduce IL-12/23-induced IFNγ production, and reduce inflammatory response. It also demonstrated significant therapeutic effects in several clinical studies.

Benefits of technology

Compound 1 significantly reduced the psoriasis area severity index (PASI) in clinical trials to a 50% to 100%, improved the patient's quality of life index (DLQI), reduced pain and itch symptoms, and at 12 At least ACR20 response was achieved within the week, significantly improving the clinical score of psoriatic arthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973583A_ABST
    Figure CN118973583A_ABST
Patent Text Reader

Abstract

Compounds, compositions thereof, and methods of using the compounds, compositions thereof in dosing regimens for inhibition of TYK2 and for the treatment of inflammatory conditions, including psoriasis and psoriatic arthritis, are described.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority declaration

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 269,943 filed on March 25, 2022, U.S. Provisional Patent Application No. 63 / 371,033 filed on August 10, 2022, and U.S. Provisional Patent Application No. 63 / 490,664 filed on March 16, 2023, each of which is incorporated by reference in its entirety. Technical Field

[0003] The present invention relates to methods of administering non-receptor tyrosine protein kinase 2 (TYK2) inhibitors such as N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridyl]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Compound 1), and their use for treating inflammatory disorders such as psoriasis and psoriatic arthritis. Background Art

[0004] Protein kinases constitute a large family of structurally related enzymes responsible for controlling a variety of signal transduction processes in cells. Protein kinases are believed to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar catalytic domain of 250-300 amino acids. They can be classified into many families based on the substrates phosphorylated by the kinases (e.g., protein-tyrosine, protein-serine / threonine, lipids, etc.).

[0005] In general, protein kinases mediate intracellular signal transduction by achieving phosphoryl transfer from nucleoside triphosphates to protein receptors involved in signal transduction pathways. These phosphorylation events act as molecular on / off switches, which can regulate or control target protein biological functions. These phosphorylation events are ultimately triggered in response to a variety of extracellular stimuli and other stimuli. Examples of such stimuli include environmental and chemical stress signals (e.g., osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxins, and H2O2), cytokines (e.g., interleukin-1 (IL-1), interleukin-8 (IL-8), interleukin-12 (IL-12), interleukin-23 (IL-23), and tumor necrosis factor α (TNF-α)) and growth factors (e.g., granulocyte macrophage colony stimulating factor (GM-CSF) and fibroblast growth factor (FGF)). Extracellular stimuli can affect one or more cellular responses related to the following: cell growth, migration, differentiation, hormone secretion, transcription factor activation, muscle contraction, glucose metabolism, control of protein synthesis, and regulation of the cell cycle.

[0006] Many diseases are associated with abnormal cellular responses triggered by kinase-mediated events. These diseases include, but are not limited to, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, some cancers, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases.

[0007] TYK2 catalyzes the phosphorylation of STAT proteins downstream of multiple cytokine receptors, including type I interferon receptors and IL-12 and IL-23 receptors. TYK2-dependent receptors are activated by their cytokine ligands, leading to STAT-dependent transcription and activation of cell function responses specific to the receptors and the cell types expressing the receptors. The cytokine signaling pathways regulated by TYK2 play a key role in several immune-mediated disorders. Cytokine IL-12 is essential for the development of type 1 T helper cells (Th1), which produce interferon-γ, a major effector molecule in systemic autoimmune disorders such as systemic lupus erythematosus. Cytokine IL-23 is essential for the expansion and survival of Th17 cells and innate lymphoid cells, and the two cells have been shown to play a key pathogenic role in autoimmunity. IL-23 stimulation drives Th17 cells to produce key proinflammatory cytokines, including IL-17A, IL-17F, and IL-22, all of which are effector molecules important in the pathogenesis of conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Because TYK2 has effects on the IL-23 / Th17 / Th22 axis, IL-12-mediated Th1 function, and type I interferon-driven regulation of different immune pathways and cell types, inhibition of TYK2 is expected to affect a variety of immune-mediated conditions.

[0008] Therefore, there remains a need to find TYK2 inhibitors that can be used as therapeutic agents. The present disclosure satisfies this need and provides other related advantages. Summary of the invention

[0009] It has been found that certain TYK2 inhibitors are suitable for oral administration to patients for the treatment of inflammatory conditions (e.g., psoriasis, psoriatic arthritis, or inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn's disease). Thus, in one aspect, a method of treating psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, or inflammatory bowel disease in a patient in need thereof may comprise administering to the patient a therapeutically effective amount of a TYK2 inhibitor (e.g., Compound 1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Compound 1 has the following structure:

[0010]

[0011] Compound 1 has the IUPAC name N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridyl]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide.

[0012] In some embodiments, an average reduction of up to about 50% (e.g., about 30%, about 47%, or about 48%) in the Psoriasis Area Severity Index (PASI) can be achieved; or an average reduction of about 25% to about 50% in the Psoriasis Area Severity Index (PASI) can be achieved. An average reduction of about 50% to 75% or about 75% to 100% in the Psoriasis Area Severity Index (PASI) can be achieved.

[0013] In some embodiments, a Physician Global Assessment (PGA) of 0 or 1 may be achieved; or a Physician Global Assessment (PGA) of 0 may be achieved.

[0014] In some embodiments, the Dermatology Life Quality Index (DLQI) score can be reduced by an amount between about 1 to about 3, about 3 to about 6, about 6 to about 9, about 9 to about 12, about 12 to about 15, about 15 to about 18, about 18 to about 21, about 21 to about 24, about 24 to about 27, or about 27 to about 30.

[0015] In some embodiments, the Dermatology Life Quality Index (DLQI) score may be reduced by an amount greater than about 5, or may be reduced by an amount between about 6 and about 9.

[0016] In some embodiments, the patient's body surface area (BSA) may be reduced by multiple percentage points between about 1 to about 10, about 10 to about 20, about 20 to about 30, about 30 to about 40, about 40 to about 50, about 50 to about 60, about 60 to about 70, about 70 to about 80, about 80 to about 90, or about 90 to about 100.

[0017] In some embodiments, a reduction of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Numerical Rating Scale (NRS) for pain can be achieved.

[0018] In some embodiments, a reduction of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Itch Numeric Rating Scale (NRS) can be achieved.

[0019] In some embodiments, about 1% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100% inhibition of IL-12 / 18 induced IFNγ production can be achieved.

[0020] In some embodiments, the patient may have plaque psoriasis; the plaque psoriasis may be moderate to severe plaque psoriasis.

[0021] In some embodiments, the patient may have psoriasis and psoriatic arthritis. The patient may have psoriatic arthritis.

[0022] In some embodiments, the methods can achieve at least an American College of Rheumatology (ACR) 20 response.

[0023] In some embodiments, the methods can achieve an improvement in tender joint count, swollen joint count, patient global assessment of psoriatic arthritis, patient global assessment of psoriatic arthritis pain, physician global assessment of psoriatic arthritis, Health Assessment Questionnaire-Disability Index (HAQ-DI) score, dactylitis count, Leed's Enthesitis Index, minimal disease activity, Disease Activity Index for Psoriatic Arthritis (DAPSA), or Psoriasis Area Severity Index (PASI)-75 at week 12 in subjects with psoriasis involving ≥3% body surface area (BSA) on day 1, or a static physician global assessment of 0 or 1 and an improvement of at least 2 points from baseline at week 12.

[0024] In some embodiments, the methods can achieve improvements in circulating cytokines and / or inflammatory biomarkers, 36-Item Short Form Health Survey, Functional Assessment of Chronic Disease-Fatigue, 28-Joint Disease Activity Score using high-sensitivity C-reactive protein (hsCRP), Psoriasis Disease Activity Score at treatment week 12, Psoriatic Arthritis Response Criteria at treatment week 12; a mean reduction of 25% or greater in Psoriasis Area Severity Index (PASI); or an improvement in Psoriasis-involved BSA at week 12; or an improvement in Physician Global Assessment of Psoriasis at treatment week 12.

[0025] In another aspect, a method of inhibiting interferon gamma (IFNγ) production may comprise administering to a patient in need thereof a therapeutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof or a composition thereof. In some embodiments, the method is associated with improvements in PASI, such as those described above and elsewhere herein.

[0026] In some cases, the disclosed methods and uses of administering Compound 1 that achieves certain pharmacokinetic parameters of the present disclosure have certain advantages in treating psoriasis and psoriatic arthritis. For example, in some embodiments, the T of Compound 1 in plasma is max The t of Compound 1 in plasma is achieved within about 3 hours to about 6 hours.1 / 2 Achieved in about 17 hours to about 37 hours.

[0027] In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient at a dose of up to about 200 mg (e.g., about 20 mg to about 100 mg). In other embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient at a dose of about 2 mg, about 5 mg, about 10 mg, about 15 mg, or about 30 mg.

[0028] In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient in a single daily dose or in multiple daily doses. In other embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient daily for 2 to 4 weeks. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered for at least 2 weeks or at least 4 weeks, for example, until the patient's psoriasis or psoriatic arthritis improves. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered for a long period of time to treat a patient. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered orally to a patient (e.g., a human).

[0029] In some embodiments, the patient may have a PASI of at least about 12 prior to administration.

[0030] In some embodiments, the patient may have a PGA of at least about 3 prior to administration.

[0031] In some embodiments, the patient may have a BSA of at least about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100% prior to administration.

[0032] In some embodiments, psoriasis does not include erythrodermic, pustular, guttate predominant psoriasis, or drug-induced psoriasis.

[0033] In some embodiments, a serum C between about 25 ng / ml to about 50 ng / ml, about 50 ng / ml to about 100 ng / ml, about 100 ng / ml to about 125 ng / ml, about 125 ng / ml to about 150 ng / ml, about 150 ng / ml to about 175 ng / ml, about 175 ng / ml to about 200 ng / ml, about 200 ng / ml to about 225 ng / ml, about 225 ng / ml to about 250 ng / ml, about 250 ng / ml to about 275 ng / ml, or about 275 ng / ml to about 300 ng / ml can be achieved. max .

[0034] In another aspect, provided is a method of treating moderate to severe plaque psoriasis in a patient in need thereof, the method comprising administering a therapeutically effective amount of Compound 1 at a daily dose of about 5 mg to about 30 mg.

[0035] In another aspect, provided is the use of Compound 1 or a pharmaceutically acceptable salt thereof for treating psoriasis or psoriatic arthritis.

[0036] These and other aspects of the disclosure will be apparent upon reference to the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 Schematic diagram depicting the research graph of Example 4.

[0038] Figure 2 Schematic diagram depicting the research graph of Example 5.

[0039] Figure 3 The maximum drug concentration (C MAX ) for JAK1 / 3IC 50 Note: Compound 1 data is PBMCpSTAT IC against TYK2 50 ; Values ​​for JAK>50,000ng / mL.

[0040] Figure 4 Shown is a graph depicting comparative levels of TYK2 inhibition - modeled based on Phase 1a data, not evaluated in head-to-head studies. Note: hWB IC of Compound 1 50 The data is 25 ng / mL and the Hill slope is 1.

[0041] Figure 5 Graph depicting Phase 1a pharmacodynamic data for Compound 1 based on IFNγ inhibition.

[0042] Figure 6 To depict images and data showing that Compound 1 reduced epidermal thickness and regressed expression of the K16 biomarker in patients across three dosing cohorts at four weeks (17 patients evaluated).

[0043] Figure 7A graph is shown depicting that 28 days of Compound 1 treatment reduces RNA expression levels of key cytokines and psoriasis gene markers in lesional skin. Quantification of mRNA from skin biopsies by RT-PCR showed reduced expression of several psoriasis-associated genes (such as KRT16, IL17A, IL17F, and IL22), and via microarray analysis, expression of the skin transcriptome previously associated with psoriasis in lesional skin was improved by up to 50% (p<0.001 compared to placebo treatment).

[0044] Figure 8 Schematic diagrams depicting X-ray crystallography results of compound 1 binding to TYK2 JH2 domain (upper panel) and molecular docking studies of compound 1 binding to JAK1 JH2 domain (lower panel).

[0045] Fig. 9 A graph is shown depicting that compound 1 inhibits disease activity in a rat adjuvant-induced arthritis (AIA) efficacy model in a dose-related manner. On day 0, adjuvant was injected. On day 9, baseline ankle diameter was measured. On days 12 to 20, ankle diameter was measured daily. On day 20, a final necropsy and paw weight measurement were performed. Compound 1 was administered daily for a total of 20 days. Compound 1 exposure was assessed on day 19. IC 50 / 90 The reference line (upper graph) represents the inhibitory concentration in the IP10 assay of TYK2-dependent IFNα induction in rat whole blood. Concentration-dependent inhibition of TYK2-dependent IL12-induced INFγ production was also observed in rats (not shown).

[0046] Fig.10 Shown are graphs depicting steady-state exposure (plasma concentration) of Compound 1 administered to mice administered anti-CD40 (upper graph), and colon weight and colon histology of mice (lower graph).

[0047] Fig.11 Graphs are shown depicting the pharmacokinetics of Compound 1 measured in healthy volunteers (PO; QD) Study 101 and Study 104. The median peak mean plasma concentrations T max 4-6 hours. max and AUC 0-24小时 The dose is increased approximately in a dose-proportional manner from 5 to 75 mg. 1 / 2 Consistent: 16.5-30.7 hrs. C max The cumulative ratios of PCR and AUC were 2.2-2.9x and 2.5-3.2x, respectively.

[0048] Fig.12A graph depicting steady-state plasma concentrations of Compound 1 based on steady-state exposures obtained from the 20 mg and 35 mg cohorts of Study 101 (Example 1), the 5 mg cohort of Study 102 (Example 2), and the 50 mg cohort of Study 104 is shown. 50 / 90 Reference lines represent inhibitory concentrations in the IP10 assay for TYK2-dependent IFNα induction in human whole blood. The 35 mg and 50 mg doses cover the IC 90 Lasts for 24 hours.

[0049] Fig.13 This is a graph depicting the fraction of patients achieving PASI 75 at Week 12 in the mITT analysis set of the study of Example 4.

[0050] Fig.14 Graph depicting the fraction of patients achieving PASI 75, PASI 90, and PASI 100 at Week 12 in the study of Example 4.

[0051] Fig.15 FIG. 4 is a graph depicting the fraction of patients achieving PGA 0 / 1 at Week 12 in the study of Example 4.

[0052] Fig.16A FIG. 4 is a graph depicting the mean DLQI scores of patients at baseline and week 12 in the study of Example 4. Fig. 16B : Change from baseline in DLQI at Week 12.

[0053] Figure 17A-17E Graphs depicting hematological parameters and CPK at Week 0, Week 1, Week 2, Week 4, Week 8, Week 12, and Week 16. Fig.17A , angiotensin-converting neutrophil count (ANC). Fig. 17B , lymphocyte count (ALC). Fig. 17C , hemoglobin. Fig.17D , platelets. Fig.17E , creatine kinase (CPK).

[0054] Figure 18A-18E Graphs depicting liver and kidney parameters. Fig.18A , alanine aminotransferase (ALT). Fig.18B , aspartate aminotransferase (AST). Fig.18C , bilirubin (total). Fig.18D , creatine. Fig.18E , estimated glomerular filtration rate (eGFR).

[0055] Figure 19A-19E Figure 2 is a graph depicting lipid parameters. Fig.19A , cholesterol (total). Fig.19B , triglycerides. Fig.19C, HDL cholesterol. Fig.19D , LDL cholesterol. Fig.19E , LDL / HDL ratio. DETAILED DESCRIPTION

[0056] TYK2 is an obligate mediator of signaling via IL-23, IL-12, and type I interferon receptors, and is a validated therapeutic target for psoriasis and psoriatic arthritis. Compound 1 is a highly selective allosteric TYK2 inhibitor and has been studied in three placebo-controlled Phase I studies: Studies 1 and 2: Healthy volunteers (HV) treated with: single dose (5-200 mg, N=5 or 6 in each of 6 groups; placebo, N=6); and multiple doses (20 mg-100 mg per day, N=6 in each of 4 groups; placebo, N=4 in each of two groups) for 2 weeks; Study 3: Patients with moderate to severe psoriasis, treated daily for 4 weeks (5, 10, or 30 mg, N=21 in total; placebo, N=5).

[0057] Compound 1 has also been studied in a randomized, double-blind, placebo-controlled Phase 2b trial in moderate to severe psoriasis (Example 4: 2 mg QD, N=50; 5 mg QD, N=52; 15 mg QD, N=53, 30 mg QD, N=52; placebo, N=52). Compound 1 has also been studied in a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study in subjects with active psoriatic arthritis (Example 5: 5 mg QD, 15 mg QD, and 30 mg QD).

[0058] Compound 1 disclosed herein is an oral allosteric selective TYK2 inhibitor for the treatment of psoriasis, psoriatic arthritis, and other inflammatory and autoimmune diseases. There are currently no approved TYK2 inhibitors, and Compound 1 is the most selective TYK2 inhibitor currently in clinical development. In addition, the selectivity of Compound 1 and the potential for once-daily (QD) dosing to provide higher levels of TYK2 inhibition over a longer period of time may give it a clinical and ultimate commercial advantage over other TYK2 inhibitors in development. TYK2 is a member of the Janus kinase (JAK) kinase family, which is a class of intracellular signaling proteins that regulate chronic inflammation in inflammatory and autoimmune diseases. Although JAK inhibition can effectively treat inflammatory and autoimmune diseases, it can also produce on-target safety issues due to the regulation of numerous cytokine pathways. Thus, while JAK inhibitors have become established oral treatments for a wide variety of inflammatory and autoimmune diseases, their clinical utility is limited by an increased risk of infection and other side effects, factors that have led the U.S. Food and Drug Administration (FDA) to mandate boxed warnings and dosing restrictions as part of the labeling of the inhibitors. Due to the structural similarities between the catalytic (orthosteric or JH1) sites targeted by drugs on the JAK catalytic domain, it is challenging to design selective JAK inhibitors and dosing regimens that directly and specifically inhibit the intended kinase function. Based on human genetic data and a growing body of clinical evidence for the selectivity of allosteric TYK2 inhibitors, the methods of selective allosteric inhibition of TYK2 of the present invention provide an optimal balance of achieving strong efficacy while potentially avoiding safety issues associated with broader JAK inhibition for the treatment of a variety of inflammatory and autoimmune diseases.

[0059] In the three Phase I studies, compound 1 was rapidly absorbed (median T max 3-6 hours), the increase in exposure is roughly proportional to the dose and the half-life (t 1 / 2) is 17-37 hours. Pharmacodynamics was tested using whole blood samples in an in vitro assay of cytokine induction. Treatment with compound 1 resulted in rapid inhibition of interferon gamma (IFNγ) production; increased exposure was associated with increased inhibition of IFNγ. No serious adverse events (SAEs) or deaths were observed. Adverse events (AEs) observed included acneiform dermatitis, papules, aphthous ulcers, headache, and diarrhea. More than one subject with a Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or above had laboratory abnormalities, including neutropenia, lymphopenia, elevated creatine phosphokinase levels, and elevated non-fasting triglycerides. Exploratory efficacy in patients with psoriasis demonstrated improvements in all doses tested (5 mg, 10 mg, and 30 mg of the Psoriasis Area Severity Index (PASI) were reduced by an average of 30%, 47%, and 48%, respectively; compared to 26% for placebo). The TYK2 inhibitors described herein are provided by oral administration at the doses and schedules described herein.

[0060] In a Phase 2b study in plaque psoriasis, the percentage of patients achieving PASI 75 was 5.8% for placebo; 18.0% for the 2 mg dose; 44.2% for the 5 mg dose; 67.9% for the 15 mg dose; and 67.3% for the 30 mg dose. Fig.13 ; Further results and discussion are in Example 4 below.

[0061] In the following disclosure, certain specific details are set forth to provide a full understanding of the various embodiments. However, those skilled in the art will appreciate that the methods and uses described herein can be practiced without these details. In other cases, well-known structures are not shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context otherwise requires, throughout the subsequent specification and claims, the word "comprise" and its variations (such as "comprises" and "comprising") should be interpreted in an open, inclusive sense, i.e., interpreted as "including but not limited to". In addition, the titles provided herein are for convenience only and do not explain the scope or meaning of the claimed invention.

[0062] Throughout this specification, references to "one embodiment," "some embodiments," or "an embodiment" mean that a particular feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment. Thus, the appearance of the phrases "in one embodiment," "in some embodiments," or "in one embodiment" throughout this specification does not necessarily refer to the same embodiment. In addition, the particular features, structures, or characteristics may be combined in one or more embodiments in any suitable manner. Likewise, unless the content clearly indicates otherwise, as used in this specification and the appended claims, the singular forms "a / an" and "the" include plural referents. It should also be noted that the term "or" is generally used in its sense including "and / or," unless the content clearly indicates otherwise.

[0063] In one aspect, a method of treating psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, or inflammatory bowel disease (IBD) in a patient in need thereof may comprise administering to the patient a therapeutically effective amount of Compound 1:

[0064]

[0065] or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0066] In some embodiments, daily administration continues for a period of between about 1 day to about 7 days, about 1 week to about 3 weeks, about 3 weeks to about 6 weeks, about 6 weeks to about 9 weeks, about 9 weeks to 12 weeks, about 12 weeks to about 15 weeks, or about 15 weeks to about 18 weeks.

[0067] In some embodiments, the methods relate to the treatment of psoriasis and / or psoriatic arthritis.

[0068] In some embodiments, the methods relate to the treatment of plaque psoriasis (eg, moderate to severe plaque psoriasis).

[0069] In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of 25% or greater is achieved.

[0070] In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of about 35% or greater is achieved.

[0071] In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of about 45% or greater is achieved.

[0072] In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of about 25% to 50% is achieved.

[0073] In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of about 50% to 75% is achieved.

[0074] In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of about 75% to 100% is achieved.

[0075] In some embodiments, a Physician Global Assessment (PGA) of 0, 1, or 2 is achieved.

[0076] In some embodiments, a Physician Global Assessment (PGA) of 0 or 1 is achieved.

[0077] In some embodiments, a Physician Global Assessment (PGA) of 0 is achieved.

[0078] In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 1 to about 3, about 3 to about 6, about 6 to about 9, about 9 to about 12, about 12 to about 15, about 15 to about 18, about 18 to about 21, about 21 to about 24, about 24 to about 27, or about 27 to about 30.

[0079] In some embodiments, the Dermatology Life Quality Index (DLQI) score may be reduced by an amount greater than about 5.

[0080] In some embodiments, the Dermatology Life Quality Index (DLQI) score may be reduced by an amount between about 6 and about 9.

[0081] In some embodiments, the patient's body surface area (BSA) is reduced by multiple percentage points between about 1 to about 10, about 10 to about 20, about 20 to about 30, about 30 to about 40, about 40 to about 50, about 50 to about 60, about 60 to about 70, about 70 to about 80, about 80 to about 90, or about 90 to about 100.

[0082] In some embodiments, a reduction of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Numerical Rating Scale (NRS) for pain is achieved.

[0083] In some embodiments, a reduction of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Itch Numeric Rating Scale (NRS) is achieved.

[0084] In some embodiments, between about 1% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100% inhibition of IL-12 / 18 induced IFNγ production is achieved.

[0085] In some embodiments, the patient has both psoriasis and psoriatic arthritis.

[0086] In some embodiments, the patient has psoriasis but does not have psoriatic arthritis.

[0087] In some embodiments, the psoriasis is moderate to severe.

[0088] In some embodiments, the psoriatic arthritis is moderate to severe.

[0089] In some embodiments, the patient has psoriatic arthritis.

[0090] In some embodiments, the method achieves a response of at least an American College of Rheumatology (ACR) 20.

[0091] In some embodiments, the method produces an ACR 20 response after about 12 weeks of treatment. In some embodiments, the method produces an ACR 50 response. In some embodiments, the method produces an ACR 70 response. In some embodiments, the method produces an ACR 50 or ACR 70 response after about 12 weeks of treatment. In some embodiments, the method produces an ACR 20 response after 18 weeks. In some embodiments, the method produces an ACR 50 response after 18 weeks. In some embodiments, the method produces an ACR 70 response after 18 weeks. In some embodiments, the ACR response is measured after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 weeks. ACR20 is a comprehensive measure defined as a 20% improvement in both joint tenderness count (68) and swelling count (66), and a 20% improvement in three of the following five criteria: Patient Global Assessment of Psoriatic Arthritis, Physician Global Assessment of Psoriatic Arthritis, Patient Pain Scale, Disability History Questionnaire (i.e., HAQ-DI), and acute phase reactants (i.e., erythrocyte sedimentation rate [ESR] or hsCRP). In some embodiments, improvements in acute phase reactants are measured by hsCRP. In some embodiments, such improvements are measured for the patient's baseline score prior to starting treatment.

[0092] In some embodiments, the methods achieve an improvement in tender joint count, swollen joint count, Patient Global Assessment of Psoriatic Arthritis, Patient Global Assessment of Psoriatic Arthritis Pain, Physician Global Assessment of Psoriatic Arthritis, Health Assessment Questionnaire-Disability Index (HAQ-DI) score, dactylitis count, Lee's Enthesitis Index, minimal disease activity, Disease Activity Index for Psoriatic Arthritis (DAPSA), or Psoriasis Area Severity Index (PASI)-75 at Week 12 in subjects with psoriasis involving ≥3% body surface area (BSA) on Day 1, or achieve a static Physician Global Assessment of 0 or 1 and an improvement of at least 2 points from baseline at Week 12.

[0093] In some embodiments, the method achieves an improvement in tender joint count. In some embodiments, the method achieves an improvement in swollen joint count. In some embodiments, the method achieves an improvement in the patient's overall assessment of psoriatic arthritis. In some embodiments, the method provides an improvement in the patient's overall assessment of psoriatic arthritis of about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more than 50; or about 1-5, 2-8, 2-15, 2-25, 3-9, 5-10, 5-20, 5-30, 7-12, 8-15, 10-20, 15-25, 20-30, 25-45 or 30-50. In some embodiments, the method achieves an improvement in the patient's overall assessment of psoriatic arthritis pain. In some embodiments, the method provides an improvement in the patient global assessment of psoriatic arthritis pain of about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more than 50; or about 1-5, 2-8, 2-15, 2-25, 3-9, 5-10, 5-20, 5-30, 7-12, 8-15, 10-20, 15-25, 20-30, 25-45, or 30-50. In some embodiments, the method achieves an improvement in the physician global assessment of psoriatic arthritis. In some embodiments, the method provides an improvement in the physician's global assessment of psoriatic arthritis of about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 or more than 50; or about 1-5, 2-8, 2-15, 2-25, 3-9, 5-10, 5-20, 5-30, 7-12, 8-15, 10-20, 15-25, 20-30, 25-45 or 30-50. In some embodiments, the method achieves an improvement in the Health Assessment Questionnaire-Disability Index (HAQ-DI) score. In some embodiments, the method achieves an improvement in dactylitis counts. In some embodiments, the method achieves an improvement in Lee's Enthesitis Index. In some embodiments, the method achieves an improvement in minimal disease activity. In some embodiments, the method achieves an improvement in the Disease Activity Index for Psoriatic Arthritis (DAPSA). A DAPSA score of 5-14 represents a low disease activity state. A score <4 represents remission. Thus, in some embodiments, the method achieves a DAPSA score of 5-14, 4, or less than 4. In some embodiments, the method achieves an improvement in Psoriasis Area Severity Index (PASI)-75. In some embodiments, the method achieves an improvement in Psoriasis Area Severity Index (PASI)-75 after about 12 weeks of treatment, wherein the patient has psoriasis involving ≥3% body surface area (BSA) on day 1 of treatment.In some embodiments, the methods achieve a static physician global assessment of 0 or 1 and an improvement of at least 2 points from baseline, e.g., after about 12 weeks of treatment. In some embodiments, the improvement is achieved after 6 weeks of treatment. In some embodiments, the improvement is achieved after 18 weeks of treatment. In some embodiments, the improvement is achieved after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 weeks.

[0094] In some embodiments, the methods achieve improvements in circulating cytokines and / or inflammatory biomarkers, 36-Item Short Form Health Survey, Functional Assessment of Chronic Disease-Fatigue, 28-Joint Disease Activity Score using high-sensitivity C-reactive protein (hsCRP), Psoriasis Disease Activity Score at treatment week 12, Psoriatic Arthritis Response Criteria at treatment week 12; a mean reduction of 25% or greater in Psoriasis Area Severity Index (PASI); or an improvement in Psoriasis-involved BSA at week 12; or an improvement in Physician's Global Assessment of Psoriasis at treatment week 12.

[0095] In some embodiments, the method achieves improvements in circulating cytokines and / or inflammatory biomarkers. In some embodiments, the biomarker comprises K16. In some embodiments, the biomarker comprises KRT16, IL17A, IL17F or IL22 expression. In some embodiments, the method achieves improvements in 36 brief health surveys as described herein. In some embodiments, the method achieves improvements in functional assessment of chronic diseases-fatigue. In some embodiments, the method achieves improvements in 28 joint disease activity scores using high-sensitivity C-reactive protein (hsCR P). In some embodiments, the method achieves improvements in psoriasis disease activity scores at week 12 of treatment. In some embodiments, the method achieves improvements in psoriatic arthritis response criteria at week 12 of treatment. In some embodiments, in subjects with psoriasis involving ≥3% BSA on day 1, the method achieves improvements in PASI, for example, at week 12 of treatment. In some embodiments, in subjects with psoriasis involving ≥ 3% BSA on day 1, the methods achieve an improvement in psoriasis involving BSA at week 12. In some embodiments, the methods achieve an improvement in Physician Global Assessment of Psoriasis, e.g., at week 12. In some embodiments, the improvement is achieved after 6 weeks of treatment. In some embodiments, the improvement is achieved after 18 weeks of treatment. In some embodiments, the improvement is achieved after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 weeks.

[0096] In one aspect, a method of inhibiting interferon gamma (IFNγ) production in a patient may comprise administering to the patient a therapeutically effective amount of Compound 1:

[0097]

[0098] or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0099] In some embodiments, the patient suffers from psoriasis.

[0100] In some embodiments, the patient has psoriatic arthritis.

[0101] In some embodiments, the psoriasis is moderate to severe.

[0102] In some embodiments, the psoriatic arthritis is moderate to severe.

[0103] In some embodiments, the T of Compound 1 in plasma is max This is achieved in about 3 hours to about 6 hours.

[0104] In some embodiments, the t of Compound 1 in plasma is 1 / 2 Achieved in about 17 hours to about 37 hours.

[0105] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered to a patient at a dose of up to about 200 mg.

[0106] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered to a patient at a dose of about 20 mg to about 100 mg.

[0107] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered to a patient at a dose of about 2 mg, about 5 mg, about 10 mg, about 15 mg, or about 30 mg.

[0108] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient as a single dose.

[0109] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered to a patient in multiple doses.

[0110] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient daily for 2 weeks.

[0111] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient daily for 4 weeks.

[0112] In some embodiments, Compound 1 is administered to a patient orally.

[0113] In some embodiments, the patient is a human.

[0114] In some embodiments, the patient has a PASI of at least about 12 prior to administration.

[0115] In some embodiments, the patient has a PGA of at least about 3 prior to administration.

[0116] In some embodiments, the patient has a BSA of at least about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100% prior to administration.

[0117] In some embodiments, psoriasis does not include erythrodermic, pustular, guttate predominant psoriasis, or drug-induced psoriasis.

[0118] In some embodiments, a serum C between about 25 ng / ml to about 50 ng / ml, about 50 ng / ml to about 100 ng / ml, about 100 ng / ml to about 125 ng / ml, about 125 ng / ml to about 150 ng / ml, about 150 ng / ml to about 175 ng / ml, about 175 ng / ml to about 200 ng / ml, about 200 ng / ml to about 225 ng / ml, about 225 ng / ml to about 250 ng / ml, about 250 ng / ml to about 275 ng / ml, or about 275 ng / ml to about 300 ng / ml is achieved. max .

[0119] In one aspect, a method of treating moderate to severe plaque psoriasis in a patient in need thereof may comprise administering a therapeutically effective amount of Compound 1:

[0120]

[0121] The daily dosage is from about 5 mg to about 30 mg.

[0122] In one aspect, Compound 1:

[0123]

[0124] Or a pharmaceutically acceptable salt thereof can be used to treat psoriasis or psoriatic arthritis.

[0125] Compounds described herein include those compounds generally described herein and are further illustrated by the classes, subclasses, and species disclosed herein. Unless otherwise indicated, as used herein, the following definitions shall apply. For purposes described herein, chemical elements are identified according to the Periodic Table of the Elements (CAS version, Handbook of Chemistry and Physics, 75th edition). In addition, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999; and "March's Advanced Organic Chemistry", 5th edition, editors: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.

[0126] As used herein, the term "about" refers to within 20% of a given value. In some embodiments, the term "about" refers to within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of a given value.

[0127] As used herein, the term "Compound 1" refers to N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridyl]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide, which has the following formula:

[0128]

[0129] In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is in amorphous form. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is in crystalline form.

[0130] As used herein, the term "aliphatic" or "aliphatic group" means a straight chain (i.e., unbranched) or branched substituted or unsubstituted hydrocarbon chain that is completely saturated or contains one or more unsaturated units, or a monocyclic hydrocarbon or bicyclic hydrocarbon (also referred to herein as "carbocycle", "cycloaliphatic" or "cycloalkyl") that is completely saturated or contains one or more unsaturated units, but is not aromatic, and has a single point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or contains one or more unsaturated units, but is not aromatic, and has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, substituted or unsubstituted straight or branched chain alkyl, alkenyl, alkynyl, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0131] As used herein, the term "bridged bicyclic" refers to any bicyclic system with at least one bridge, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated. As defined by IUPAC, "bridge" is an unbranched atomic chain or atom or valence bond connecting two bridgeheads, wherein "bridgehead" is any backbone atom bonded to three or more backbone atoms (excluding hydrogen) in a ring system. In some embodiments, the bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Such bridged bicyclic groups are well known in the art, and include those groups described below, wherein each group is connected to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, the bridged bicyclic group is optionally substituted by one or more substituents as described for an aliphatic group. Additionally or alternatively, any substitutable nitrogen of the bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:

[0132]

[0133]

[0134] The term "lower alkyl" refers to a C 1-4 Straight or branched chain alkyl. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0135] The term "lower haloalkyl" refers to a C 1-4 Straight chain or branched chain alkyl.

[0136] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (as in N-substituted pyrrolidinyl)).

[0137] As used herein, the term "unsaturated" means that the moiety has one or more units of unsaturation.

[0138] As used herein, the term "divalent C 1-8 (or C 1-6 ) saturated or unsaturated straight or branched hydrocarbon chain" refers to straight or branched divalent alkylene, alkenylene and alkynylene chains as defined herein.

[0139] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n-, wherein n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2 or 2 to 3. A substituted alkylene chain is a polymethylene chain in which one or more methylene hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0140] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0141] The term "halogen" means F, Cl, Br or I.

[0142] The term "aryl" used alone or as part of a larger moiety (as in "aralkyl", "aralkyloxy" or "aryloxyalkyl") refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" can be used interchangeably with the term "aryl ring". In certain embodiments, "aryl" refers to an aromatic ring system, which includes, but is not limited to, phenyl, biphenyl, naphthyl, anthracenyl, and the like, which may bear one or more substituents. As used herein, the term "aryl" also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.

[0143] The terms "heteroaryl" and "heteroar-" (e.g., "heteroaralkyl" or "heteroaralkoxy"), used alone or as part of a larger moiety, refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 pi electrons shared in a cyclic array; and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur and any quaternized form of basic nitrogen. Heteroaryl includes, but is not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. As used herein, the terms "heteroaryl" and "heteroaromatic-" also include groups in which a heteroaromatic ring is fused to one or more aryl rings, cycloaliphatic rings, or heterocyclyl rings, wherein, unless otherwise specified, the connecting group or point of attachment is located on the heteroaromatic ring or on a ring to which the heteroaromatic ring is fused. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, and tetrahydroisoquinolyl. The heteroaryl group may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which includes rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group, wherein the alkyl and heteroaryl portions are independently optionally substituted.

[0144] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical" and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety which is saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four heteroatoms as defined above. The term "nitrogen" when used with respect to a ring atom of a heterocycle includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or + NR (as in N-substituted pyrrolidinyl).

[0145] The heterocyclic ring may be attached to its side group at any heteroatom or carbon atom to obtain a stable structure, and any ring atom may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepine, oxazepine, thiazepine, morpholinyl, 2-oxa-6-azaspiro[3.3]heptane, and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl. The heterocyclyl group may be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group, wherein the alkyl and heterocyclyl moieties are independently optionally substituted.

[0146] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.

[0147] As described herein, compounds may contain "optionally substituted" parts. In general, the term "substituted" means that one or more hydrogens of the specified part are replaced by suitable substituents, regardless of whether there is a preceding term "optionally". Unless otherwise indicated, the "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from a specified group, the substituent at each position may be the same or different. The substituent combinations contemplated and described herein are preferably those substituent combinations that form stable or chemically feasible compounds. As used herein, the term "stable" means that for one or more purposes disclosed herein, the compound does not undergo substantial changes when subjected to conditions that allow it to be produced, detected, and in certain embodiments, to be recovered, purified, and used.

[0148] Suitable monovalent substituents on the substitutable carbon atoms of an "optionally substituted" group are independently halogen; -(CH2) 0- 4R o ; -(CH2) 0-4 OR o ; -O(CH2) 0-4 R o 、-O-(CH2)0-4 C(O)OR o ; -(CH2) 0-4 CH(OR o )2; -(CH2) 0-4 SR o ; -(CH2) 0-4 Ph, which can be o Substitution; -(CH2) 0-4 O(CH2) 0-1 Ph, which can be o Substitution; -CH=CHPh, which can be R o Substitution; -(CH2) 0-4 O(CH2) 0-1 -pyridyl, which may be R o Substitution; -NO2; -CN; -N3; ​​-(CH2) 0-4 N(R o )2; -(CH2) 0-4 N(R o )C(O)R o ;-N(R o )C(S)R o ; -(CH2) 0-4 N(R o )C(O)NR o 2;-N(R o )C(S)NR o 2; -(CH2) 0-4 N(R o )C(O)OR o ;-N(R o )N(R o )C(O)R o ;-N(R o )N(R o )C(O)NR o 2;-N(R o )N(R o )C(O)OR o ;-N(R o )C(NR o )N(R o )2; -(CH2) 0- 4C(O)R o ;-C(S)R o ; -(CH2) 0-4 C(O)OR o ; -(CH2) 0-4 C(O)SR o ; -(CH2) 0-4 C(O)OSiR o 3; -(CH2)0-4 OC(O)R o ;-OC(O)(CH2) 0-4 SR o ;-SC(S)SR o ; -(CH2) 0-4 SC(O)R o ; -(CH2) 0-4 C(O)NR o 2; -C(S)NR o 2; -C(S)SR o ;-SC(S)SR o 、-(CH2) 0-4 OC(O)NR o 2; -C(O)N(OR o )R o ; -C(O)C(O)R o ; -C(O)CH2C(O)R o ;-C(NOR o )R o ; -(CH2) 0-4 SSR o ; -(CH2) 0-4 S(O)2R o ; -(CH2) 0-4 S(O)2OR o ; -(CH2) 0-4 OS(O)2R o ; -S(O)2NR o 2; -(CH2) 0-4 S(O)R o ;-N(R o )S(O)2NR o 2;-N(R o )S(O)2R o ;-N(OR o )R o ; -C(NH)NR o 2;-P(O)2R o ;-P(O)R o 2;-OP(O)R o 2;-OP(O)(OR o )2;-SiR o 3;-(C 1-4 Straight or branched alkylene)ON(R o )2; or -(C 1-4 Straight or branched alkylene)C(O)ON(R o )2, where each R o may be substituted as defined below and are independently hydrogen, C1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2-(5-6 membered heteroaryl ring) or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definitions, two independent occurrences of R o Together with its central atoms it forms a 3-12 membered saturated, partially unsaturated or aromatic mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which may be substituted as defined below.

[0149] R o (or two independent occurrences of R o Suitable monovalent substituents on the ring formed by the middle atom thereof are independently halogen, -(CH2) 0-2 R · 、-(halogen R · )、-(CH2) 0-2 OH, -(CH2) 0-2 OR · 、-(CH2) 0-2 CH(OR · )2; -O(halogen R · )、-CN、-N3、-(CH2) 0-2 C(O)R · 、-(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR · 、-(CH2) 0-2 SR · 、-(CH2) 0- 2SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR · 、-(CH2) 0-2 NR · 2. -NO2, -SiR · 3. -OSiR · 3. -C(O)SR · 、-(C 1-4 Straight or branched alkylene)C(O)OR · or -SSR · , where each R · unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.o Suitable divalent substituents on a saturated carbon atom of include =0 and =S.

[0150] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR * 2. =NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O)2R * , =NR * , =NOR * 、-O(C(R * 2)) 2-3 O-or-S(C(R * 2)) 2-3 S-, where each independent occurrence of R * is selected from hydrogen, C which may be substituted as defined below 1-6 aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Suitable divalent substituents attached to the ortho-substitutable carbon of the "optionally substituted" group include: -O(CR * 2) 2-3 O-, where each independent occurrence of R * is selected from hydrogen, C which may be substituted as defined below 1-6 Aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0151] R * Suitable substituents on the aliphatic group include halogen, -R · 、-(halogen R · ), -OH, -OR · 、-O(halogen R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R · unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0152] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include or Each of these are independently hydrogen, C which may be substituted as defined below 1-6 aliphatic, unsubstituted -OPh or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definition, two independent occurrences of Together with its central atoms, it forms an unsubstituted 3-12 membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0153] Suitable substituents on the aliphatic group are independently halogen, -R · 、-(halogen R · ), -OH, -OR · 、-O(halogen R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R · unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0154] As used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction and the like within the scope of reasonable medical judgment and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid) or by using other methods used in the art (such as ion exchange) formed salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.

[0155] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1–4 Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations, where appropriate, which are formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.

[0156] Unless otherwise stated, the structures depicted herein are also intended to include all isomeric (e.g., mirror image, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations, Z and E double bond isomers, and Z and E conformational isomers for each asymmetric center. Therefore, single stereochemical isomers as well as mirror image, diastereomeric, and geometric (or conformational) mixtures of the compounds of the present invention are within the scope of the present invention. Unless otherwise stated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention. In addition, unless otherwise stated, the structures depicted herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, having the structures of the present invention (including replacement of hydrogen with deuterium or tritium, or with 13 C or 14 Compounds containing C-enriched carbon replacing carbon) are within the scope of the present invention. According to the present invention, such compounds can be used as (for example) analytical tools, as probes in biological assays, or as therapeutic agents. In certain embodiments, the warhead portion R of the provided compounds is 1 Contains one or more deuterium atoms. In certain embodiments, Ring B of provided compounds may be substituted with one or more deuterium atoms.

[0157] As used herein, the term "inhibitor" is defined as a compound that binds to and / or inhibits TYK2 with measurable affinity. In certain embodiments, the IC 50 and / or a binding constant of less than about 50 μM, less than about 1 μM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.

[0158] As used herein, the terms "measurable affinity" and "measurably inhibit" mean a measurable change in TYK2 protein kinase activity between a sample comprising a compound or composition thereof described herein and TYK2 protein kinase and an equivalent sample comprising TYK2 protein kinase in the absence of the compound or composition thereof.

[0159] As used herein, the "Dermatology Life Quality Index" or DLQI is a simple 10-question validated questionnaire that has been used in more than 40 different skin conditions. See Finlay AY, Khan GK. "Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use", Clin Exp Dermatol. 1994; 19(3): 210-216, the entire disclosure of which is incorporated herein by reference in its entirety.

[0160] As used herein, "body surface area" refers to the % of surface area covered by psoriasis. A "percent point" reduction refers to the amount by which the % of surface area is reduced following treatment. For example, a 7 percentage point reduction would describe a reduction from 57% BSA to 50% BSA.

[0161] As used herein, "numeric rating scale" (NRS) refers to a scale from 1 to 10 where symptoms (eg, pain or pruritus) are rated by the patient, with 10 being the worst pain imaginable and 0 being no pain at all.

[0162] As used herein, “C max " is the maximum (or peak) serum concentration of a drug achieved in a specified compartment or test area of ​​the body after administration of the drug and before administration of a second dose."

[0163] As used herein, "SDD" refers to a pharmaceutical formulation (e.g., a pharmaceutical formulation of Compound 1 or a pharmaceutically acceptable salt thereof) that is a spray-dried formulation. The formulation may include a compound of the present disclosure and hydroxypropylmethylcellulose acetate succinate (HPMCAS). In one embodiment, HMPCAS is HPMCAS-M, where "M" indicates (acetyl content 7.0% to 11.0%, succinyl content 10% to 14%). The use of spray drying to produce powders from fluid raw materials is well known, and its applications range from milk powder to bulk chemicals and drugs. See U.S. Patent No. 4,187,617 and Mujumbar et al., 91Drying, pp. 56-73 (1991). It is also known to use spray drying to form solid amorphous dispersions of drugs and thickening polymers. See European Patent Application Nos. 0 901 786, 1 027 886, 1 027 887, 1 027 888, and PCT Application Nos. WO 00 / 168092 and WO 00 / 168055, each of which is incorporated herein by reference. Typical spray drying equipment comprises a drying chamber, an atomizing device for atomizing a solvent-containing liquid fed into the drying chamber, a heated drying gas source directed into the drying chamber, and a drying product collecting device for separating the dried product from the cooled drying gas and vaporized solvent streams and then the dried product leaving the drying chamber. Examples of such equipment include Niro Models PSD-1, PSD-2, and PSD-4 (Niro A / S, Soeborg, Denmark).

[0164] As used herein, "TPGS" or "Vitamin E TPGS" as a descriptor of a pharmaceutical formulation of a compound of the present disclosure refers to a pharmaceutical formulation (e.g., a pharmaceutical formulation of Compound 1 or a pharmaceutically acceptable salt thereof) that includes the following components: (a) an active compound; (b) one or more diluents (e.g., microcrystalline cellulose); (c) one or more solubilizers (e.g., D-α-tocopheryl polyethylene glycol succinate [Vitamin E TPGS]); and (d) one or more binders (e.g., povidone). The formulation can be prepared using a granulation method (e.g., wet granulation). As used herein, "granulation" refers to a method of producing larger or smaller particles or particles of a substance or mixture of substances. The method can also remove fine particles and improve flowability within the formulation. Both wet granulation and / or dry granulation can be used. Dry granulation is achieved using only a combination of particles without any liquid on them. Tablet compression uses a tablet press to form large tablets, the weight of which varies due to the poor flowability of the formulation. The resulting mass is then passed through a granulator to break it into granules, and then pressed again to obtain the final granulated product.

[0165] 3. Exemplary compounds:

[0166] According to one aspect, a method of treating an inflammatory disorder (e.g., psoriasis or psoriatic arthritis) in a patient in need thereof may include administering a therapeutically effective amount of a TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof. In some embodiments, the method comprises administering up to 100 mg of a TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof in a single or multiple (e.g., divided) doses.

[0167] U.S. Patent No. 11,046,698 describes certain therapeutically beneficial compounds, the entire contents of which are hereby incorporated by reference herein. Such compounds include Compound 1. Compound 1 is named I-908 in US11,046,698, and its synthesis, properties, and use in treating various diseases and conditions are described in detail in the patent. Numerous other TYK2 inhibitors are described in US11,046,698, which can be used in the methods of the present disclosure. Therefore, in some embodiments, the TYK2 inhibitor is one of those described in US11,046,698.

[0168] In certain embodiments, the TYK2 inhibitor used in the disclosed methods has Formula I:

[0169]

[0170] or a pharmaceutically acceptable salt thereof, wherein:

[0171] R 3-C(O)NH2; -C(O)NHR 3A ;-C(O)N(R 3A )2; or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the ring is surrounded by m R 5B replace;

[0172] R 5 is hydrogen or -L 1 -R 5A ;

[0173] R 6 is hydrogen, R A or R B ;

[0174] or R 5 and R 6 Together with its central atoms, it forms a 4-7 membered partially unsaturated or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the ring is R 5A and n R C replace;

[0175] R 7 For hydrogen, halogen, -NH2, -NHR 7A or -NHC(O)R 7A ;

[0176] or R 6 and R 7 Together with its central atoms, it forms a 4-7 membered partially unsaturated or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; wherein the ring is surrounded by p R C replace;

[0177] L 1 For covalent bonds or C 1-4 A divalent saturated or unsaturated straight or branched hydrocarbon chain, wherein one or two methylene units of the chain are optionally and independently replaced by -C(R 5B )2-、-CH(R 5B )-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)2-, -S(O)2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2- substitution;

[0178] R 3A and R 7A Each independently is R B , and each is represented by q R C replace;

[0179] R5A and each R 5B Each independently is R A or R B , and each is represented by r R C replace;

[0180] Each R A are independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2 or -N(R)S(O)2R;

[0181] Each R B Independently for C 1-6 aliphatic; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 3-7 membered saturated or partially unsaturated carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0182] Each R C wherein the substituted radicals are independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2 or -N(R)S(O)2R, or an optionally substituted radical selected from: C(O) 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0183] Each R is independently hydrogen, or an optionally substituted group selected from the following: C 1-6aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or: two R groups on the same nitrogen together with their middle atom form a 4-7 membered saturated, partially unsaturated or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0184] wherein each hydrogen bonded to carbon may optionally and independently be replaced with deuterium; and

[0185] Each of m, n, p, q and r is independently 0, 1, 2, 3 or 4.

[0186] In some embodiments, the TYK2 inhibitor used in the disclosed methods is compound 1a:

[0187]

[0188] or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0189] In some embodiments, the TYK2 inhibitor used in the disclosed methods is Compound 1:

[0190]

[0191] or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

[0192] The compounds and compositions described herein are generally useful for inhibiting the kinase activity of one or more enzymes. In some embodiments, the kinase inhibited by the compounds and methods described herein is TYK2.

[0193] TYK2 is a non-receptor tyrosine kinase member of the Janus kinase (JAK) protein kinase family. The mammalian JAK family consists of four members: TYK2, JAK1, JAK2, and JAK3. JAK proteins (including TYK2) are essential for cytokine signaling. TYK2 associates with the cytoplasmic domains of type I and type II cytokine receptors and interferon type I and type III receptors, and is activated by those receptors when cytokines bind. Cytokines involved in TYK2 activation include interferons (e.g., IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ (also known as limitin)) and interleukins (e.g., IL-4, IL-6, IL-10, IL-11, IL-12, IL-13, IL-22, IL-23, IL-27, IL-31, oncostatin M, ciliary neurotrophic factor, cardiotrophin 1, cardiotrophin-like cytokine, and LIF).Velasquez et al., "Aprotein kinase in the interferonα / β signaling pathway", Cell (1992) 70:313; Stahl et al., "Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6βreceptor components", Science (1994) 263:92; Finbloom et al., "IL-10 induces thetyrosine Phosphorylation of Tyk2 and Jak1 and the differential assembly ofStat1and Stat3 complexes in human T cells and monocytes", J. Immunol. (1995) 155:1079; Bacon et al., "Interleukin 12(IL-12) induces tyrosine phosphorylation of Jak2and Tyk2: differential use of Janus family kinases by IL-2and IL-12", J. Exp. Med. (1995) 181: 399; Welham et al., "Interleukin-13 signal transduction in lymphohemopoietic cells: similarities and differences in signal transduction with interleukin-4 and insulin", J. Biol. Chem. (1995) 270: 12286; Parham et al., "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R", J. Immunol. (2002) 168: 5699. Activated TYK2 then goes on to phosphorylate other signaling proteins, such as members of the STAT family, including STAT1, STAT2, STAT4 and STAT6.

[0194] IL-23 activation of TYK2 is associated with inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Duerr et al., "A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene", Science (2006) 314: 1461-1463. TYK2, as a downstream effector of IL-23, is also involved in psoriasis, ankylosing spondylitis, and Behcet's disease ( disease). Cho et al., "Genomics and the multifactorial nature of human auto-immune disease", N.Engl.J.Med(2011) 365:1612-1623; Cortes et al., "Identification of multiple riskvariants for ankylosing spondylitis through high-density genotyping ofimmune-related loci", Nat. Genet. (2013) 45(7):730-738; Remmers et al., "Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with disease”, Nat. Genet. (2010) 42: 698-702. A genome-wide association study of 2,622 individuals with psoriasis identified an association between disease susceptibility and TYK2. Strange et al., “A genome-wide association study identifies new psoriasissusceptibility loci and an interaction between HLA-C and ERAP1”, Nat. Genet. (2010) 42: 985-992. Knockout or tyrosine phosphorylation inhibitor inhibition of TYK2 significantly reduced both IL-23 and IL-22-induced dermatitis. Ishizaki et al., “Tyk2 is a therapeutic target for psoriasis-like skin inflammation”, Intl. Immunol. (2013), doi: 10.1093 / intimm / dxt062.

[0195] TYK2 also plays a role in respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and cystic fibrosis. Goblet cell hyperplasia (GCH) and mucus hypersecretion are mediated by IL-13-induced TYK2 activation, which in turn activates STAT6. Zhang et al., "Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2 / STAT6 pathway", FASEB J. (2012) 26: 1-11.

[0196] Reduced TYK2 activity protects joints from collagen antibody-induced arthritis, a model of human rheumatoid arthritis. Mechanistically, reduced TYK2 activity reduces T h 1 / T h 17 related cytokines and matrix metalloproteinases and other key markers of inflammation. Ishizaki et al., “Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice”, Intl. Immunol. (2011) 23(9): 575-582.

[0197] Compared with controls, TYK2 knockout mice showed complete resistance in experimental autoimmune encephalomyelitis (EAE, an animal model of multiple sclerosis (MS)), with no infiltration of CD4 T cells in the spinal cord, indicating that TYK2 is essential for pathogenic CD4-mediated disease development in MS. Oyamada et al., "Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis", J. Immunol. (2009) 183: 7539-7546. This confirms previous studies linking increased TYK2 expression to MS susceptibility. Ban et al., "Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor", Eur J. Hum. Genet. (2009) 17: 1309-1313. Loss-of-function mutations in TYK2 result in reduced demyelination and increased remyelination of neurons, further suggesting a role for TYK2 inhibitors in the treatment of MS and other CNS demyelinating disorders.

[0198] TYK2 is the only signaling messenger common to both IL-12 and IL-23. TYK2 knockout reduces footpad thickness induced by methylated BSA injection, psoriasis-like skin inflammation induced by imiquimod, and colitis induced by dextran sulfate sodium or 2,4,6-trinitrobenzenesulfonic acid in mice.

[0199] Common associations of various type I IFN signaling genes with systemic lupus erythematosus (SLE, an autoimmune disorder) and association studies have shown a strong and significant correlation between loss-of-function mutations in TYK2 and reduced prevalence of SLE in families with affected members. Sigurdsson et al., "Polymorphisms in the Tyrosine Kinase 2 and Interferon Regulatory Factor 5 Genes Are Associated with Systemic Lupus Erythematosus", Am. J. Hum. Genet. (2005) 76: 528-537. A genome-wide association study of individuals with SLE versus an unaffected cohort showed a highly significant association between the TYK2 locus and SLE. Graham et al., "Association of NCF2, IKZF1, IRF8, IFiH1, and TYK2 with Systemic Lupus Erythematosus", PLoS Genetics (2011) 7(10): e1002341.

[0200] TYK2 has been shown to play an important role in maintaining tumor surveillance, and TYK2 knockout mice show impaired cytotoxic T cell responses and accelerated tumor development. However, these effects are associated with effective inhibition of natural killer (NK) and cytotoxic T lymphocytes, indicating that TYK2 inhibitors will be highly suitable for treating autoimmune disorders or transplant rejection. Although other JAK family members (such as JAK3) have similar effects in the immune system, TYK2 is considered an excellent target because it involves fewer and more closely related signal transduction pathways, thereby making off-target effects less. Simma et al., "Identification of an Indispensable Role for Tyrosine Kinase 2in CTL-Mediated Tumor Surveillance", Cancer Res. (2009) 69: 203-211.

[0201] However, in contradiction to the reduced tumor surveillance observed by Simma et al., studies in T-cell acute lymphoblastic leukemia (T-ALL) indicate that T-ALL is highly dependent on IL-10 to maintain cancer cell survival via upregulation of anti-apoptotic protein BCL2 via STAT1-mediated signal transduction via TYK2. Knockdown of TYK2, rather than other JAK family members, reduces cell growth. Specific activating mutations of TYK2 that promote cancer cell survival include those of the FERM domain (G36D, S47N, and R425H), the JH2 domain (V731I), and the kinase domain (E957D and R1027H). However, the kinase function of TYK2 has also been identified to be essential for prolonging cancer cell survival, because TYK2 enzymes characterized by kinase-dead mutations (M978Y or M978F) in addition to activating mutations (E957D) lead to transformation failure. Sanda et al., "TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia", CancerDisc. (2013) 3(5):564-577.

[0202] Therefore, selective inhibition of TYK2 has been considered a suitable target for patients with IL-10 and / or BCL2 addicted tumors, such as 70% of adult T-cell leukemia cases. Fontan et al., "Discovering What Makes STATSignaling TYK in T-ALL", Cancer Disc. (2013) 3:494-496.

[0203] It has also been shown that TYK2-mediated STAT3 signaling mediates neuronal cell death caused by amyloid-β (Aβ) peptide. Reduced TYK2 phosphorylation of STAT3 after Aβ administration reduces neuronal cell death, and increased STAT3 phosphorylation is observed in autopsy brains of Alzheimer's patients. Wan et al., "Tyk / STAT3 Signaling Mediates β-Amyloid-Induced Neuronal Cell Death: Implications in Alzheimer's Disease", J. Neurosci. (2010) 30(20): 6873-6881.

[0204] Inhibition of the JAK-STAT signaling pathway has also been associated with hair growth and reversal of hair loss associated with alopecia areata. Xing et al., “Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition”, Nat. Med. (2014) 20: 1043-1049; Harel et al., “Pharmacologic inhibition of JAK-STAT signaling promotes hair growth”, Sci. Adv. (2015) 1(9): e1500973.

[0205] Therefore, compounds that inhibit TYK2 activity are beneficial, especially those that are selective over JAK2.Such compounds should deliver a pharmacological response that advantageously treats one or more of the conditions described herein without the side effects associated with JAK2 inhibition.

[0206] Even though TYK2 inhibitors are known in the art, there continues to be a need to provide novel inhibitors with more effective or advantageous pharmaceutically relevant properties. For example, compounds with increased activity, selectivity over other JAK kinases (particularly JAK2), and ADMET (absorption, distribution, metabolism, excretion, and / or toxicity) properties. Thus, in some embodiments, TYK2 inhibitors may show selectivity over JAK2.

[0207] The activity of the compounds described herein as inhibitors of TYK2 or its mutants can be determined in vitro, in vivo or in a cell line. In vitro assays include assays for the inhibition of phosphorylation activity and / or subsequent functional results or ATPase activity of activated TYK2 or its mutants. Alternative in vitro assays quantify the ability of inhibitors to bind to TYK2. Inhibitor binding can be measured by radiolabeling the inhibitor before binding, separating the inhibitor / TYK2 complex and determining the amount of radiolabeled binding. Alternatively, inhibitor binding can be determined by running a competition experiment in which a new inhibitor is incubated with TYK2 bound to a known radioligand. Representative in vitro and in vivo assays that can be used to determine TYK2 inhibitors include, for example, those described and disclosed in each reference incorporated herein by reference in its entirety. Detailed conditions for determining the compounds described herein as inhibitors of TYK2 or its mutants are described in the following examples and in US 11,046,698 incorporated herein by reference.

[0208] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset or inhibiting the progression of a disease or disorder as described herein or one or more symptoms thereof. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., in view of a history of symptoms and / or in view of genetic or other susceptibility factors). Treatment may also be continued after the symptoms subside, for example, to prevent or delay their recurrence.

[0209] The compounds provided are TYK2 inhibitors and are therefore useful for treating one or more conditions associated with the activity of TYK2 or a mutant thereof. Thus, in certain embodiments, a method of treating a TYK2-mediated condition may comprise the step of administering to a patient in need thereof a compound described herein or a pharmaceutically acceptable composition thereof.

[0210] As used herein, the term "TYK2-mediated" disorder, disease and / or condition as used herein means any disease or other deleterious condition in which TYK2 or a mutant thereof is known to play a role. Thus, another embodiment is directed to treating or lessening the severity of one or more diseases in which TYK2 or a mutant thereof is known to play a role. Such TYK2-mediated disorders include, but are not limited to, autoimmune disorders, inflammatory disorders, proliferative disorders, endocrine disorders, neurological disorders, and transplantation-related disorders.

[0211] In some embodiments, a method for treating one or more disorders selected from the group consisting of autoimmune disorders, inflammatory disorders, proliferative disorders, endocrine disorders, neurological disorders, and transplantation-related disorders may comprise administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof.

[0212] In some embodiments, the disorder is an autoimmune disorder. In some embodiments, the disorder is selected from type 1 diabetes, cutaneous lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, psoriasis (e.g., plaque psoriasis), Behcet's disease, POEMS syndrome, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.

[0213] In some embodiments, the disorder is an inflammatory disorder. In some embodiments, the inflammatory disorder is rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis (e.g., plaque psoriasis), psoriatic arthritis, hepatomegaly, Crohn's disease, ulcerative colitis, or inflammatory bowel disease.

[0214] In some embodiments, a method of treating psoriasis (eg, plaque psoriasis) or psoriatic arthritis in a patient in need thereof may comprise administering a TYK2 inhibitor described herein (eg, Compound 1) or a pharmaceutically acceptable salt thereof.

[0215] In some embodiments, a method of treating psoriasis (eg, plaque psoriasis) in a patient in need thereof may comprise administering a TYK2 inhibitor described herein (eg, Compound 1) or a pharmaceutically acceptable salt thereof.

[0216] In some embodiments, a method of treating psoriatic arthritis in a patient in need thereof may comprise administering a TYK2 inhibitor described herein (eg, Compound 1) or a pharmaceutically acceptable salt thereof.

[0217] In some embodiments, the disorder is a proliferative disorder. In some embodiments, the proliferative disorder is a blood cancer. In some embodiments, the proliferative disorder is a leukemia. In some embodiments, the leukemia is a T-cell leukemia. In some embodiments, the T-cell leukemia is T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the proliferative disorder is polycythemia vera, primary myelofibrosis, or thrombocythemia.

[0218] In some embodiments, the disorder is an endocrine disorder. In some embodiments, the endocrine disorder is polycystic ovary syndrome, Crouzon's syndrome, or type 1 diabetes.

[0219] In some embodiments, the disorder is a neurological disorder. In some embodiments, the neurological disorder is Alzheimer's disease.

[0220] In some embodiments, the proliferative disorder is associated with one or more activating mutations in TYK2. In some embodiments, the activating mutation in TYK2 is a mutation in the FERM domain, the JH2 domain, or the kinase domain. In some embodiments, the activating mutation in TYK2 is selected from G36D, S47N, R425H, V731I, E957D, and R1027H.

[0221] In some embodiments, the disorder is associated with transplantation. In some embodiments, the disorder associated with transplantation is transplant rejection or graft-versus-host disease.

[0222] In some embodiments, the disorder is associated with type I interferon, IL-10, IL-12, or IL-23 signaling. In some embodiments, the disorder is associated with type I interferon signaling. In some embodiments, the disorder is associated with IL-10 signaling. In some embodiments, the disorder is associated with IL-12 signaling. In some embodiments, the disorder is associated with IL-23 signaling.

[0223] The compounds described herein can also be used to treat inflammatory or allergic disorders of the skin, such as psoriasis (e.g., plaque psoriasis), contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, allergic vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, cutaneous lupus erythematosus, systemic lupus erythematosus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquired, acne vulgaris, and other inflammatory or allergic disorders of the skin.

[0224] The compounds described herein may also be used to treat other diseases or conditions, such as those with an inflammatory component, for example, to treat diseases and conditions of the eye (such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis), diseases affecting the nose (including allergic rhinitis), and inflammatory diseases involving an autoimmune response or having an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), cutaneous lupus erythematosus, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, syndrome), idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine eye disease, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary sclerosis, uveitis (anterior and posterior), Sjogren's syndrome, keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, cryptopyrin-associated periodic syndromes, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis (with and without nephrotic syndrome,Examples include idiopathic nephrotic syndrome or minimal change disease), chronic granulomatous disease, endometriosis, leptospirosis nephropathy, glaucoma, retinal disease, aging, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscular dystrophy, cataracts, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, antihidrotic ectodermal dysplasia, Behçet's disease, incontinence pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndromes, asthma (allergic and nonallergic, mild, moderate, severe, bronchitis, and exercise-induced asthma), acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivity, anaphylaxis, sinusitis, ocular allergy, silica-induced disease, COPD (damage, airway inflammation, bronchial hyperresponsiveness, remodeling, or decreased disease progression), lung disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation combined with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease disease), lichen planus, type 1 or type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergies, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henoch-Schonlein purpura purpura), hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, eustachian tube inflammation, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, or vulvitis.

[0225] In some embodiments, the inflammatory disease that can be treated according to the methods described herein is selected from acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic juvenile idiopathic arthritis (SJIA), cryptopyrin-associated periodic syndrome (CAPS), and osteoarthritis.

[0226] In some embodiments, the inflammatory disease that can be treated according to the methods described herein is T h 1 or Th 17-mediated diseases. In some embodiments, T h The 17-mediated disease is selected from the group consisting of cutaneous lupus erythematosus, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease (including Crohn's disease or ulcerative colitis).

[0227] In some embodiments, the inflammatory disease treatable according to the methods described herein is selected from Sjögren's syndrome, allergic disorders, osteoarthritis, eye disorders (such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis), and diseases affecting the nose (such as allergic rhinitis).

[0228] Furthermore, the present invention may provide the use of a compound as defined herein, or a pharmaceutically acceptable salt, or hydrate or solvate thereof, for the preparation of a medicament for the treatment of an autoimmune, inflammatory or proliferative disorder or a disorder generally associated with transplantation.

[0229] Without wishing to be bound by any particular theory, it is believed that the proximity of the inhibitor compound or the side chain moiety of the inhibitor compound to the water of interest facilitates displacement or destruction of the water by the inhibitor compound or the side chain moiety of the inhibitor compound. In some embodiments, the water molecule displaced or destroyed by the inhibitor compound or the side chain moiety of the inhibitor compound is a labile water molecule.

[0230] In certain embodiments, the methods employ a complex comprising TYK2 and an inhibitor, wherein at least one labile water of TYK2 is displaced or destroyed by the inhibitor. In some embodiments, at least two selected labile waters are displaced or destroyed by the inhibitor.

[0231] 5. Pharmacokinetics / pharmacodynamics

[0232] In some embodiments, the present disclosure provides a method of administering a TYK2 inhibitor (e.g., Compound 1) to a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof, or a composition thereof, wherein certain pharmacokinetic parameters are achieved. In some embodiments, the disclosed methods and uses of administering Compound 1 that achieves certain pharmacokinetic parameters of the present disclosure have advantages in treating diseases described herein, such as inflammatory conditions. Such diseases include psoriasis and psoriatic arthritis.

[0233] In some embodiments, the T level of a TYK2 inhibitor (eg, Compound 1) in plasma is max In up to about 10 hours, for example, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours, or any time range generated by using two of the above times as endpoints. In some embodiments, Tmax In about 1 to about 10 hours, about 1 to about 9 hours, about 2 to about 10 hours, about 2 to about 9 hours, about 3 to about 10 hours, about 3 to about 9 hours, about 4 to about 10 hours, about 4 to about 9 hours, about 5 to about 10 hours, about 5 to about 9 hours, about 6 to about 10 hours, about 6 to about 9 hours, about 7 to about 10 hours, about 7 to about 9 hours, about 8 to about 10 hours, about 9 to about 10 hours, or about 8 to about 9 hours. In some embodiments, the T of a TYK2 inhibitor (e.g., Compound 1) in plasma is about 10 hours, about 10 hours, about 10 hours, about 10 hours, or about 10 hours. max In some embodiments, the T of the TYK2 inhibitor (e.g., Compound 1) in plasma is max In some embodiments, the T of Compound 1 in plasma is max In some embodiments, the T of the TYK2 inhibitor (e.g., Compound 1) in plasma is max This is achieved in up to about 6 hours.

[0234] In some embodiments, the T level of a TYK2 inhibitor (eg, Compound 1) in plasma is max In about 1 hour to about 4 hours, about 2 hours to about 5 hours, about 3 hours to about 6 hours, about 4 hours to about 7 hours, about 5 hours to about 8 hours, about 6 hours to about 9 hours, or about 7 hours to about 10 hours. In some embodiments, the T of the TYK2 inhibitor (e.g., Compound 1) in plasma is about 1 hour to about 4 hours, about 2 hours to about 5 hours, about 3 hours to about 6 hours, about 4 hours to about 7 hours, about 5 hours to about 8 hours, about 6 hours to about 9 hours, or about 7 hours to about 10 hours. max This is achieved in about 3 hours to about 6 hours.

[0235] In some embodiments, the t of the TYK2 inhibitor (eg, Compound 1) in plasma is 1 / 2 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours, about 33 hours, about 34 hours, about 35 hours, 36 hours, about 37 hours, about 38 hours, about 39 hours, about 40 hours, about 41 hours, about 42 hours, about 43 hours, about 44 hours, about 45 hours, 46 hours, about 47 hours, about 48 hours, about 49 hours, or about 50 hours, or any time range generated by using two of the above times as endpoints. In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is about 50 hours. 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is about 1.5-1.5 hours.1 / 2 In some embodiments, the t of Compound 1 in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of Compound 1 in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of Compound 1 in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of Compound 1 in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is about 1.5 to about 2.5 μg / mL. 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is about 1. 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is about 1.5-1.5 hours. 1 / 2 In some embodiments, the t of Compound 1 in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is 1 / 2 This is achieved in up to about 37 hours.

[0236] In some embodiments, the t of the TYK2 inhibitor (eg, Compound 1) in plasma is 1 / 2 In about 10 hours to 30 hours, about 12 hours to 32 hours, about 14 hours to 34 hours, about 16 hours to 36 hours, about 18 hours to 38 hours, about 20 hours to 40 hours, or about 22 hours to 42 hours. In some embodiments, the t of the TYK2 inhibitor (e.g., Compound 1) in plasma is about 10 hours to 30 hours, about 12 hours to 32 hours, about 14 hours to 34 hours, about 16 hours to 36 hours, about 18 hours to 38 hours, about 20 hours to 40 hours, or about 22 hours to 42 hours. 1 / 2 Achieved in about 17 hours to 37 hours.

[0237] In some embodiments, the present disclosure provides methods of administering a TYK2 inhibitor (e.g., Compound 1) to a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, wherein certain pharmacodynamic results are achieved.

[0238] In some embodiments of the methods and uses disclosed herein, administration of a TYK2 inhibitor (e.g., Compound 1) results in rapid inhibition of interferon gamma (IFNγ) production, and increased exposure is associated with increased inhibition of IFNγ. In some embodiments, a method of inhibiting IFNγ production in a patient may comprise administering to the patient a TYK2 inhibitor described herein (e.g., Compound 1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0239] In some embodiments, the disclosed methods and uses of administering Compound 1 include an average reduction in the Psoriasis Area Severity Index (PASI) of up to about 100% or up to about 90%, such as up to about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90%, or any % range generated by using two of the above % as endpoints. The PASI score is a tool for measuring the severity and extent of psoriasis and is well known to those of ordinary skill in the art. In some embodiments, an average reduction in the Psoriasis Area Severity Index (PASI) of up to about 50% is achieved. In some embodiments, an average reduction in the Psoriasis Area Severity Index (PASI) of up to about 75% is achieved. In some embodiments, an average reduction in the Psoriasis Area Severity Index (PASI) of up to about 90% is achieved. In some embodiments, a mean reduction in Psoriasis Area Severity Index (PASI) of up to about 100% is achieved. In some embodiments, a mean reduction in Psoriasis Area Severity Index (PASI) of about 30%, about 47%, or about 48% is achieved.

[0240] In some embodiments, the disclosed methods and uses achieve an average reduction in PASI of at least 25%. In some embodiments, the disclosed methods and uses achieve an average reduction in PASI of at least 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65% or more. In some embodiments, the disclosed methods and uses achieve an average reduction in PASI of about 26%-65%, 26%-60%, 26%-55%, 26%-50%, 26%-45%, 26%-40%, 26%-35%, 26%-30%, 27%-65%, 27%-65%, 27%-60%, 27%-55%, 27%-50 %, 27%-45%, 27%-40%, 27%-35%, 27%-30%, 28%-65%, 28%-65%, 28%-60%, 28%-55%, 28%-50%, 28%-45%, 28%-40%, 28%-35%, 28%-30%, 29%-65%, 29%-65%, 29%-60%, 2 9%-55%, 29%-50%, 29%-45%, 29%-40%, 29%-35%, 30%-65%, 30%-60%, 30%-55%, 30%-50%, 30%-45%, 30%-40%, 30%-35%, 35%-65%, 35%-60%, 35%-55%, 35%-50%, 35%- 45%, 35%-40%, 40%-65%, 40%-60%, 40%-55%, 40%-50%, 40%-45%, 45%-65%, 45%-60%, 45%-55%, 45%-50%, 50%-65%, 50%-65%, 50%-60%, 50%-55%, 55%-65% or 55%-60%.

[0241] In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of about 50% to 75% is achieved. In some embodiments, a mean reduction in the Psoriasis Area Severity Index (PASI) of about 75% to 100% is achieved.

[0242] In some embodiments, the disclosed methods and uses provide a statistically significant (p<0.05) improvement in PASI in a group of patients with an inflammatory disease, such as psoriasis or psoriatic arthritis.

[0243] In some embodiments, the patient has a PASI of at least about 12 prior to administration. In some embodiments, the patient has a PASI of about 10 to about 20 prior to administration. In some embodiments, the patient has a PASI of about 20 to about 30 prior to administration. In some embodiments, the patient has a PASI of about 30 to about 40 prior to administration. In some embodiments, the patient has a PASI of about 40 to about 50 prior to administration. In some embodiments, the patient has a PASI of about 50 to about 60 prior to administration. In some embodiments, the patient has a PASI of about 60 to about 72 prior to administration.

[0244] In some embodiments, a Physician Global Assessment (PGA) of 0, 1, or 2 is achieved. In some embodiments, a Physician Global Assessment (PGA) of 0 or 1 is achieved. In some embodiments, a Physician Global Assessment (PGA) of 0 is achieved.

[0245] In some embodiments, the patient's PGA prior to administration is 1. In some embodiments, the patient's PGA prior to administration is 2. In some embodiments, the patient's PGA prior to administration is 3. In some embodiments, the patient's PGA prior to administration is 4. In some embodiments, the patient's PGA prior to administration is 5.

[0246] In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 1 to about 3, about 3 to about 6, about 6 to about 9, about 9 to about 12, about 12 to about 15, about 15 to about 18, about 18 to about 21, about 21 to about 24, about 24 to about 27, or about 27 to about 30. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 1 to about 3. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 3 to about 6. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 6 to about 9. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 9 to about 12. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 12 to about 15. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 15 to about 18. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 18 to about 21. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 21 to about 24. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 24 to about 27. In some embodiments, the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 27 to about 30.

[0247] In some embodiments, the body surface area (BSA) of a patient affected by psoriasis is reduced by multiple percentage points between about 1 to about 10, about 10 to about 20, about 20 to about 30, about 30 to about 40, about 40 to about 50, about 50 to about 60, about 60 to about 70, about 70 to about 80, about 80 to about 90, or about 90 to about 100. In some embodiments, the body surface area (BSA) of a patient affected by psoriasis is reduced by multiple percentage points between about 1 to about 10. In some embodiments, the body surface area (BSA) of a patient is reduced by multiple percentage points between about 10 to about 20. In some embodiments, the body surface area (BSA) of a patient is reduced by multiple percentage points between about 20 to about 30. In some embodiments, the body surface area (BSA) of a patient is reduced by multiple percentage points between about 30 to about 40. In some embodiments, the body surface area (BSA) of a patient is reduced by multiple percentage points between about 40 to about 50. In some embodiments, the body surface area (BSA) of a patient is reduced by multiple percentage points between about 50 to about 60. In some embodiments, the patient's body surface area (BSA) is reduced by multiple percentage points between about 60 and about 70. In some embodiments, the patient's body surface area (BSA) is reduced by multiple percentage points between about 70 and about 80. In some embodiments, the patient's body surface area (BSA) is reduced by multiple percentage points between about 80 and about 90. In some embodiments, the patient's body surface area (BSA) is reduced by multiple percentage points between about 90 and about 100.

[0248] In some embodiments, the patient's BSA affected by psoriasis before administration is at least about 10%, such as about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100%. In some embodiments, the patient's BSA affected before administration is about 10% to about 20%. In some embodiments, the patient's BSA before administration is about 20% to about 30%. In some embodiments, the patient's BSA before administration is about 30% to about 40%. In some embodiments, the patient's BSA before administration is about 40% to about 50%. In some embodiments, the patient's BSA before administration is about 50% to about 60%. In some embodiments, the patient's BSA before administration is about 60% to about 70%. In some embodiments, the patient's BSA before administration is about 70% to about 80%. In some embodiments, the patient's BSA prior to administration is about 80% to about 90%. In some embodiments, the patient's BSA prior to administration is about 90% to about 100%.

[0249] In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 1 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 2 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 3 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 4 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 5 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 6 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 7 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 8 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 9 is achieved. In some embodiments, a decrease in a pain numeric rating scale (NRS) of about 10 is achieved.

[0250] In some embodiments, a decrease of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 1 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 2 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 3 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 4 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 5 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 6 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 7 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 8 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 9 in the Itch Numeric Rating Scale (NRS) is achieved. In some embodiments, a decrease of about 10 in the Itch Numeric Rating Scale (NRS) is achieved.

[0251] In some embodiments, an inhibition of IFNγ production induced by IL-12 / 18 of about 1% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100% is achieved. In some embodiments, an inhibition of IFNγ production induced by IL-12 / 18 of about 1% to about 10% is achieved. In some embodiments, an inhibition of IFNγ production induced by IL-12 / 18 of about 10% to about 20% is achieved. In some embodiments, an inhibition of IFNγ production induced by IL-12 / 18 of about 20% to about 30% is achieved. In some embodiments, an inhibition of IFNγ production induced by IL-12 / 18 of about 30% to about 40% is achieved. In some embodiments, about 40% to about 50% inhibition of IL-12 / 18 induced IFNγ production is achieved. In some embodiments, about 50% to about 60% inhibition of IL-12 / 18 induced IFNγ production is achieved. In some embodiments, about 60% to about 70% inhibition of IL-12 / 18 induced IFNγ production is achieved. In some embodiments, about 70% to about 80% inhibition of IL-12 / 18 induced IFNγ production is achieved. In some embodiments, about 80% to about 90% inhibition of IL-12 / 18 induced IFNγ production is achieved. In some embodiments, about 90% to about 100% inhibition of IL-12 / 18 induced IFNγ production is achieved.

[0252] In some embodiments, psoriasis does not include erythrodermic, pustular, guttate predominant psoriasis, or drug-induced psoriasis.

[0253] In some embodiments, a serum C between about 25 ng / ml to about 50 ng / ml, about 50 ng / ml to about 100 ng / ml, about 100 ng / ml to about 125 ng / ml, about 125 ng / ml to about 150 ng / ml, about 150 ng / ml to about 175 ng / ml, about 175 ng / ml to about 200 ng / ml, about 200 ng / ml to about 225 ng / ml, about 225 ng / ml to about 250 ng / ml, about 250 ng / ml to about 275 ng / ml, or about 275 ng / ml to about 300 ng / ml is achieved. max In some embodiments, a serum C between about 25 ng / ml and about 50 ng / ml is achieved. max In some embodiments, a serum C between about 50 ng / ml and about 75 ng / ml is achieved. maxIn some embodiments, a serum C between about 75 ng / ml and about 100 ng / ml is achieved. max In some embodiments, a serum C between about 100 ng / ml and about 125 ng / ml is achieved. max In some embodiments, a serum C between about 125 ng / ml and about 175 ng / ml is achieved. max In some embodiments, a serum C between about 175 ng / ml and about 200 ng / ml is achieved. max In some embodiments, a serum C between about 200 ng / ml and about 225 ng / ml is achieved. max .

[0254] In some embodiments, a serum C between about 225 ng / ml and about 250 ng / ml is achieved. max .

[0255] In some embodiments, a serum C between about 250 ng / ml and about 300 ng / ml is achieved. max .

[0256] 6. Dosage and Schedule

[0257] In some embodiments, the methods and uses described herein, such as methods or uses in treating inflammatory disorders (e.g., psoriasis and psoriatic arthritis) in patients in need thereof, are achieved by administering (e.g., orally) a therapeutically effective amount of a TYK2 inhibitor (e.g., Compound 1), such as in single or multiple doses up to 200 mg. In some embodiments, the TYK2 inhibitor is administered once, twice, three times, four times, five times, six times, seven times, or eight times per day. In some embodiments, the method comprises administering (e.g., orally) a single or multiple dose in the range of about 2 to about 200 mg / dose (such as about 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 145 mg, 150 mg, 160 mg, 170 mg, 185 mg, 190 mg, 195 mg, or about 200 mg) or any amount range produced by using two of the above amounts as endpoints. For example, an oral dose may include 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg / dose form of a TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof.

[0258] In some embodiments, the methods include administering (e.g., orally) in a single or multiple doses within the range of about 2 to about 200 mg / dose, such as about 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 145 mg, 150 mg, 160 mg, 170 mg, 185 mg, 190 mg, 195 mg, or about 200 mg per day.

[0259] In some embodiments, the method comprises administering (e.g., orally) in a single or multiple doses within the range of about 2 to about 200 mg, about 2 mg to about 10 mg, about 15 mg to about 20 mg, about 25 mg to about 30 mg, about 35 mg to about 40 mg, about 45 mg to about 50 mg, about 60 mg to about 70 mg, about 80 mg to about 90 mg, about 100 mg to about 110 mg, about 120 mg to about 130 mg, about 140 mg to about 150 mg, about 150 mg to about 160 mg, about 170 mg to about 185 mg, about 190 mg to about 200 mg per day. g, about 5 mg to about 30 mg, about 10 mg to about 30 mg, about 10 mg to about 50 mg, about 10 mg to about 100 mg, about 25 mg to about 50 mg, about 25 mg to about 100 mg, about 25 mg to about 200 mg, about 30 mg to about 50 mg, about 30 mg to about 100 mg, about 40 mg to about 50 mg, about 40 mg to about 100 mg, about 50 mg to about 100 mg, about 75 mg to about 100 mg, about 75 mg to about 200 mg, about 100 mg to about 200 mg, about 125 mg to about 150 mg, or about 150 to about 200 mg. Any specific dosage amount between the ranges of this paragraph is contemplated. For example, for the statement of "about 2 mg to about 10 mg", this encompasses the administration of about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, or about 10 mg. Any non-integer doses between ranges are also contemplated, e.g., for the range "about 2 mg to about 10 mg," values ​​of about 2 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about 2.6 mg, etc. are contemplated.

[0260] Any dose in the preceding paragraph may be administered in one, two, three or four doses in one day. For example, a 2 mg dose may be administered as a 1 mg dose followed by a second 1 mg dose after a period of time to achieve a 2 mg dose. For another example, a 2 mg dose may be administered in one day by administering 0.5 mg, administering a second 0.5 mg after a certain period of time, administering a third 0.5 mg after a certain period of time, and administering a fourth 0.5 mg after a certain period of time to achieve a total of 2 mg administered throughout the day.

[0261] Thus, in some embodiments, administering 2 mg of Compound 1 comprises administering 1 mg, over a determined period of time, and administering a second 1 mg dose. In some embodiments, administering 5 mg of Compound 1 comprises administering 2.5 mg, over a determined period of time, and administering a second 2.5 mg dose. In some embodiments, administering 10 mg of Compound 1 comprises administering 5 mg, over a determined period of time, and administering a second 5 mg dose. In some embodiments, administering 15 mg of Compound 1 comprises administering 7.5 mg, over a determined period of time, and administering a second 7.5 mg dose. In some embodiments, administering 30 mg of Compound 1 comprises administering 15 mg, over a determined period of time, and administering a second 15 mg dose. The determined period of time may be determined by a clinician and is subject to individual patient metabolic considerations. In some embodiments, the determined time period is between about 2.5 hours to about 5 hours, about 5 hours to about 7.5 hours, about 7.5 hours to about 10 hours, about 10 hours to about 12.5 hours, about 12.5 hours to about 15 hours, about 15 hours to about 17.5 hours, about 17.5 hours to about 20 hours, about 20 hours to about 22.5 hours, or about 22.5 hours to about 24 hours.

[0262] In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 2 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 5 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 10 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 15 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 20 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 25 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 30 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 35 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 40 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 45 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of up to 50 mg. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of about 5 mg to about 30 mg (such as about 5 mg, about 10 mg, or about 30 mg). In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (e.g., orally) at a dose of about 10 mg to about 40 mg. In some embodiments, the TYK2 inhibitor (eg, Compound 1) or a pharmaceutically acceptable salt thereof is administered to a patient (eg, orally) at a dose of about 25 mg to about 50 mg.

[0263] As provided in view of the preclinical data described herein, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered to the patient at a dosing schedule suitable for producing the desired disease regression with minimal side effects. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutical composition thereof is administered to the patient every day (QD) for a period of about 1 day to about 7 days, about 1 week to about 3 weeks, about 3 weeks to about 6 weeks, about 6 weeks to about 9 weeks, about 9 weeks to 12 weeks, about 12 weeks to about 15 weeks, or about 15 weeks to about 18 weeks. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutical composition thereof is administered to the patient every day (QD) for 2 weeks, 4 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, or 18 weeks.

[0264] In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered to a patient at a single daily dose of 2-200 mg for 2 weeks. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutical composition thereof is administered to a patient at multiple daily doses of 20-200 mg for 2 weeks. In some embodiments, the TYK2 inhibitor (e.g., Compound 1) or a pharmaceutical composition thereof is administered to a patient at a daily dose of 2, 5, 10, 15 or 30 mg for 2 weeks, 4 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks or 18 weeks.

[0265] 7. Preparation and Combination

[0266] Pharmaceutically acceptable compositions

[0267] According to the methods described herein, the compounds and compositions can be administered using any amount and any route of administration that is effective for treating or alleviating the severity of any condition disclosed herein. The exact amount required will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the infection, the specific agent, its mode of administration, and the like. The compounds described herein are preferably formulated in dosage unit form for ease of administration and uniform dosage. As used herein, the expression "unit dosage form" refers to a physical discrete unit of an agent suitable for a patient to be treated. However, it should be understood that the total daily dosage of the compounds and compositions described herein will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient or organism will depend on a variety of factors, including the condition being treated and the severity of the condition; the activity of the specific compound being used; the specific composition being used; the age, weight, general health, sex and diet of the patient; the time of administration, route of administration and excretion rate of the specific compound being used; the duration of treatment; the drugs used in combination with the specific compound being used or happen to be used together and similar factors well known in the medical field.

[0268] According to another embodiment, the composition may include a compound as described herein or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. The amount of the compound in the composition as described herein is effective to measurably inhibit TYK2 protein kinase or a mutant thereof in a biological sample or in a patient. In certain embodiments, the amount of the compound in the composition as described herein is effective to measurably inhibit TYK2 protein kinase or a mutant thereof in a biological sample or in a patient. In certain embodiments, the composition as described herein is formulated for administration to a patient in need of such a composition. In some embodiments, the composition as described herein is formulated for oral administration to a patient.

[0269] As used herein, the term "patient" means an animal, preferably a mammal, and most preferably a human.

[0270] The term "pharmaceutically acceptable carrier, adjuvant or vehicle" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated therewith. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and lanolin.

[0271] "Pharmaceutically acceptable derivative" means any non-toxic salt, ester, ester salt or other derivative of a compound described herein which, upon administration to a recipient, is capable of providing, directly or indirectly, a compound described herein or an inhibitorily active metabolite or residue thereof.

[0272] As used herein, the term "inhibitory active metabolites or residues thereof" means that the metabolites or residues thereof are also inhibitors of TYK2 protein kinase or mutants thereof.

[0273] The compositions described herein can be administered orally, parenterally, by inhalation spray, topically, rectally, intracisternal, intraperitoneally, nasally, buccally, vaginally or via an implantable reservoir. In certain embodiments, the compounds described herein can be administered orally or parenterally at a dosage level of about 0.01 mg / kg to about 50 mg / kg and preferably about 1 mg / kg to about 25 mg / kg of subject body weight per day, once or multiple times a day, to obtain the desired therapeutic effect. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally or intravenously. The sterile injectable form of the composition described herein may be an aqueous or oily suspension. The suspension may be formulated using a suitable dispersant or wetting agent and a suspending agent according to techniques known in the art. Sterile injectable preparations can also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, for example as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used are especially water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are routinely used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectables.

[0274] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0275] To prolong the effect of the compounds described herein, it is generally desirable to slow down the absorption of the compounds from subcutaneous or intramuscular injections. This can be achieved by using a liquid suspension of crystalline or amorphous materials with poor water solubility. Therefore, the absorption rate of the compound depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, delayed absorption of the compound form administered parenterally is achieved by dissolving or suspending the compound in an oily vehicle. Injectable depot forms are prepared by forming a microcapsule matrix of the compound in a biodegradable polymer (such as polylactide-polyglycolide). Depending on the ratio of the compound to the polymer and the properties of the specific polymer used, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable preparations are also prepared by encapsulating the compound in a liposome or microemulsion compatible with body tissues.

[0276] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing a compound described herein with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active compound.

[0277] For this purpose, any gentle fixed oil can be used, including synthetic monoglycerides or diglycerides. Like pharmaceutically acceptable natural oils (such as olive oil or castor oil, especially in its polyoxyethylated form), fatty acids (such as oleic acid and its glyceride derivatives) can be used to prepare injectables. The oil solution or suspension may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersants commonly used in the preparation of pharmaceutically acceptable dosage forms including emulsions and suspensions. For the purpose of preparation, other commonly used surfactants may also be used, such as Tween, Span and other emulsifiers or bioavailability enhancers commonly used in the manufacture of pharmaceutically acceptable solids, liquids or other dosage forms.

[0278] The pharmaceutically acceptable compositions described herein can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also usually added. For oral administration in capsule form, available diluents include lactose and dry corn starch. When an aqueous suspension is required for oral use, the active ingredient is combined with an emulsifier and a suspending agent. If necessary, certain sweeteners, aromatics, flavorings or coloring agents may also be added.

[0279] Alternatively, the pharmaceutically acceptable compositions described herein can be administered in the form of suppositories for rectal administration. The compositions can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[0280] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier, such as sodium citrate or calcium hydrogen phosphate, and / or a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and silicic acid, b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic, c) humectants, such as glycerol, d) disintegrators, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) dissolution retardants, such as paraffin, f) absorption promoters, such as quaternary ammonium compounds, g) wetting agents, such as cetyl alcohol and glyceryl monostearate, h) absorbents, such as kaolin and bentonite, and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also include a buffer. In soft and hard filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycol and the like, similar types of solid compositions may also be used as fillers. The solid dosage forms of tablets, dragees, capsules, pills and granules may be prepared to have coatings and shells, such as other coatings known in the field of enteric coatings and pharmaceutical formulations. It may optionally contain an opacifier, and may also have a composition that optionally releases active ingredients only or preferentially in a certain part of the intestinal tract in a delayed manner. Examples of usable embedded compositions include polymeric substances and waxes. In soft and hard filled gelatin capsules using excipients such as lactose (lactose or milk sugar) and high molecular weight polyethylene glycol and the like, similar types of solid compositions may also be used as fillers.

[0281] The pharmaceutically acceptable compositions described herein may also be administered topically, especially when the target of treatment includes areas or organs accessible by topical application, including diseases of the eye, skin, or lower intestinal tract. Suitable topical formulations for each of these areas or organs are readily prepared.

[0282] Topical application to the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.Topical transdermal patches may also be used.

[0283] For topical application, the pharmaceutically acceptable composition provided can be formulated into a suitable ointment containing an active component suspended or dissolved in one or more carriers. Other topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. Carriers for topical application of the compounds described herein include, but are not limited to, mineral oil, liquid vaseline, white vaseline, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water. Alternatively, the pharmaceutically acceptable composition provided can be formulated into a suitable lotion or cream containing an active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The active component can be mixed with a pharmaceutically acceptable carrier and any desired preservative or buffer as may be required under aseptic conditions. Absorption enhancers can also be used to increase the flux of the compound through the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel, such as in a topically applied transdermal patch.

[0284] For ophthalmic use, provided pharmaceutically acceptable compositions can be formulated as micronized suspensions in isotonic, pH-adjusted sterile saline, or preferably as solutions in isotonic, pH-adjusted sterile saline, with or without preservatives such as benzalkonium chloride. Alternatively, for ophthalmic use, pharmaceutically acceptable compositions can be formulated in ointments such as petrolatum.

[0285] The pharmaceutically acceptable compositions described herein may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters (to enhance bioavailability), fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0286] Most preferably, the pharmaceutically acceptable compositions described herein are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharmaceutically acceptable compositions described herein are not administered with food. In other embodiments, the pharmaceutically acceptable compositions described herein are administered with food.

[0287] The amount of the compounds described herein that can be combined with the carrier materials to produce a single dosage form of the composition will vary depending on the host being treated, the particular mode of administration. Preferably, the provided compositions should be formulated so that a dosage of 0.01-100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.

[0288] Liquid dosage forms for oral administration can be used, and include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may also contain an inert diluent commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (particularly cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof.

[0289] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound employed, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination and the judgment of the treating physician and the severity of the specific disease being treated. The amount of the compound described herein in the composition will also depend on the specific compound in the composition.

[0290] Depending on the specific disorder or disease to be treated, additional therapeutic agents that are normally administered to treat that disorder may be administered in combination with the compounds and compositions described herein. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or disorder are referred to as "appropriate for the disease or disorder being treated."

[0291] In certain embodiments, provided combinations or compositions thereof are administered in combination with another therapeutic agent.

[0292] Examples of agents that may also be combined as described herein include, but are not limited to: for the treatment of Alzheimer's disease, such as and Treatments for HIV, such as ritonavir; treatments for Parkinson's Disease, such as L-DOPA / carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating multiple sclerosis (MS), such as beta interferon (e.g. and ), and mitoxantrone; for asthma treatments such as albuterol and Agents used to treat schizophrenia, such as Zyprexa, Risperdal, Seroquel, and Haloperidol; anti-inflammatory agents, such as corticosteroids, TNF blockers, IL-1RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulators and immunosuppressants, such as cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, and tacrolimus. mofetil), interferon, corticosteroids, cyclophosphamide, azathioprine and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferon, anticonvulsants, ion channel blockers, riluzole and anti-Parkinson's disease agents; agents for treating cardiovascular diseases such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers and statins; agents for treating liver diseases such as corticosteroids, cholestyramine, interferon and antiviral agents; agents for treating blood disorders such as corticosteroids, anti-leukemia agents and growth factors; agents that prolong or improve pharmacokinetics such as cytochrome P450 inhibitors (i.e., metabolic destruction inhibitors) and CYP3A4 inhibitors (e.g., ketoconazole and ritonavir); and agents for treating immunodeficiency disorders such as gamma globulin.

[0293] In certain embodiments, the combination therapies described herein, or pharmaceutically acceptable compositions thereof, are administered in combination with a monoclonal antibody or siRNA therapeutic.

[0294] Those other agents may be administered separately from the provided combination therapies as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds described herein in a single composition. If administered as part of a multiple dosage regimen, the two active agents may be presented simultaneously, sequentially, or within a certain time period of each other, typically within five hours of each other.

[0295] As used herein, the term "combination", "combined" and related terms refer to the simultaneous or sequential administration of therapeutic agents according to the present invention. For example, the combination described herein can be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms or together in a single unit dosage form.

[0296] The amount of the other therapeutic agent present in the compositions described herein will not exceed the amount normally administered in a composition comprising the therapeutic agent as the only active agent. Preferably, the amount of the other therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount normally present in a composition comprising the agent as the only therapeutically active agent.

[0297] In one embodiment, the composition may include a compound of formula I and one or more other therapeutic agents. The therapeutic agent may be administered together with the compound of formula I, or may be administered before or after the compound of formula I is administered. Suitable therapeutic agents are further described in detail below. In certain embodiments, the compound of formula I may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours or 18 hours before the therapeutic agent. In other embodiments, the compound of formula I may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours or 18 hours after the therapeutic agent.

[0298] In another embodiment, a method of treating psoriasis and / or psoriatic arthritis may include administering to a patient in need thereof a compound of Formula I (e.g., Compound 1) and one or more other therapeutic agents. Such other therapeutic agents may be small molecules or recombinant biological agents, and include, for example, clobetasol, methotrexate, triamcinolone, ustekinumab, adalimumab, Etanercept, guselkumab, Ixekizumab, Risankizumab, secukinumab, tildrakizumab, fluocinonide, triamcinolone acetonide, Calcipotriene, mometasone, prednisone, desonide, hydrocortisone, betamethasone, betamethasone / calcipotriol, halobetasol, Coal tar, Fluocinolone, tazarotene, calcitriol, Dexamethasone, Methylprednisolone, prednisolone, Taclonex Tacrolimus, Alclometasone, ammonium lactate / halobetasol, Aquanil Aristocort Aristocort Beta BioelementsImmediate Dermarest Plus Diflorasone, flurandrenolide, Infliximab, Itch-X Locoid Amcinonide, Ammonium lactate / urea, Anthralin, A Brodalumab, clocortolone, Coal Tar / Salicylic Acid / Sulfur, Coal Tar / Salicylic Acid, Cordran Cormax ACTH, (Body Oil), Derma-S / FS(scalp), DHS Tar Doak HPActhar Halcinonide, halobetasol / tazarotene, HC Hydrocortisone / pramoxine, hydroxyurea, Kerasal Ultra Meth oxsalen, MG217 Medicated Neutrogena Neutrogena Oxipor Prednicarbate, Proctofoam RA Resorcinol, Synalar Theraplex and

[0299] In another embodiment, a method of treating an inflammatory disease, disorder or condition may comprise administering to a patient in need thereof a compound of Formula I and one or more other therapeutic agents. Such other therapeutic agents may be small molecules or recombinant biologics and include, for example, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), colchicine Corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like), probenecid, allopurinol, febuxostat Sulfasalazine Antimalarial drugs (such as hydroxychloroquine and chloroquine ), methotrexate Gold salts (such as gold thioglucosidase gold thiomalate and auranofin )、D-penicillamine or Cu ), azathioprine Cyclophosphamide Chlorambucil Cyclosporine Leflunomide and “anti-TNF” agents (such as etanercept Infliximab Golimumab Certolizumabpegol and adalimumab ), "anti-IL-1" agents (such as anakinra) and rilonacept ), canakinumab Anti-Jak inhibitors (such as tofacitinib), antibodies (such as rituximab ), "anti-T cell" agents (such as abatacept ), "anti-IL-6" agents (such as tocilizumab) ), diclofenac, cortisone, hyaluronic acid ( or H ), monoclonal antibodies (such as tanezumab), anticoagulants (such as heparin ( or ) and warfarin ), antidiarrheal drugs (such as diphenoxylate) and loperamide ), bile acid binders (such as cholestyramine), alosetron Lubiprostone Laxatives (such as Milk of Magnesia, polyethylene glycol and ), anticholinergics or antispasmodics (such as dicyclomine) ), beta-2 agonists (such as albuterol ( HFA, HFA), levosalbutamol Metaproterenol (A ), pirbuterol acetate Terbutaline sulfate Salmeterol xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium bromide ), inhaled corticosteroids (such as beclomethasone dipropionate) ( and ), triamcinolone acetonide Mometasone Budesonide and flunisolide ), Cromolynsodium Methylxanthines (such as theophylline) and aminophylline), IgE antibodies (such as omalizumab) ), nucleoside reverse transcriptase inhibitors (such as zidovudine) Abacavir Abacavir / lamivudine Abacavir / Lamivudine / Zidovudine Didanosine Emtricitabine Lamivudine Lamivudine / zidovudine Stavudine and zalcitabine ), non-nucleoside reverse transcriptase inhibitors (such as delavirdine) Efavirenz Nevairapine and etravirine ), nucleotide reverse transcriptase inhibitors (such as tenofovir ), protease inhibitors (such as amprenavir) Atazanavir Darunavir Fosamprenavir Indinavir (Crix Lopinavir and ritonavir ), nelfinavir Ritonavir Saquinavir or ) and tipranavir Entry inhibitors (such as enfuvirtide and maraviroc ), integrase inhibitors (such as raltegravir) Doxorubicin Vincristine Bortezomib and dexamethasone With lenalidomide or any combination thereof.

[0300] In another embodiment, a method of treating rheumatoid arthritis may comprise administering to a patient in need thereof a compound of Formula I and one or more other therapeutic agents selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like), sulfasalazine Antimalarial drugs (such as hydroxychloroquine and chloroquine ), methotrexate Gold salts (such as gold thioglucosidase gold thiomalate Auranofin )、D-Penicillamine( or ), azathioprine Cyclophosphamide Chlorambucil Cyclosporine Leflunomide and “anti-TNF” agents (such as etanercept Infliximab Golimumab Certolizumab Adalimumab ), "anti-IL-1" agents (such as anakinra and linacept ), antibodies (such as rituximab ), "anti-T cell" agents (such as abatacept ) and “anti-IL-6” agents (such as tocilizumab ).

[0301] In some embodiments, a method of treating osteoarthritis may comprise administering to a patient in need thereof a compound of Formula I and one or more other therapeutic agents selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), diclofenac, cortisone, hyaluronic acid ( or ) and monoclonal antibodies (such as tanezumab).

[0302] In some embodiments, the method of treating cutaneous lupus erythematosus or systemic lupus erythematosus may comprise administering to a patient in need thereof a compound of Formula I and one or more other therapeutic agents selected from the group consisting of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS) (such as aspirin, ibuprofen, naproxen, etodolac, and celecoxib), corticosteroids (such as prednisone, prednisolone, methylprednisolone, hydrocortisone, and the like), antimalarials (such as hydroxychloroquine and chloroquine ), cyclophosphamide Methotrexate Azathioprine and anticoagulants such as heparin ( or ) and warfarin ).

[0303] In some embodiments, a method of treating Crohn's disease, ulcerative colitis, or inflammatory bowel disease may comprise administering to a patient in need thereof a compound of Formula I and one or more additional therapeutic agents selected from the group consisting of: mesalamine Sulfasalazine Antidiarrheal drugs (such as diphenoxylate and loperamide ), bile acid binders (such as cholestyramine), alosetron Lubiprostone Laxatives (such as milk of magnesia, polyethylene glycol and ) and anticholinergics or antispasmodics (such as dicyclomine ), anti-TNF therapy, steroids, and antibiotics such as metronidazole (Flagyl) or ciprofloxacin.

[0304] In some embodiments, a method of treating asthma may comprise administering to a patient in need thereof a compound of Formula I and one or more additional therapeutic agents selected from: Beta-2 agonists (such as albuterol ( HFA, HFA), levosalbutamol Iproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol Xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium ), inhaled corticosteroids (such as prednisone, prednisolone, beclomethasone dipropionate ( and ), triamcinolone acetonide Mometasone Budesonide Flunisolide and ), Sodium Cromolyn Methylxanthines (such as theophylline and aminophylline) and IgE antibodies (such as omalizumab ).

[0305] In some embodiments, a method of treating COPD may comprise administering to a patient in need thereof a compound of Formula I and one or more additional therapeutic agents selected from the group consisting of: a beta-2 agonist (such as albuterol ( HFA, HFA), levosalbutamol Iproterenol Pirbuterol acetate Terbutaline sulfate Salmeterol Xinafoate and formoterol ), anticholinergics (such as ipratropium bromide and tiotropium ), methylxanthines (such as theophylline and aminophylline), inhaled corticosteroids (such as prednisone, prednisolone, beclomethasone dipropionate ( and ), triamcinolone acetonide Mometasone Budesonide Flunisolide and ).

[0306] In another embodiment, a method of treating a hematological malignancy may comprise administering to a patient in need thereof a compound of Formula I and one or more additional therapeutic agents selected from the group consisting of: rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, PI3K inhibitors, SYK inhibitors, and combinations thereof.

[0307] In another embodiment, a method of treating a solid tumor may comprise administering to a patient in need thereof a compound of Formula I and one or more additional therapeutic agents selected from: rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, PI3K inhibitors, SYK inhibitors, and combinations thereof.

[0308] In another embodiment, the method of treating a hematological malignancy may include administering a compound of Formula I and a Hedgehog (Hh) signaling pathway inhibitor to a patient in need thereof. In some embodiments, the hematological malignancy is DLBCL (Ramirez et al., "Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma" Leuk. Res. (2012), published online on July 17, and incorporated herein by reference in its entirety).

[0309] In another embodiment, a method of treating diffuse large B-cell lymphoma (DLBCL) may comprise administering to a patient in need thereof a compound of Formula I and one or more additional therapeutic agents selected from: rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone, hedgehog signaling inhibitors, and combinations thereof.

[0310] In another embodiment, a method of treating multiple myeloma may comprise administering to a patient in need thereof a compound of Formula I and one or more additional therapeutic agents selected from the group consisting of: bortezomib and dexamethasone Hedgehog signaling inhibitors, BTK inhibitors, JAK / pan-JAK inhibitors, TYK2 inhibitors, PI3K inhibitors, SYK inhibitors and lenalidomide combination.

[0311] In another embodiment, the method of treating or lessening the severity of a disease may comprise administering to a patient in need thereof a compound of Formula I and a BTK inhibitor, wherein the disease is selected from inflammatory bowel disease, arthritis, cutaneous lupus erythematosus, systemic lupus erythematosus (SLE), vasculitis, idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, autoimmune thyroiditis, Sjögren's syndrome, multiple sclerosis, systemic sclerosis, Lyme neurobor reliosis, Guillain-Barre syndrome, syndrome), acute diffuse encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, autoimmune gastritis, pernicious anemia, celiac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary sclerosis, Reiter's syndrome, Takayasu's arteritiseritis), temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, generalized alopecia, Behcet's disease, chronic fatigue, dysautonomia, membranous glomerulonephropathy, endometriosis, interstitial cystitis, pemphigus vulgaris, bullous pemphigoid, neuromyotonia, scleroderma, vulvodynia, hyperproliferative disorders, transplanted organ or tissue rejection, acquired immunodeficiency syndrome (AIDS, also known as HIV), type 1 diabetes, graft-versus-host disease, transplantation, blood transfusion , allergic reactions, allergies (e.g. to plant pollens, latex, drugs, foods, insect toxins, animal hair, animal dander, dust mites or cockroach calyx), type I allergic, allergic conjunctivitis, allergic rhinitis and atopic dermatitis, asthma, appendicitis, atopic dermatitis, asthma, allergies, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis Inflammation, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henlein-Schönlein purpura, hepatitis, suppurative hidradenitis, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonia, pneumonia, polymyositis, Proctitis, prostatitis, pyelonephritis, rhinitis, eustachian tube inflammation, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis or vulvitis, B-cell proliferative disorders (e.g., diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma / Waldenstrom's macroglobulinemia, macroglobulinemia, splenic marginal zone lymphoma, multiple myeloma (also called plasma cell myeloma), non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmacytoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt's lymphomalymphoma / leukemia or lymphomatoid granulomatosis), breast cancer, prostate cancer, or mast cell cancer (e.g., mastocytoma, mast cell leukemia, mast cell sarcoma, systemic mastocytosis), bone cancer, colorectal cancer, pancreatic cancer, bone and joint diseases (including but not limited to rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis, and Reiter's disease), disease), Behçet's disease, Sjögren's syndrome, systemic sclerosis, osteoporosis, bone cancer, bone metastasis), thromboembolic disorders (e.g., myocardial infarction, angina, reocclusion after angioplasty, restenosis after angioplasty, reocclusion after aortocoronary bypass, restenosis after aortocoronary bypass, stroke, transient ischemia, peripheral arterial occlusive disorder, pulmonary embolism, deep vein thrombosis), inflammatory pelvic disease, urethritis, sunburn, sinusitis, pneumonia, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholecystitis, agammaglobulinemia, psoriasis, allergies, Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjögren's disease ( disease), tissue graft rejection, hyperacute rejection of transplanted organs, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), autoimmune polyglandular disease (also called autoimmune polyglandular syndrome), autoimmune alopecia, pernicious anemia, glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma, vasculitis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, atherosclerosis, Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes mellitus, septic shock, erythromycin lupus, systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenic purpura, Waldenstrom's macroglobulinemia, myasthenia gravis, Hashimoto's thyroiditis, atopic dermatitis, degenerative joint disease, vitiligo, autoimmune hypopituitarism, Guillain-Barré syndrome, Behcet's disease, scleroderma, mycosis fungoides, acute inflammatory reactions (such as acute respiratory distress syndrome and ischemia / reperfusion injury) and Graves' disease.

[0312] In another embodiment, the method of treating or lessening the severity of a disease may comprise administering to a patient in need thereof a compound of Formula I and a PI3K inhibitor, wherein the disease is selected from cancer, neurodegenerative disorders, angiogenic disorders, viral diseases, autoimmune diseases, inflammatory disorders, hormone-related diseases, disorders associated with organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, disorders associated with cell death, thrombin-induced platelet aggregation, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), liver disease, pathological immune disorders involving T cell activation, cardiovascular disorders, and CNS disorders.

[0313] In another embodiment, the method of treating or lessening the severity of a disease may comprise administering to a patient in need thereof a compound of Formula I and a PI3K inhibitor, wherein the disease is selected from benign or malignant tumors, cancer or solid tumors of the brain, kidney (e.g., renal cell carcinoma (RCC)), liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovary, colon, rectum, prostate, pancreas, lung, vagina, endometrium, cervix, testis, urogenital tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastoma, neuroblastoma, polycystic ovary syndrome ... myeloma or gastrointestinal cancer (particularly colon cancer or colorectal adenoma) or head and neck tumors, epidermal hyperproliferation, psoriasis, prostatic hyperplasia, neoplasia, neoplasia of epithelial character, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer, lymphoma (including, for example, non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (also known as Hodgkin's or Hodgkin's disease)), breast cancer, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma or leukemia, including Cowden syndrome, Lhermitte-Dudos disease and Bannayan-Zonana syndrome. syndrome) or abnormal activation of the PI3K / PKB pathway, asthma of any type or origin (including both intrinsic (non-allergic) asthma and non-intrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitis asthma, exercise-induced asthma, occupational asthma and asthma induced after bacterial infection), acute lung injury (ALI), adult / acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airway or lung disease (COPD, COAD or COLD) (including chronic bronchitis or dyspnea associated therewith, emphysema) and exacerbation of airway hypersensitivity with other drug therapy (particularly other inhaled drug therapy), bronchitis of any type or origin (including but not limited to acute, arachidic, catarrhal, croupus, chronic or tuberculous bronchitis), pneumoconiosis of any type or origin (an inflammatory, usually occupational lung disease,These include allergic rhinitis, eosinophilic pneumonia, eosinophilic pneumonia, parasitic (particularly metazoan) infections (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), and eosinophilic pneumonia. syndrome), eosinophilic granulomas and eosinophil-related disorders affecting the airways triggered by drug-reactions, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, allergic vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphigus, acquired epidermolysis bullosa, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, disorders affecting the nose (including allergic rhinitis), and inflammatory disorders involving autoimmune reactions or having an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopenia), cutaneous lupus erythematosus, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener's granulomatosis, Dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), endocrine eye diseases, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary sclerosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, and glomerulonephritis (with and without nephrotic syndrome, including, for example, idiopathic nephrotic syndrome or minimal change disease), restenosis, cardiomegaly, atherosclerosis, myocardial infarction, ischemic stroke and congestive heart failure, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease disease) and cerebral ischemia, as well as neurodegenerative diseases caused by traumatic injury, glutamate neurotoxicity, and hypoxia.

[0314] In some embodiments, the method of treating a disease or reducing its severity may include administering a compound of Formula I and a Bcl-2 inhibitor to a patient in need thereof, wherein the disease is an inflammatory disorder, an autoimmune disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder. In some embodiments, the disorder is a proliferative disorder, lupus, or lupus nephritis. In some embodiments, the proliferative disorder is chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Hodgkin's disease, small cell lung cancer, non-small cell lung cancer, myelodysplastic syndrome, lymphoma, hematological neoplasm, or solid tumor.

[0315] In some embodiments, the method for treating a disease or reducing its severity may include administering a TYK2 pseudokinase (JH2) domain binding compound and a TYK2 kinase (JH1) domain binding compound to a patient in need. In some embodiments, the disease is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation. In some embodiments, the JH2 binding compound is a compound of formula I. Other suitable JH2 domain binding compounds include those described in WO2014074660A1, WO2014074661A1, WO2015089143A1, and the entire contents of each of the applications are incorporated herein by reference. Suitable JH1 domain binding compounds include those described in WO2015131080A1, and the entire contents of the application are incorporated herein by reference.

[0316] According to one embodiment, a method of inhibiting protein kinase activity in a biological sample may include the step of contacting the biological sample with a compound described herein or a composition comprising the compound.

[0317] According to another embodiment, the method of inhibiting the activity of TYK2 or a mutant thereof in a biological sample may include the step of contacting the biological sample with a compound described herein or a composition comprising the compound. In certain embodiments, the method of irreversibly inhibiting the activity of TYK2 or a mutant thereof in a biological sample may include the step of contacting the biological sample with a compound described herein or a composition comprising the compound.

[0318] In another embodiment, a method of selectively inhibiting TYK2 relative to one or more of JAK1, JAK2, and JAK3 is described. In some embodiments, the selectivity of the compounds described herein is more than 2 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compounds described herein is more than 5 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compounds described herein is more than 10 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compounds described herein is more than 50 times that of JAK1 / 2 / 3. In some embodiments, the selectivity of the compounds described herein is more than 100 times that of JAK1 / 2 / 3.

[0319] As used herein, the term "biological sample" includes, but is not limited to, cell cultures or extracts thereof; biopsy material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears or other body fluids or extracts thereof.

[0320] Inhibiting TYK2 (or its mutant) activity in a biological sample can be used for a variety of purposes known to those skilled in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological sample storage, and bioassays.

[0321] Another embodiment A method of inhibiting protein kinase activity in a patient may include the step of administering to the patient a compound described herein or a composition comprising the compound.

[0322] According to another embodiment, a method of inhibiting the activity of TYK2 or a mutant thereof in a patient may include the step of administering to the patient a compound described herein or a composition comprising the compound. According to certain embodiments, a method of reversibly or irreversibly inhibiting the activity of one or more TYK2 or a mutant thereof in a patient may include the step of administering to the patient a compound described herein or a composition comprising the compound. In other embodiments, a method for treating a disorder mediated by TYK2 or a mutant thereof in a patient in need thereof may include the step of administering to the patient a compound described herein or a pharmaceutically acceptable composition thereof. Such disorders are described in detail herein.

[0323] Depending on the specific disorder or disease to be treated, additional therapeutic agents that are normally administered to treat that disorder may also be present in the compositions described herein. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or disorder are referred to as "appropriate for the disease or disorder being treated."

[0324] The compounds described herein may also be advantageously used in combination with other therapeutic compounds. In some embodiments, the other therapeutic compounds are antiproliferative compounds. Such antiproliferative compounds include, but are not limited to, aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule-active compounds; alkylating compounds; histone deacetylase inhibitors; compounds that induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; anti-tumor antimetabolites; platinum compounds; compounds that target / reduce protein or lipid kinase activity and other anti-angiogenic compounds; compounds that target, reduce or inhibit the activity of protein or lipid phosphatases; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; matrix metalloproteinase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds for the treatment of hematological malignancies; compounds that target, reduce or inhibit Flt-3 activity; Hsp90 inhibitors, such as those from Conforma Therapeutics' 17-AAG (allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010; temozolomide Kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine / chlorpromazine from CombinatoRx; MEK inhibitors, such as ARRY142886 from Array BioPharma, AZD6244 from AstraZeneca, PD181461 from Pfizer, and leucovorin. The term "aromatase inhibitor" as used herein relates to compounds that inhibit estrogen production (e.g., the conversion of the substrates androstenedione and testosterone into estrone and estradiol, respectively). The term includes, but is not limited to, steroids, particularly atamestane, exemestane and formestane, and specifically nonsteroids, particularly aminoglutethimide, rogletimide, pyridoglutethimide, trilostane, testolactone, ketoconazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane is marketed under the trade name Aromasin TM Formestane is sold under the brand name Lentaron TM Fadroxil is sold under the brand name Afema TM Anastrozole is sold under the brand name Arimidex TM Letrozole is sold under the brand name Femara TM or Femar TM Aminoglutethimide is sold under the trade name Orimeten TM The combinations described herein may include a chemotherapeutic agent that is an aromatase inhibitor, which is particularly useful in treating hormone receptor positive tumors, such as breast tumors.

[0325] As used herein, the term "anti-estrogen" refers to a compound that antagonizes the effects of estrogen at the estrogen receptor level. The term includes, but is not limited to, tamoxifen, fulvestrant, raloxifene, and raloxifene hydrochloride. Tamoxifen is marketed under the trade name Nolvadex. TM Raloxifene hydrochloride is sold under the brand name Evista TM Fulvestrant is sold under the brand name Faslodex TMAdministration. The combinations described herein may include a chemotherapeutic agent that is an antiestrogen, which is particularly useful in treating estrogen receptor positive tumors, such as breast tumors.

[0326] As used herein, the term "antiandrogen" refers to any substance that is capable of inhibiting the biological effects of androgens and includes, but is not limited to, bicalutamide (Casodex TM As used herein, the term "gonadorelin agonist" includes, but is not limited to, abarelix, goserelin, and goserelin acetate. Goserelin is available under the brand name Zoladex TM Application.

[0327] As used herein, the term "topoisomerase I inhibitors" include, but are not limited to, topotecan, gimatecan, irinotecan, camptothecian and its analogs, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148. Irinotecan can be marketed, for example, in its commercial form (e.g., under the trademark Camptosar TM ) administration. Topotecan is sold under the brand name Hycamptin TM Sale.

[0328] As used herein, the term "topoisomerase II inhibitors" include, but are not limited to, anthracyclines such as doxorubicin (including liposomal formulations such as Caelyx TM ), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide is marketed under the trade name Etopophos TM Teniposide is sold under the trade name VM 26-Bristol. Doxorubicin is sold under the trade name Acriblastin TM or Adriamycin TM Epirubicin is sold under the brand name Farmorubicin TM Idarubicin is marketed under the brand name Zavedos TM Mitoxantrone is sold under the trade name Novantron.

[0329] The term "microtubule active agent" refers to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors, including but not limited to taxanes, such as paclitaxel and docetaxel; vinca alkaloids, such as vinblastine or vinblastine sulfate, vincristine or vincristine sulfate and vinorelbine; discodermolide; cochicine and epothilone and its derivatives. Paclitaxel is sold under the trade name Taxol TM Docetaxel is sold under the brand name Taxotere TM Vinblastine sulfate is sold under the trade name Vinblastin RP TM Vincristine sulfate is sold under the trade name Farmistin TM Sale.

[0330] As used herein, the term "alkylating agent" includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan, or nitrosourea (BCNU or Gliadel). Cyclophosphamide is marketed under the trade name Cyclostin. TM Ifosfamide is sold under the brand name Holoxan TM Sale.

[0331] The term "histone deacetylase inhibitor" or "HDAC inhibitor" refers to compounds that inhibit histone deacetylase and have antiproliferative activity. This includes, but is not limited to, suberoylanilide hydroxamic acid (SAHA).

[0332] The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating compounds such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine is marketed under the trade name Xeloda TM Gemcitabine is sold under the brand name Gemzar TM Sale.

[0333] As used herein, the term "platinum compound" includes, but is not limited to, carboplatin, cis-platin (cisplatinum) and oxaliplatin. Carboplatin can be obtained, for example, in its commercially available form (e.g., under the trademark Carboplat TM ) is administered. Oxaliplatin can be administered, for example, in the form as it is marketed (e.g. under the trademark Eloxatin TM ) application.

[0334] As used herein, the term "compounds that target / reduce the activity of a protein or lipid kinase, or a protein or lipid phosphatase; or other anti-angiogenic compounds" includes, but is not limited to, protein tyrosine kinase and / or serine and / or threonine kinase inhibitors or lipid kinase inhibitors, such as a) compounds that target, reduce or inhibit the activity of platelet-derived growth factor receptor (PDGFR), such as compounds that target, reduce or inhibit the activity of PDGFR, especially compounds that inhibit PDGF receptor, such as N-phenyl-2-pyrimidine-amine derivatives, such as imatinib, SU101, SU6668 and GFB-111; b) compounds that target, reduce or inhibit the activity of fibroblast growth factor receptor (FGFR); c) compounds that target, reduce or inhibit the activity of insulin-like growth factor receptor I (IGF-IR), such as compounds that target, reduce or inhibit the activity of IGF-IR, especially compounds that inhibit the kinase activity of IGF-I receptor or antibodies that target the extracellular domain of IGF-I receptor or its growth factor; d) compounds that target, reduce or inhibit T e) compounds that target, decrease or inhibit the activity of the AxI receptor tyrosine kinase family; f) compounds that target, decrease or inhibit the activity of the Ret receptor tyrosine kinase; g) compounds that target, decrease or inhibit the activity of the Kit / SCFR receptor tyrosine kinase, such as imatinib; h) compounds that target, decrease or inhibit the activity of the c-kit receptor tyrosine kinase, which is part of the PDGFR family, such as compounds that target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase. i) compounds that inhibit the activity of members of the c-Abl family, their gene fusion products (e.g., BCR-Abl kinase) and mutants, such as compounds that target, decrease or inhibit the activity of c-Abl family members and their gene fusion products, such as N-phenyl-2-pyrimidine-amine derivatives, such as imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825);j) compounds that target, decrease or inhibit the activity of members of the Raf family of protein kinase C (PKC) and serine / threonine kinases, MEK, SRC, JAK / pan-JAK, FAK, PDK1, PKB / Akt, Ras / MAPK, PI3K, SYK, BTK and TEC families and / or members of the cyclin-dependent kinase family (CDK), including staurosporine derivatives such as midostaurin; examples of other compounds include UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO320432; GO 6976; lsis 3521; LY333531 / LY379196; isoquinoline compounds; FTI; PD184352 or QAN697 (P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds that target, reduce or inhibit the activity of protein tyrosine kinases, such as compounds that target, reduce or inhibit the activity of protein tyrosine kinases, including imatinib mesylate (Gleevec; TM ) or tyrosine phosphorylation inhibitors, such as tyrosine phosphorylation inhibitor A23 / RG-50810; AG 99; tyrosine phosphorylation inhibitor AG 213; tyrosine phosphorylation inhibitor AG 1748; tyrosine phosphorylation inhibitor AG 490; tyrosine phosphorylation inhibitor B44; tyrosine phosphorylation inhibitor B44(+) spiegelmer; tyrosine phosphorylation inhibitor AG555; AG 494; tyrosine phosphorylation inhibitor AG 556, AG957 and adaphostin (4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); 1) targeting, decreasing or inhibiting the epidermal growth factor family of receptor tyrosine kinases (EGFR1 in the form of homodimers or heterodimers) Compounds that inhibit the activity of ErbB2, ErbB3, ErbB4) and their mutants, such as compounds that target, reduce or inhibit the activity of the epidermal growth factor receptor family, especially compounds, proteins or antibodies that inhibit members of the EGF receptor tyrosine kinase family (such as EGF receptor, ErbB2, ErbB3 and ErbB4) or bind to EGF or EGF-related ligands, CP 358774, ZD 1839, ZM105180; trastuzumab (Herceptin TM ), cetuximab (Erbitux TM), Iressa, Tarceva, OSI-774, Cl-1033, EKB-569, GW-2016, E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives; m) compounds that target, decrease or inhibit the activity of c-Met receptors, such as compounds that target, decrease or inhibit the activity of c-Met, especially compounds that inhibit c-Met receptors or target c- Compounds that target, decrease or inhibit the kinase activity of one or more JAK family members (JAK1 / JAK2 / JAK3 / TYK2 and / or pan-JAK), including but not limited to PRT-062070, SB-1578, baricitinib, pacritinib, momelotinib, VX-509, AZD-1480, TG-1 o) compounds that target, decrease or inhibit the kinase activity of PI3 kinase (PI3K), including but not limited to ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparlisib, pictrelisib, PF-4691502, BYL-719, dactolisib, sib), XL-147, XL-765 and idelalisib; and q) compounds that target, reduce or inhibit the signaling effects of the hedgehog protein (Hh) or smoothened receptor (SMO) pathway, including but not limited to cyclopamine, vismodegib, itraconazole, erismodegib and IPI-926 (saridegib).

[0335] The term "PI3K inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against one or more enzymes in the phosphatidylinositol-3-kinase family, including but not limited to PI3Kα, PI3Kγ, PI3Kδ, PI3Kβ, PI3K-C2α, PI3K-C2β, PI3K-C2γ, Vps34, p110-α, p110-β, p110-γ, p110-δ, p85-α, p85-β, p55-γ, p150, p101 and p87. Examples of PI3K inhibitors that can be used in the methods described herein include, but are not limited to, ATU-027, SF-1126, DS-7423, PBI-05204, GSK-2126458, ZSTK-474, buparix, pitrix, PF-4691502, BYL-719, datelix, XL-147, XL-765, and idelalisib.

[0336] As used herein, the term "BTK inhibitor" includes, but is not limited to, compounds having inhibitory activity against Bruton's Tyrosine Kinase (BTK), including, but not limited to, AVL-292 and ibrutinib.

[0337] The term "SYK inhibitor" as used herein includes, but is not limited to, compounds having inhibitory activity against spleen tyrosine kinase (SYK), including, but not limited to, PRT-062070, R-343, R-333, Excellair, PRT-062607, and fostamatinib.

[0338] As used herein, the term "Bcl-2 inhibitor" includes, but is not limited to, compounds with inhibitory activity against B-cell lymphoma 2 protein (Bcl-2), including, but not limited to, ABT-199, ABT-731, ABT-737, apogossypol, Ascenta's pan-Bcl-2 inhibitor, curcumin (and its analogs), dual Bcl-2 / Bcl-xL inhibitors (Infinity Pharmaceuticals / Novartis Pharmaceuticals), Genasense (G3139), HA14-1 (and its analogs; see WO2008118802), navitoclax (and its analogs, see US7390799), NH-1 (Shenayng Pharmaceutical University), obatoclax (and its analogs, see WO2004106328), S-001 (Gloria Pharmaceuticals), TW series compounds (Univ. of Mich. In some embodiments, the Bcl-2 inhibitor is a small molecule therapeutic. In some embodiments, the Bcl-2 inhibitor is a peptide mimetic.

[0339] Other examples of BTK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2008039218 and WO2011090760, the entire contents of which are incorporated herein by reference.

[0340] Other examples of SYK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2003063794, WO2005007623 and WO2006078846, the entire contents of which are incorporated herein by reference.

[0341] Other examples of PI3K inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2004019973, WO2004089925, WO2007016176, US8138347, WO2002088112, WO2007084786, WO2007129161, WO2006122806, WO2005113554 and WO2007044729, the entire contents of which are incorporated herein by reference.

[0342] Other examples of JAK inhibitory compounds and conditions that can be treated by combinations of such compounds with the compounds described herein can be found in WO2009114512, WO2008109943, WO2007053452, WO2000142246 and WO2007070514, the entire contents of which are incorporated herein by reference.

[0343] Other antiangiogenic compounds include compounds that have another mechanism for their activity (e.g., not related to protein or lipid kinase inhibition), such as thalidomide. TM ) and TNP-470.

[0344] Examples of proteasome inhibitors that can be used in combination with the compounds described herein include, but are not limited to, bortezomib, disulfiram, epigallocatechin-3-gallate (EGCG), salinosporamide A, carfilzomib, ONX-0912, CEP-18770, and MLN9708.

[0345] Compounds that target, decrease or inhibit the activity of a protein or lipid phosphatase are, for example, inhibitors of phosphatase 1, phosphatase 2A or CDC25, such as okadaic acid or a derivative thereof.

[0346] Compounds that induce cell differentiation processes include, but are not limited to, retinoic acid, α-, γ- or δ-tocopherol or α-, γ- or δ-tocotrienol.

[0347] The term cyclooxygenase inhibitors as used herein include, but are not limited to, Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acids and derivatives such as celecoxib (Celebrex TM ), etoricoxib, valdecoxib or 5-alkyl-2-arylaminophenylacetic acid, such as 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, lumiracoxib.

[0348] As used herein, the term "bisphosphonates" includes, but is not limited to, etridonic acid, clodronic acid, tiludronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, and zoledronic acid. TM Clodronic acid is sold under the trade name Bonefos TM Tiludronic acid is sold under the brand name Skelid TM Pamidronate is sold under the brand name Aredia TM Alendronate is sold under the brand name Fosamax TM Ibandronic acid is sold under the brand name Bondranat TM Risedronate is sold under the brand name Actonel TM Zoledronic acid is sold under the brand name Zometa TM The term "mTOR inhibitor" refers to compounds that inhibit the mammalian target of rapamycin (mTOR) and have antiproliferative activity, such as sirolimus. Everolimus (Certican TM ), CCI-779 and ABT578.

[0349] As used herein, the term "heparanase inhibitor" refers to a compound that targets, reduces or inhibits the degradation of heparan sulfate. The term includes, but is not limited to, PI-88. As used herein, the term "biological response modifier" refers to a lymphokine or interferon.

[0350] As used herein, the term "inhibitor of an oncogenic isoform of Ras (such as H-Ras, K-Ras or N-Ras)" refers to a compound that targets, decreases or inhibits the oncogenic activity of Ras; for example, a "farnesyl transferase inhibitor" such as L-744832, DK8G557 or R115777 (Zarnestra TM ). As used herein, the term "telomerase inhibitor" refers to a compound that targets, reduces or inhibits telomerase activity. Compounds that target, reduce or inhibit telomerase activity are particularly compounds that inhibit telomerase receptors, such as telomestatin.

[0351] The term "methionine aminopeptidase inhibitor" as used herein refers to a compound that targets, reduces or inhibits the activity of methionine aminopeptidase. Compounds that target, reduce or inhibit the activity of methionine aminopeptidase include, but are not limited to, bengamide or its derivatives.

[0352] As used herein, the term "proteasome inhibitor" refers to a compound that targets, decreases or inhibits the activity of the proteasome. Compounds that target, decrease or inhibit the activity of the proteasome include, but are not limited to, bortezomib (Velcade TM ) and MLN341.

[0353] As used herein, the term "matrix metalloproteinase inhibitors" or ("MMP" inhibitors) includes, but is not limited to, collagen peptide mimetics and non-peptide mimetic inhibitors, tetracycline derivatives, such as the hydroxamate peptide mimetic inhibitor batimastat and its orally bioavailable analogs marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251, BAY 12-9566, TAA211, MMI270B or AAJ996.

[0354] The term "compounds for treating hematological malignancies" as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors, which are compounds that target, decrease or inhibit the activity of FMS-like tyrosine kinase receptor (Flt-3R); interferons, 1-β-D-arabinofuranosylcytosine (ara-c) and bisulfan; ALK inhibitors, which are compounds that target, decrease or inhibit anaplastic lymphoma kinase; and Bcl-2 inhibitors.

[0355] Compounds that target, decrease or inhibit the activity of the FMS-like tyrosine kinase receptor (Flt-3R) are especially compounds, proteins or antibodies that inhibit members of the Flt-3R receptor kinase family, such as PKC412, midostaurin, staurosporine derivatives, SU11248 and MLN518.

[0356] As used herein, the term "HSP90 inhibitor" includes, but is not limited to, compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90; compounds that degrade, target, reduce or inhibit HSP90 client proteins via the ubiquitin proteasome pathway. Compounds that target, reduce or inhibit the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies that inhibit the ATPase activity of HSP90, such as 17-allylamino, 17-demethoxygeldanamycin (17AAG, a geldanamycin derivative); other geldanamycin-related compounds; radicicol and HDAC inhibitors.

[0357] As used herein, the term "anti-proliferative antibodies" includes, but is not limited to, trastuzumab (Herceptin TM ), trastuzumab-DM1, erbitux, bevacizumab (Avastin TM ), rituximab PRO64553 (anti-CD40) and 2C4 antibodies. Antibodies refer to intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibody fragments, so long as the fragments exhibit the desired biological activity.

[0358] For the treatment of acute myeloid leukemia (AML), the compounds described herein can be used in combination with standard leukemia therapies, particularly in combination with therapies for the treatment of AML. Specifically, the compounds described herein can be administered in combination with, for example, farnesyl transferase inhibitors and / or other drugs that can be used to treat AML, such as daunomycin, adriamycin, Ara-C, VP-16, teniposide, mitoxantrone, idarubicin, carboplatin, and PKC412. In some embodiments, the method for treating AML associated with ITD and / or D835Y mutations can include administering the compounds described herein together with one or more FLT3 inhibitors. In some embodiments, the FLT3 inhibitor is selected from quizartinib (AC220), a staurosporine derivative (e.g., midostaurin or lestaurtinib), sorafenib, tandutinib, LY-2401401, LS-104, EB-10, famitinib, NOV-110302, NMS-P948, AST-487, G-749, SB-1317, S-209, SC-110219, AKN-028, fedratinib, tozasertib, and sunitinib. In some embodiments, the FLT3 inhibitor is selected from quizartinib, midostaurin, lestaurtinib, sorafenib, and sunitinib.

[0359] Other anti-leukemic compounds include, for example, Ara-C, a pyrimidine analog, which is a 2'-α-hydroxyribose (arabinoside) derivative of deoxycytidine. Also included are purine analogs of hypoxanthine, 6-mercaptopurine (6-MP), and fludarabine phosphate. Compounds that target, reduce, or inhibit the activity of histone deacetylase (HDAC) inhibitors, such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA), inhibit the activity of an enzyme called histone deacetylase. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly known as FR901228), Trichostatin A and compounds disclosed in US 6,552,065, including but not limited to N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-acrylamide or a pharmaceutically acceptable salt thereof and N-hydroxy-3-[4-[(2-hydroxyethyl){2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-acrylamide or a pharmaceutically acceptable salt thereof, especially lactate. As used herein, a somatostatin receptor antagonist refers to a compound that targets, treats or inhibits a somatostatin receptor, such as octreotide and SOM230. Tumor cell destruction methods refer to methods such as ionizing radiation. The term "ionizing radiation" referred to above and below means ionizing radiation that occurs in the form of electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in (but not limited to) radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, Principles and Practice of Oncology, Devita et al., eds., 4th edition, volume 1, pages 248-275 (1993).

[0360] Also included are EDG binders and ribonucleotide reductase inhibitors. As used herein, the term "EDG binder" refers to a class of immunosuppressants that regulate lymphocyte recirculation, such as FTY720. The term "ribonucleotide reductase inhibitor" refers to pyrimidine or purine nucleoside analogs, including but not limited to fludarabine and / or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C to resist ALL) and / or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1H-isoindole-1,3-dione derivatives.

[0361] Specifically, compounds, proteins or monoclonal antibodies of VEGF, such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate; Angiostatin TM ;Endostatin TM ; anthranilamide; ZD4190; ZD6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, such as rhuMAb and RHUFab, VEGF aptamers, such as Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibodies, Angiozyme (RPI 4610) and bevacizumab (Avastin TM ).

[0362] As used herein, photodynamic therapy refers to therapy that uses certain chemicals known as photosensitive compounds to treat or prevent cancer. Examples of photodynamic therapy include the use of photosensitive agents such as Visudyne TM and porfimersodium compounds.

[0363] As used herein, angiostatic steroids refer to compounds that block or inhibit angiogenesis, such as anecortave, triamcinolone, hydrocortisone, 11-alpha-epihydrocortisol, cortexolone, 17alpha-hydroxyprogesterone, corticosterone, deoxycorticosterone, testosterone, estrone, and dexamethasone.

[0364] Implants containing corticosteroids refer to compounds such as fluocinolone and dexamethasone.

[0365] Other chemotherapeutic compounds include, but are not limited to, plant alkaloids, hormone compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or various compounds or compounds with other or unknown mechanisms of action.

[0366] The compounds described herein may also be used as co-therapeutic compounds for use in combination with other bulk drugs, such as anti-inflammatory, bronchodilatory or antihistamine bulk drugs, particularly for the treatment of obstructive or inflammatory airway diseases, such as those mentioned above, for example as a synergist of the therapeutic activity of such drugs or as a means of reducing the required dose or potential side effects of such drugs. The compounds described herein may be mixed with other bulk drugs in a fixed pharmaceutical composition, or they may be administered separately before, at the same time or after other bulk drugs. Thus, the combination of the compounds described herein with anti-inflammatory, bronchodilatory, antihistamine or antitussive bulk drugs, the compounds described herein and the bulk drugs may be in the same or different pharmaceutical compositions as described above.

[0367] Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids, such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate; nonsteroidal glucocorticoid receptor agonists; LTB4 antagonists, such as LY293111, CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247; LTD4 antagonists, such as montelukast and zafirlukast; PDE4 inhibitors, such as cilomilast GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SeICID(TM) CC-10004 (Celgene), VM554 / UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko) Kogyo); A2a agonists; A2b antagonists; and beta-2 adrenergic receptor agonists, such as albuterol, salbutamol, iproterol, terbutaline, salmeterol, fenoterol, procaterol and especially formoterol and pharmaceutically acceptable salts thereof. Suitable bronchodilators include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium bromide salts and CHF 4226 (Chiesi) and glycopyrrolate.

[0368] Suitable antihistamine APIs include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine.

[0369] Other useful combinations of the compounds described herein with anti-inflammatory drugs are those with chemokine receptor (e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5) antagonists, particularly CCR-5 antagonists such as the Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D, and Takeda antagonists such as N-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-ammonium chloride (TAK-770).

[0370] The structures of the active compounds identified by code names, generic names or trade names can be taken from the current edition of the standard compendium "The Merck Index" or from databases of, for example, international patents (eg IMS World Publications).

[0371] The compounds described herein may also be used in combination with known therapeutic procedures, such as administration of hormones or radiation. In certain embodiments, provided compounds are used as radiosensitizers, which are particularly useful in treating tumors that exhibit poor sensitivity to radiation therapy.

[0372] The compounds described herein may be administered alone or in combination with one or more other therapeutic compounds, with possible combination therapies taking the form of fixed combinations, or staggered administration of the compounds described herein with one or more other therapeutic compounds or administered independently of one another, or combined administration of fixed combinations with one or more other therapeutic compounds. In addition or in addition, the compounds described herein may be administered in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these therapies for tumor therapy. As described above, long-term therapy is also possible, as is adjuvant therapy in the context of other treatment strategies. Other possible treatments are therapies to maintain the patient's status after tumor regression, or even, for example, chemopreventive therapy in patients at risk.

[0373] Those other agents may be administered separately from the compositions containing the compounds of the invention as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds described herein in a single composition. If administered as part of a multiple dosage regimen, the two active agents may be presented simultaneously, sequentially, or within a certain time period of each other, usually within five hours of each other.

[0374] As used herein, the terms "combination," "combined," and related terms refer to the simultaneous or sequential administration of therapeutic agents. For example, a compound described herein may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Thus, a single unit dosage form may comprise a compound described herein, the other therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0375] The amount of both the compound of the invention and the other therapeutic agent (in those compositions comprising other therapeutic agents as described above) that can be combined with the carrier materials to produce a single dosage form will vary depending on the host being treated and the particular mode of administration. Preferably, the compositions described herein should be formulated so that a dose of 0.01-100 mg / kg body weight / day of the compound of the invention can be administered.

[0376] In those compositions containing other therapeutic agents, the other therapeutic agent and the compounds described herein may act synergistically. Thus, the amount of the other therapeutic agent in such compositions will be less than the amount required in a monotherapy utilizing only the therapeutic agent. In such compositions, a dosage of 0.01-1,000 μg / kg body weight / day of the other therapeutic agent may be administered.

[0377] The amount of the other therapeutic agent present in the compositions described herein will not exceed the amount normally administered in a composition comprising the therapeutic agent as the only active agent. Preferably, the amount of the other therapeutic agent in the compositions disclosed herein will be in the range of about 50% to 100% of the amount normally present in a composition comprising the agent as the only therapeutically active agent.

[0378] The compounds described herein or their pharmaceutical compositions may also be incorporated into compositions for coating implantable medical devices such as prostheses, artificial valves, vascular grafts, stents, and catheters. For example, vascular stents have been used to overcome restenosis (re-narrowing of the blood vessel wall after injury). However, patients using stents or other implantable devices are at risk of blood clot formation or platelet activation. These unwanted effects can be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with the compounds described herein are another embodiment.

[0379] Example

[0380] As described in the examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It should be understood that although the general method depicts the synthesis of certain compounds described herein, the following general methods and other methods known to those skilled in the art are applicable to all compounds as described herein and their respective subclasses and species of the compounds. Other compounds described herein can be prepared by methods substantially similar to those described in the examples herein and methods known to those skilled in the art. The TYK2 inhibitors described herein (e.g., compound 1) can be prepared by methods known to those skilled in the art, for example, as described in US11,046,698, the contents of which are incorporated herein by reference in their entirety.

[0381] Example 1: Safety and Tolerability in Healthy Subjects (Study 101)

[0382] Study 101 is a randomized, single-center, double-blind, placebo-controlled single and multiple ascending dose study in healthy subjects aged 18 to 55 years. The study studied single ascending doses (SAD) of 5 mg, 20 mg, 75 mg, 100 mg and 200 mg and multiple ascending doses (MAD) of 20 mg and 35 mg given QD for 14 days. Another open-label group was also included to evaluate the relative bioavailability of two drug product formulations (original d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) formulation and new spray-dried dispersion (SDD) formulation) to evaluate the PK of a single oral dose of the SDD formulation of compound 1 in healthy subjects under fed and fasting conditions. The SDD formulation is being used in clinical studies of compound 1.

[0383] In this study, 47 participants (healthy volunteers) were enrolled in a single-dose cohort (35 treated with Compound 1 in the range of 5 mg to 200 mg, and 12 treated with placebo). Treatment with Compound 1 was generally safe and well tolerated. A total of 14 of the 35 participants treated with Compound 1 (40%) experienced at least one treatment-emergent adverse event (TEAE), compared to 3 of the 12 (25%) treated with placebo. The most common AEs associated with Compound 1 treatment were acneiform dermatitis / papules and aphthous stomatitis; these events were mild and did not lead to treatment discontinuation. No deaths, serious or severe AEs, or AEs leading to study or study drug discontinuation occurred in either active or placebo-treated participants. No adverse trends were noted in safety laboratory tests, ECGs, vital signs, or physical examination findings.

[0384] In this study, 16 participants (healthy volunteers) were included in multiple dose groups (12 were treated with 20 mg or 35 mg of compound 1 daily for two weeks, and 4 were treated with placebo daily for two weeks). Treatment with compound 1 was generally safe and well tolerated. During the study period, a total of 12 of the 12 participants treated with compound 1 (100%) had at least one TEAE, compared to 2 of the 4 receiving placebo (50%). The most common (≥2 subjects) TEAE observed by priority was acne-like dermatitis, which was reported in 8 subjects treated with compound 1 (all 6 subjects receiving 20 mg daily for 2 weeks and 2 subjects receiving 35 mg). Papules were reported in 3 subjects treated with 35 mg of compound 1. All acne-like dermatitis or papule events were considered to be drug-related. They were mild in intensity and subsided within one to two weeks of onset without interruption of treatment. Aphthous ulcers occurred in 2 subjects in the 20 mg group and in 1 subject in the 35 mg group, all of whom also experienced acneiform dermatitis. All events were considered drug-related. These events were not observed in the placebo group. There were no deaths, serious or severe AEs, or AEs leading to study discontinuation. One participant in the 20 mg group discontinued treatment due to atrial fibrillation associated with hyperthyroidism but completed study follow-up. This event was considered unrelated to the study drug and was not serious. No adverse trends were noted in safety laboratory tests, ECGs, vital signs, or physical examination findings.

[0385] Of the 6 subjects included in the open-label cohort, only 1 oral herpes TEAE was observed in 1 subject (16.7%) after receiving a single dose of 35 mg of Compound 1 (SDD formulation) under fasting conditions. The severity of this TEAE was mild and the investigator judged it to be unrelated to Compound 1. This event was also a TEAE of special concern and resolved before the end of the study. No SAEs were observed during the study period, and no subject experienced a TEAE that led to dose interruption.

[0386] Pharmacokinetic results: In this study, the absorption of compound 1 was generally rapid, with mean peak plasma concentrations observed at a median time of maximum observed concentration (Tmax) of 3-5 hours post-dose in SAD cohorts 1 to 6 and MAD cohorts 7 and 8. For Periods 1 and 2 of SAD cohort 9, compound 1 (as TPGS formulation and SDD formulation, respectively) was administered to fasting subjects, and Tmax was similar to other SAD cohorts and observed at a median time of 4-5 hours post-dose. For Period 3 of SAD cohort 9, compound 1 (as SDD formulation) was administered to fed subjects, and Tmax was observed at a median of 8 hours post-dose and individual values ​​were within the range of 8-24 hours post-dose.

[0387] For Cohorts 1 to 3 (5, 20 and 75 mg doses of Compound 1), the mean maximum observed concentration (Cmax) increased in an approximately dose-proportional manner.

[0388] The mean Cmax was 21.6-237.4 ng / mL (or 11-fold increase in Cmax for a 15-fold increase in dose), and the inter-subject variability in Cmax was moderate (coefficient of variation [CV] 20%-28%). For the 100, 150, and 200 mg doses (Cohorts 5, 4, and 6, respectively), the mean Cmax was 21.6-237.4 ng / mL (or 11-fold increase in Cmax for a 15-fold increase in dose), and the inter-subject variability in Cmax was moderate (coefficient of variation [CV] 20%-28%). max It increased in a less than dose-proportional manner (232.5-250 mg / mL) with slightly greater inter-subject variability (CV 35%-57%).

[0389] Similarly, for groups 1 to 3 (5, 20 and 75 mg doses of Compound 1), the mean area under the plasma concentration versus time curve from time 0 to infinity (AUC0-inf) increased in an approximately dose-proportional manner (589.4-8369.8 h*ng / mL, or a 14-fold increase in AUC0-inf when the dose increased 15-fold). For the 100 and 150 mg doses (groups 5 and 4), the mean AUC0-inf increased in a less than dose-proportional manner (10744.9 and 12190.8 h*ng / mL, respectively). Exposure in group 6 (200 mg dose) did not increase further, and the mean AUC0-inf was 9015 h*ng / mL. For single dose groups 1 to 6, the extrapolated concentration versus time curve area percentage (AUC%) was moderate, ranging from 9.9% to 30.9%.

[0390] After 14 days of multiple dosing at 20 or 35 mg daily (cohorts 7 and 8, respectively), C max The cumulative ratios of 1:1 and 2:1 were 2.6 and 2.2, respectively, and the area under the plasma concentration versus time curve (AUC0-tau) from time 0 to the end of the dosing period was 2.9 and 2.4, respectively. After repeated dosing at 20 or 35 mg on day 14, the minimum observed concentration (C min ) were 82.7 and 169.9 ng / mL respectively.

[0391] Across single dose Cohorts 1 to 6 and multiple dose Cohorts 7 and 8, the terminal half-life (t1 / 2) was consistent across the dose levels tested and ranged from 17.1 to 37.4 hours.

[0392] Periods 1 and 2 of Cohort 9 allowed for the assessment of the comparative bioavailability of the TPGS formulation (used to formulate Compound 1 for dosing in Cohorts 1 to 8) to the SDD formulation as a single 35 mg dose in fasting subjects. max (112.3 ng / mL and 148 ng / mL, respectively) and AUC 0-inf (3146.3 and 4027.5 h*ng / mL, the relative oral bioavailability (F%) of the SDD formulation relative to the TPGS formulation was calculated to be 128%), the exposure of Compound 1 after a single dose as TPGS or SDD formulation was similar. The 2nd period (fasting, SDD formulation) and the 3rd period (fed, SDD formulation) of Cohort 9 allowed the evaluation of the potential effect of food on exposure. In general, the exposure of the two periods was similar, C max (0.91), AUC 0-inf (1.07), the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration (AUC 0-最后 The ratios of the pharmacokinetic parameters of fed to fasted food (t1 / 2; 1.02) and t1 / 2 (0.95) were close to 1. Therefore, no food effect was observed in the study.

[0393] In summary, the renal elimination of the parent drug as a percentage of the total administered dose of Compound 1 was low but measurable, and the dose fraction excreted in urine (FE%) ranged from 0.37% to 1.89% of the dose. Therefore, renal excretion may contribute to the elimination of the parent drug, but is expected to be a relatively minor elimination pathway based on this study. Renal clearance (CLr) ranged from 0.06-0.30 L / hr.

[0394] Pharmacodynamic results: The PD effects of treatment in this study were assessed using an ex vivo immunoassay that measures the amount of TYK2-dependent interferon gamma (IFNγ) produced by whole blood samples stimulated with the cytokines IL-12 and IL-18 at baseline (pre-dose) and post-treatment. Increased exposure to compound 1 resulted in a greater reduction in IFNγ, demonstrating that this compound has a robust effect on biological endpoints relevant to the pathogenesis of several autoimmune diseases.

[0395] To assess the relative risk of JAK1 / 3 inhibition by deuterocelexin and compound 1, we targeted the physiologically relevant IC 50 Inhibition levels were modeled for the peak concentration of each compound achieved in human trials. Figure 3 Deuterated lecitinib and compound 1 have an inhibitory effect on JAK1 / 3 IC in human cells (peripheral blood mononuclear cells or PBMCs). 50Fold Selectivity of Inhibition. Based on published PK data from a Phase 1a clinical trial of deuterocelexinib, deuterocelexinib administered once daily at 12 mg showed a fold selectivity of approximately 370 ng / ml for JAK1 / 3pSTAT inhibition at the peak concentration achieved (approximately 120 ng / ml). 50 There is a four-fold difference between the concentrations. Without wishing to be bound by theory, it is believed that based on the PK data from our Phase 1a clinical trial, the margin for Compound 1 is greater than 50-fold based on a peak concentration of approximately 320 ng / ml after once-daily administration of 30 mg. We have not yet conducted head-to-head comparative preclinical studies or clinical trials for deuterocelexinib and Compound 1. Therefore, no comparative conclusions can be drawn between the data presented by BMS on deuterocelexinib and the data we observed for Compound 1.

[0396] Without wishing to be bound by theory, we believe that increased TYK2 inhibition over a 24-hour period has the potential to result in increased responses in patients with inflammatory and autoimmune diseases, particularly those requiring higher levels of cytokine modulation, such as ulcerative colitis and Crohn's disease. In a Phase 2b trial of moderate to severe ulcerative colitis with 6 mg of deuterated lexitinib administered once daily, deuterated lexitinib did not achieve its primary endpoint of clinical remission at 12 weeks or its secondary endpoints of clinical response using modified Mayo score, endoscopic response, and histologic improvement. BMS is currently conducting a second trial of deuterated lexitinib in ulcerative colitis that includes a higher dose. Based on the PK data observed in our Phase 1a clinical trial, shown below, we believe that the trial dose of Compound 1 may achieve greater TYK2 inhibition over a 24-hour period than the Phase 2b trial dose of deuterated lexitinib, which we believe supports further evaluation of Compound 1 in ulcerative colitis. See Figure 4 .

[0397] We also calculated the IC of TYK2 inhibition in human whole blood cells based on PK data from a Phase 1a clinical trial of deuterocelexin and similar data from our Phase 1a clinical trial. 50 Based on our Figure 4 Based on the modeling shown in Figure 2, a once-daily dose of 6 mg deuteroceletinib (the dose used in the Phase 3 psoriasis trial and Phase 2b ulcerative colitis trial of deuteroceletinib) provided TYK2 IC in human whole blood. 50 Based on this model, once daily doses of 5 mg and 30 mg of Compound 1 would be able to maintain a TYK2 IC50 covering 24 hours. Furthermore, in this model, a 30 mg dose of Compound 1 achieves an IC of approximately 24 hours per day. 75 Coverage and several hours of IC 90 cover.

[0398] Without wishing to be bound by theory, it is believed that the PK and pharmacodynamic (PD) data from our Phase 1a trial allow for flexibility in upward dosing of Compound 1 due to its broad therapeutic index relative to JAK1 / 3 inhibition. Based on publicly available information, BMS has not explored doses higher than 12 mg twice daily in any of its patient studies for any indication. Figure 5 As shown in , PK and PD data from our Phase 1a trial demonstrated a favorable linear response and robust response between dose and drug levels in the blood, including dose-dependent inhibition of IFNγ, a cytokine regulated by TYK2 signaling. Based on PD data (via greater than IC in human leukocytes) 50 The predicted effective dose range is 3 to 30 mg once a day.

[0399] Example 2: Safety and Tolerability in Psoriasis Subjects (Study 102)

[0400] This study is a Phase 1 randomized, multicenter, double-blind, placebo-controlled, multiple ascending dose study of Compound 1 in subjects with moderate to severe plaque psoriasis. The purpose of this study is to provide preliminary evidence of safety, tolerability, pharmacokinetics, pharmacodynamics, and early efficacy in the moderate to severe plaque psoriasis population.

[0401] The study enrolled a total of 26 subjects who were randomized to daily treatment with placebo (N=5) or 1 of 3 doses of Compound 1 (N=21) for a total duration of 28 days. The dose levels were 5 mg (N=8), 10 mg (N=7), or 30 mg (N=6). The 5 mg dose level used the TPGS formulation, and the 10 mg and 30 mg dose levels used the SDD formulation. Food intake was not restricted except when performing study procedures during clinic visits.

[0402] Efficacy Results: Exploratory efficacy data in psoriasis (PASI, static PGA [sPGA]) were obtained in the study. The sample size of this study was small (25 subjects contributed efficacy data), and the duration of treatment was limited to 28 days. A total of 25 subjects (N=8 for 5 mg, N=7 for 10 mg, N=5 for 30 mg, and N=5 for placebo) were included in the efficacy analysis set, which included subjects with PASI and / or sPGA data on Days 1 and 28. The efficacy data for these 25 subjects were complete, and no interpolation of missing data was required. PGA assessment was performed according to Table 1.

[0403] Table 1: Physician Global Assessment (PGA) Evaluation

[0404]

[0405]

[0406] Treatment with Compound 1 showed a dose-dependent trend in reducing disease severity, with mean percentage reductions in PASI scores on Day 28 compared to Day 1 of 30% (mean PASI decreased from 15.4 on Day 1 to 10.9 on Day 28), 47% (mean PASI decreased from 18.2 on Day 1 to 9.6 on Day 28), and 48% (mean PASI decreased from 20.0 on Day 1 to 10.4 on Day 28) in the 5, 10, and 30 mg groups, respectively, compared to a reduction of 26% in the placebo group (mean PASI decreased from 13.5 on Day 1 to 10.0 on Day 28).

[0407] In the 5, 10 and 30 mg groups, PASI-50 was achieved at 13% (1 / 8), 57% (4 / 7) and 40% (2 / 5), respectively, compared to 0% (0 / 5) in the placebo group.

[0408] • In the 30 mg group, 1 subject (1 / 5; 20%) achieved PASI-75, but not in the other groups. The same subject also achieved PASI 90.

[0409] • Treatment with Compound 1 also improved sPGA scores compared to placebo, with one subject in the 30-mg cohort achieving a sPGA of 1 (minimal disease) on Day 28.

[0410] Safety results: Treatment with compound 1 was generally safe and well tolerated. There were no deaths or serious AEs. Among the subjects receiving 5, 10 or 30 mg of compound 1, 38% (3 / 8), 57% (4 / 7) and 67% (4 / 6) experienced TEAEs, compared with 20% (1 / 5) of the subjects in the placebo group. All TEAEs were mild (grade 1) or moderate (grade 2) in intensity, except for one subject treated with 30 mg of compound 1 who had a severe (grade 3) adverse event of neutropenia that led to treatment interruption. This event was observed on day 8 of treatment, resulting in interruption of the study drug on day 12. The subject's neutrophil count was normal on day 15, 3 days after treatment cessation.

[0411] Grade 3 neutropenia was the only adverse event constituting grade 2 or higher hematologic toxicity observed in this study. This event was considered related to study drug but was not serious. No events of acneiform dermatitis, papules, or aphthous ulcers were reported in this study. There were no clinically significant changes in vital signs, physical examinations, or ECGs. One subject in the 30 mg group received only one dose of study drug and discontinued the study after day 1 due to a positive TB test. This subject was included in the safety analysis set but not in the efficacy analysis.

[0412] Pharmacokinetic results: In this study, the absorption of compound 1 was generally rapid, and in groups 1 to 3 (5 to 30 mg, once a day), the average peak plasma concentration was observed at a median of 3-4 hours after dosing. Between the 5 mg and 30 mg doses, the average Cmax under steady-state conditions (i.e., on the 28th day of dosing) generally increased in a slightly greater than dose-proportional manner, with Cmax increasing 8-fold when the dose increased 6-fold. Similarly, the exposure AUC0-tau observed during the dosing interval increased in a greater than dose-proportional manner, with AUC0-tau increasing 11-fold when the dose increased 6-fold. Due to the small sample size and the large inter-subject variability observed in the study (CV of Cmax was 55%-111% and CV of AUC0-tau was 47%-269%), the observed lack of dose proportionality may not be related to pharmacokinetics or pharmacology. In this study, the cumulative ratio observed between day 1 and day 28 was consistent with the values ​​previously obtained in healthy volunteer studies.

[0413] Risks: No significant risks were identified in Study 101 in healthy volunteers or in Study 102 in subjects with moderate to severe plaque psoriasis.

[0414] In contrast, third-party In clinical trials, 30 mg twice daily was given to patients with moderate to severe psoriasis. The average PASI reduction reported in the Phase 3 trial of deuterated correxitinib was 37% at four weeks. The average PASI reduction of deuterated correxitinib has not been reported, and BMS has not conducted a Phase 1b trial of deuterated correxitinib. In our four-week Phase 1b trial, compound 1 showed exploratory signals of clinical activity, which we believe are consistent with the four-week results of deuterated correxitinib and guselkumab (anti-IL-23 monoclonal antibody) in its Phase 2b trial. In those trials, clinical responses increased significantly from the fourth week to the twelfth week. Within the dose range used in the Phase 3 trial of deuterated correxitinib and guselkumab, the response at 12 weeks increased threefold to fourfold compared to four weeks. Therefore, we believe that in our ongoing Phase 2b trial of moderate to severe psoriasis, as measured by PASI scores, we can see an increase in the clinical response rate of compound 1 at twelve weeks.

[0415] PD marker results: We believe that PD markers from skin punch biopsies support exploratory signals for clinical activity of Compound 1, consistent with expectations for allosteric TYK2 inhibitors. Skin PD markers were evaluated based on changes in epidermal thickness (via hematoxylin and eosin or H&E staining) and the presence of the type I keratin K16 hyperproliferation marker. K16 expression is upregulated in psoriasis and downregulated when psoriasis improves. Figure 6 As can be seen in FIG, at four weeks, Compound 1 reduced epidermal thickness and regressed expression of the K16 biomarker in patients across three dosing cohorts (17 patients evaluated).

[0416] like Figure 7 As shown in , 28 days of treatment reduced RNA expression levels of key cytokines and psoriasis gene markers in lesional skin. Methods: mRNA from skin biopsies was isolated and targeted (RT-PCR) or global (microarray) gene expression was assessed. For microarray analysis, differential gene expression comparing baseline lesions to non-lesional samples (psoriasis transcriptome, PSTR) and comparing baseline lesions to day 28 lesional samples (Compound 1 response) was assessed. Gene sets significantly differentially expressed in lesional versus non-lesional baseline skin biopsies (PSTR) (FC >2, pval<0.05) showed high overlap with several public datasets of differentially expressed genes in psoriasis lesions and non-lesional skin. Results: Quantification of mRNA from skin biopsies by RT-PCR showed a suggestive reduction in the expression of several psoriasis-related genes (such as KRT16, IL17A, IL17F and IL22), and via microarray analysis, the expression of the skin transcriptome previously associated with psoriasis in lesional skin was improved by up to 50% (p<0.001 compared to placebo treatment). These results support the further development of compound 1 in psoriasis. Genes that were shown to be upregulated or downregulated in the public psoriasis skin dataset showed significant improvement after 28 days of treatment with all doses of compound 1. The numbers in brackets are (Nimbus PSTR overlap with the probe set of the indicated dataset / total number of probe sets in the dataset). The percentage of improvement was assessed as the mean change % (+ / -SEM) of the expression of the overlapping probe set relative to the baseline non-lesional expression (***p<0.001, comparing treatment with placebo).

[0417] Example 3: Phase 1 randomized, double-blind,

[0418] Placebo-controlled, multiple-dose study (Study 104)

[0419] summary

[0420] Rationale: In a previous study (Study 101), 2 groups of healthy participants received 20 mg or 35 mg daily doses of Compound 1 for 2 weeks. Treatment was generally safe and well tolerated, with no serious or severe adverse events reported. This study is designed to continue dose escalation in healthy participants to define a relatively wide dose range to help select doses for future studies in patients with psoriasis and other autoimmune diseases. Nonclinical pharmacology, toxicology, and pharmacokinetic (PK) studies and early clinical data support the proposed multiple-dose study of Compound 1 in healthy participants.

[0421] Goals and End Points

[0422]

[0423] Overall Design

[0424] This was a Phase 1 randomized, double-blind, placebo-controlled, multiple-dose study of Compound 1 in healthy participants.

[0425] The study population included healthy male participants aged 18 to 65 years and / or female participants of no reproductive potential. There were two multiple dose groups of 8 healthy participants (Groups 1 and 2) who received daily doses of Compound 1 (N=6) or placebo (N=2) for 2 weeks. Study participants entered the CRU on Day -1. Participants remained restrained in the CRU until all planned procedures were completed on Day 22, and then were discharged if medically appropriate. Safety laboratories, PK blood draws, PD blood draws, and adverse event evaluations were performed according to the schedule of activities (SoA).

[0426] Cohort 2 will not be enrolled until the PI and Sponsor determine that Cohort 1 demonstrates adequate safety and tolerability.

[0427] Patients were questioned about potential COVID-19 exposure / symptoms and tested for COVID-19 via PCR test at the screening visit and Day -1, and samples were sent to a central laboratory. Patients who tested positive for PCR at screening or Day -1 were considered to have failed the screening. Participants who developed symptoms consistent with COVID-19 infection after dosing were tested via PCR test and, if they had a positive result, were withdrawn from the study. This was recorded as an adverse event.

[0428] Disclosure Statement: This was a follow-up group intervention study with 2 cohorts, and the sponsor, participants, and investigators were blinded to the cohorts.

[0429] Number of participants:

[0430] Approximately 16 participants were randomized to the study intervention and 16 evaluable participants (8 in each group).

[0431] Intervention Groups and Duration:

[0432] 16 participants are expected to receive active study drug or placebo at the doses specified below.

[0433] Table 1: Groups and dose levels

[0434] Groups Dosage Levels dose Group 1 DL1 50 mg or matching placebo Group 2 DL2 100 mg or matching placebo

[0435] The screening period was approximately 28 days. Participants were restrained in the CRU from Day -1 to Day 22. Treatment was given daily for 14 days, and an SFU visit was planned prior to discharge from the CRU on Day 22. The total duration of study participation was approximately 50 days.

[0436] Dose escalation stopping rules

[0437] The Sponsor and PI jointly decided to continue Cohort 1 to the next higher dose in Cohort 2 after reviewing all relevant blinded safety / tolerability (e.g., AEs, clinical laboratory tests, physical examinations, vital signs, and safety ECGs) and PK data for at least 6 participants in Cohort 1 through Day 15. The Sponsor and PI jointly decided whether to continue the study as planned, whether to continue the study with additional safety assessments, whether to continue the study at a dose different from that planned for Cohort 2, or whether to interrupt dose escalation.

[0438] Dose escalation was terminated if at least 2 participants in the cohort met any of the following criteria attributable to study drug:

[0439] ·Having a drug-related SAE.

[0440] ·Experienced drug-related grade 3 or higher toxicity.

[0441] Dose escalation was terminated if at a given dose level even 1 participant met the following criteria attributable to study drug:

[0442] 1. Evidence of drug-induced liver injury (DILI).

[0443] If a treatment-related SAE, grade ≥3 AE, and / or evidence of DILI was observed, PK samples were collected and the Sponsor was notified. At the discretion of the PI, the corresponding participant's treatment assignment could be unblinded to determine whether the event was related to Compound 1 and whether stopping criteria were met. Any unblinding of the participant's treatment was recorded.

[0444] Provide a written statement to the IRB fully documenting the reasons for study termination, when applicable. Monitor the study by the research team.

[0445] Dosage justification

[0446] Compound 1 has previously been studied at single and two multiple doses (SAD and MD) levels in the first human study (study 101) in healthy volunteers. Single doses between 5 mg and 200 mg per day and multiple doses of 20 mg or 35 mg for 2 weeks are generally safe and well tolerated. There are no serious or severe AEs, and there are no AEs that lead to treatment interruption. The most common adverse effect is a form of rash, i.e., acneiform dermatitis, which was observed in 7 (41%) of 17 subjects receiving a single dose of 100 mg or higher and in 8 (67%) of 12 subjects receiving multiple doses. Although common, these events are mild in intensity, and even in the multiple dose group, they resolve within 1 to 2 weeks with limited or no intervention, and there is no need to interrupt treatment.

[0447] In the single dose cohort using the TPGS formulation, the overall exposure of Compound 1 increased in an approximately dose-proportional manner between 5 mg and 75 mg, and increased in a less than dose-proportional manner between 100 mg and 200 mg. In summary, the exposure of Compound 1 after a single dose was similar as a TPGS or SDD formulation. Similar oral exposures were observed when Compound 1 and SDD formulations were administered in the fed or fasted state.

[0448] In the multiple dose cohort using the TPGS formulation, moderate accumulation of Compound 1 was observed at the 20 and 35 mg daily dose levels, with C max and AUC 0-tau The cumulative ratios for both were <3. At steady state, treatment with 20 mg achieved a C of approximately 207 ng / mL. max and AUC of approximately 3160 h*ng / mL 最后 The corresponding C observed at steady state was 2.5 % at 35 mg daily for 2 weeks. max and AUC 最后 The values ​​were approximately 325 ng / mL and 5839 h*ng / mL. The AUC exposure levels achieved with the highest dose tested, 35 mg, were approximately 8- to 9-fold lower than the NOAEL determined in 28-day repeat dose toxicity studies in monkeys and rats, respectively.

[0449] This study investigated 2 additional multiple doses, 50 mg in cohort 1 and up to 100 mg in cohort 2, to expand the range of doses studied. The SDD formulation was used in this study. Following administration of the 50 mg and 100 mg doses (given daily for 2 weeks), the inferred exposure levels were inferred to be approximately 7-fold and 8-fold (50 mg) and 3-fold and 4-fold (100 mg) lower than the NOAEL determined in the 28-day repeated dose toxicity studies in monkeys and rats, respectively.

[0450] Nonclinical pharmacology, toxicology and pharmacokinetic (PK) studies, early clinical data, and modeling data at 50 mg and 100 mg doses support the proposed multiple-dose study of Compound 1 in healthy participants, with 50 mg as the first dose tested.

[0451] Registration Procedure (Day -1)

[0452] On the morning of Day -1, all participants returned to the CRU. Inclusion and exclusion criteria were reviewed to ensure that participants still met all inclusion criteria. A second PCR COVID-19 test was also performed, and samples were sent to a central laboratory. After the PCR test was performed, participants remained in quarantine until test results were received later that day. Participants who did not meet all inclusion criteria or met any of the exclusion criteria (including a positive COVID-19 test) on Day -1 were considered to have failed the screening.

[0453] Replacements who meet the inclusion criteria at screening also return to the CRU to complete Day -1 activities. If a replacement is not randomized because the target number of participants for each cohort has been met, they remain eligible for the next cohort. If a replacement is enrolled the day after the initial Day -1 assessment, the Day -1 laboratory tests do not need to be repeated.

[0454] Treatment and monitoring period

[0455] Pre-dose evaluations were obtained on the morning of Day 1. After review of all criteria was completed, participants were randomized.

[0456] Participants received a single oral dose of compound 1 or placebo in a blinded manner on the morning of day 1, and then received daily for a total of 14 days. During the treatment period, safety and tolerability were assessed via monitoring, including vital signs, clinical laboratory tests, 12-lead ECG and AEs. Blood samples for PK and PD evaluation and urine samples for metabolite analysis were collected at the time points as listed. Cardiac dynamics monitoring was also performed.

[0457] SFU Visit / Early Termination

[0458] The SFU visit was performed before discharge on day 22.

[0459] Safety and tolerability were assessed via monitoring including vital signs, clinical laboratory tests, 12-lead ECG, and AEs.

[0460] In case of premature termination, the procedures listed in the SoA for the SFU visit should be performed. However, blood samples for PK assessments are also collected. Following the premature termination visit, participants should return to the site for an SFU visit no more than 7 days after the last study drug administration.

[0461] Meal Schedule

[0462] Provide meals and / or snacks as appropriate on Day -1.

[0463] Participants were required to fast for a minimum of 8 hours overnight prior to study drug administration and to continue fasting for at least 4 hours thereafter on Day 1 only.

[0464] Water was restricted from 1 hour before dosing until 1 hour after dosing (except for water provided at the time of dosing), but was allowed ad libitum at all other times. Other fluids were allowed as part of standard meals and / or snacks, but were restricted at all other times throughout the restraint period.

[0465] Constraint Duration

[0466] Participants were restrained in the CRU for 22 days.

[0467] Inclusion criteria

[0468] Participants were eligible for inclusion in this study only if all of the following criteria applied:

[0469] age

[0470] 1. Participants must be between 18 and 65 years old (inclusive) when signing the informed consent form.

[0471] Participant Type and Disease Characteristics

[0472] 2. Participants are medically healthy volunteers who, in the opinion of the PI, have no clinically significant history, physical examination, laboratory profile, vital signs, or ECG at Screening and Day -1. All laboratory results should normally be within the normal range specified by the CRU laboratory.

[0473] 3. Non-smokers (defined as individuals who have not used nicotine-containing products (including cigarettes and e-cigarettes) for at least 3 months prior to dosing).

[0474] weight

[0475] 4. Body mass index (BMI) between 18-35 kg / m at screening and clinical admission 2 range (including the end value).

[0476] gender

[0477] 5. Males or females of no reproductive potential. Male participants and their female partners must use two methods of contraception, one considered highly effective (less than 1% failure rate per year) as defined by the CTFG guidelines (CTFG 2014) and the other a barrier method during sexual intercourse during the study period. Male participants and their partners should continue to use contraception after the last dose and refrain from sperm donation for 90 days. Female participants must have been sterilized or postmenopausal (confirmed by FSH testing) at least 6 months prior to screening.

[0478] Informed consent

[0479] 6. Ability to sign informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and this protocol.

[0480] Exclusion criteria

[0481] Participants were excluded from the study if any of the following criteria applied:

[0482] medical illness

[0483] 1. Any acute or chronic medical condition, including the presence of laboratory abnormalities (greater than grade 1) or electrocardiogram (ECG) abnormalities, or psychiatric illness that would prevent the participant from signing the informed consent, place the participant at unacceptable risk if participating in this study, or confound the ability to interpret data from the study. Participants with evidence of mild active infection (e.g., upper respiratory tract, urinary, gastrointestinal) at screening may be brought back for rescreening after symptoms have fully resolved and an appropriate course of treatment has been completed.

[0484] 2. Female participants of childbearing potential.

[0485] 3. Positive serology for hepatitis B, hepatitis C or human immunodeficiency virus (HBsAg, HCV Ab or HIVAb positive).

[0486] 4. Positive PCR test for COVID-19 at the screening or Day -1 visit; or suspected COVID-19 infection within 10 days of the screening visit; or prior contact with another person diagnosed with or under investigation for COVID-19 within 10 days of screening. However, Cohort 1 subjects who have tested positive for COVID-19 during the screening period may be rescreened in Cohort 2 after completing an appropriate quarantine period per CDC guidelines. Subjects who were previously infected with COVID-19 (based on clinical symptoms or laboratory testing) but have recovered symptomatically, tested negative for COVID-19 antigen by PCR, and have no sequelae may also be screened for inclusion in the study if the PI deems it appropriate.

[0487] 5. Participants with any surgical or medical disease that may affect the absorption, distribution, metabolism or excretion of the study drug.

[0488] 6. Blood pressure is less than 90 / 40 mmHg or greater than 140 / 90 mmHg during screening.

[0489] 7. Heart rate is lower than 40bpm or higher than 99bpm during screening.

[0490] 8. QTcF (Fridericia correction) interval > 450 ms for males or > 470 ms for females at screening, or history of prolonged QT syndrome.

[0491] 9. Blood donation (including whole blood, platelets, or plasma) or massive blood loss within 56 days before dosing, or planned blood donation within 30 days after the last administration of study medication.

[0492] 10. Inability to tolerate oral medications.

[0493] 11. History of solid malignancies or hematologic malignancies within the past 5 years (including precancerous conditions such as myelodysplastic syndrome or lymphoproliferative disorders); excluding history of localized basal cell or squamous cell carcinoma of the skin that has been surgically removed with no evidence of recurrence, successfully treated ductal carcinoma in situ of the breast, and successfully treated cervical cancer in situ.

[0494] Prior / concomitant medications, supplements, or procedures

[0495] 12. Participants who have received any vaccine (including COVID-19) within 28 days of administration.

[0496] 13. Participants who have used systemic prescription medications within 30 days of dosing (or 5 half-lives of concomitant therapy, whichever is longer) or over-the-counter medications, herbal remedies, vitamin supplements, or topical agents within 14 days of dosing. Use of self-limiting medications (e.g., Tylenol) may be considered an exception if approved by the PI and the sponsor.

[0497] 14. Participants who plan to undergo elective medical procedures during the study.

[0498] 15. Participants who engage in recreational drug use or test positive on a drug screening test at the time of screening.

[0499] 16. Participants who tested positive for cotinine.

[0500] Previous / concurrent clinical research experience

[0501] 17. Participants who have been administered an investigational or approved drug in an investigational setting within 30 days or 5 half-lives (whichever is longer) or if the investigational drug is a biologic (e.g., antibody), within 6 months of study drug administration, or participants currently enrolled in an investigational study.

[0502] Diagnostic evaluation

[0503] 18. Participants who may have any other criteria (such as clinically significant screening blood test results) that, in the opinion of the PI, may interfere with study conduct or results.

[0504] Other exclusion criteria

[0505] 19. Participants with any known allergy to any excipients contained in the study drug or placebo formulation.

[0506] 20. Drinking alcohol within 14 days of randomization.

[0507] Lifestyle considerations

[0508] During participation in this study, restrictions on diet, medication use, and activity level will be required as outlined in the following sections.

[0509] Meals and dietary restrictions

[0510] Participants were prohibited from consuming grapefruit or grapefruit juice for 14 days prior to dosing, throughout the treatment period, and throughout the PK sample collection period.

[0511] Caffeine, alcohol, tobacco and marijuana restrictions

[0512] Avoid foods and drinks containing the following as directed:

[0513] Participants were not allowed to consume products containing xanthine or caffeine from 48 hours before dosing and throughout the PK sample collection period.

[0514] Participants should not consume alcohol or alcohol-containing products within 14 days of dosing or as described for concomitant medication use. Cold medications and other medications containing small amounts of alcohol were permitted if deemed necessary by the PI.

[0515] Participants should not use tobacco or nicotine products (including smokeless tobacco, nicotine patches, or nicotine gum) while on the clinical unit and should refrain from using such products during the study screening period.

[0516] Participants should not use recreational drugs, including cannabis products (in any form, including oral or sublingual) while on the clinical unit. Participants should also refrain from using recreational drugs during the study screening period.

[0517] Activity

[0518] From 48 hours prior to dosing until the SFU visit, participants should limit physical activity to a level sufficient to perform activities of daily living (e.g., eating, bathing, dressing). Moderate or strenuous activity (e.g., double tennis, 3-5k runs, marathon training / running, CrossFit training, or weightlifting) is not permitted during this time.

[0519] Study intervention administered

[0520]

[0521] Safety Assessment

[0522] The primary objective of the study was to evaluate the safety and tolerability of Compound 1. Safety was determined by evaluating physical examination, vital signs, ECG, clinical laboratory parameters, and AEs.

[0523] If deemed necessary, additional safety measures were implemented at the discretion of the PI. Throughout the study, the Sponsor Medical Monitor was available for consultation on any potential safety issues.

[0524] Physical examination

[0525] Measure height (cm) and weight (kg).

[0526] Objective physical examination includes, at a minimum, assessment of the cardiovascular, respiratory, gastrointestinal, musculoskeletal, and neurologic systems. Height (at screening only) and weight are also measured and recorded. BMI is calculated at screening and clinical admission only. A licensed physician or qualified designee examines each participant. Physical examinations may be performed at various unscheduled time points if deemed necessary by the PI.

[0527] Any abnormal findings during the screening period were recorded as medical history.

[0528] The PI or qualified designee should note clinical signs associated with preexisting illness.

[0529] Vital signs

[0530] Participants' vital signs were measured in the supine position after 5 minutes of rest in a quiet environment free of distractions (e.g., television, mobile phones). Vital signs were collected after at least 10 minutes of rest, with the safety ECG coinciding with the time points of defined cardiodynamic ECG extraction. Signs included measurements of temperature (oral or tympanic), systolic and diastolic blood pressure, heart rate, and respiratory rate.

[0531] Blood pressure and heart rate measurements were assessed using automated devices. Manual techniques were used only when automated devices were unavailable. For blood pressure and heart rate, 3 readings were taken. The average of the three readings was used to determine the eligibility of the participant at screening.

[0532] Vital signs are measured on Day -1. For blood pressure and heart rate, three readings should be taken and recorded. The average of the three readings should be used to confirm compliance.

[0533] On Days 1 and 2, vital signs should be obtained within 30 minutes before dosing. Post-dose vital signs should be obtained within 30 minutes of designated time points in the activity schedule (i.e., 2, 4, 8, and 24 hours after dosing).

[0534] Vital signs will also be measured on the last day of study drug administration and at the SFU (see SoA). For blood pressure and heart rate, three readings should be taken and recorded.

[0535] Additional measurements should be performed if deemed necessary by the PI.

[0536] Electrocardiogram

[0537] For the study, ECGs were classified as either safety ECGs or cardiodynamic ECGs and were performed.

[0538] Standard 12-lead ECG (safety ECG)

[0539] A 12-lead ECG was performed. Timing and recording techniques for ECGs were standardized for all participants. All safety ECGs were obtained and recorded in triplicate after study drug administration on Day 1.

[0540] Holter monitoring (cardiodynamic ECG)

[0541] The timing and recording technique of the ECG were standardized for all participants who underwent cardiodynamic monitoring. Holter monitoring was performed on Days 1 and 14 to collect continuous 12-lead ECG data from 2 hours before dosing to 24 hours after dosing. During this period, ECG extraction was performed by a third-party vendor using data from the Holter monitor at defined time points that were usually paired with PK blood draws (except before dosing, for which cardiodynamic monitoring required 3 separate predose measurements at 60, 45, and 30 minutes before dosing).

[0542] Clinical safety laboratory evaluation

[0543] Clinical safety laboratory assessments were performed as summarized above.

[0544] The PI or qualified individual must review laboratory reports, document the review, and record any clinically relevant changes that occur during the study.

[0545] For values ​​considered to be clinically significant abnormal during study participation, laboratory testing should be repeated until the value returns to the participant's baseline or is no longer considered clinically significant by the PI.

[0546] If these values ​​do not return to normal / baseline within a period of time that is reasonable in the judgment of the PI, the cause should be investigated and the Sponsor notified.

[0547] Non-protocol-specified laboratory evaluations that require changes in participant management or that are deemed clinically significant by the PI (e.g., resulting in an AE) must also be documented in the CRF.

[0548] Drug-induced liver injury (DILI)

[0549] Events meeting the definition of drug-induced liver injury (DILI):

[0550] Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3X ULN and total bilirubin (TBL) > 2X ULN in the presence of normal alkaline phosphatase (ALP) requires immediate intensified monitoring (among all liver tests, at a minimum: ALT, AST, ALP, and TBL and prothrombin time (PT) / INR) and evaluation for the cause of the liver test abnormalities (FDA 2009).

[0551] ALT or AST > 3xULN, fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and / or eosinophilia (>5%) (FDA 2009).

[0552] The medical supervisor should be contacted immediately. Additional medical control considerations (for the specific participant and potentially for the broader group) should be discussed while the evaluation is ongoing.

[0553] The following adverse events of special concern need to be reported to the sponsor immediately. The PI should inform the sponsor within 24 hours of becoming aware of the following events.

[0554] >Grade 2 cytopenia

[0555] Platelet count less than 75,000 / mm3

[0556] WBC less than 3000 / mm3

[0557] Neutrophils less than 1500 / mm3

[0558] Lymphocytes less than 800 / mm3

[0559] Hemoglobin less than 10 g / dL

[0560] Creatine phosphokinase (CPK) elevation > Grade 3 [> 5X ULN]

[0561] Pharmacokinetic measurements

[0562] Approximately 5 mL of blood samples were collected for measuring plasma concentrations of Compound 1 and its metabolites.

[0563] The actual date and time (24 hour clock time) was recorded for each sample.

[0564] The samples were used to evaluate the PK of Compound 1. Each sample was divided into 2 aliquots (1 each for PK and backup). The samples collected for analysis of plasma concentrations may also be used to evaluate metabolite formation or safety aspects related to issues arising during or after the study.

[0565] Pharmacokinetic blood samples were collected as follows.

[0566] PK sampling

[0567]

[0568]

[0569] Urine samples were collected from all participants in Cohort 2 on Day 1, pre-dose, and on Day 14 as follows:

[0570]

[0571] Pharmacodynamics

[0572] As a measure of the pharmacodynamic response to treatment with Compound 1, approximately 1 mL of whole blood samples were collected directly from selected time points into the provided TruCulture (Myriad RBM) whole blood assay collection tubes. Collection was performed within a window of ±30 minutes at the designated time point. These samples were incubated in vitro at 37°C for approximately 24 hours in CRU, and the levels of IFNγ produced in response to cytokine stimulation in the cell supernatant were quantified using appropriate immunoassays.

[0573] Example 4: Phase 2b Study in Subjects with Plaque Psoriasis

[0574] This study is based on Figure 1 The study was conducted. About 250 subjects will be randomized in this study (about 50 subjects / group). The longest study duration for each subject is about 20 weeks, including a 30-day screening period, a 12-week treatment period, and a 4-week safety follow-up period. Compound 1 or placebo at a dose of 2mg, 5mg, 15mg or 30mg will be administered orally once a day (QD) for 12 weeks. Compound 1 will be available in 2mg, 5mg and 15mg strength capsules. Matching placebo will be consistent with compound 1, but will not contain active ingredients. Subjects will be randomized at a 1:1:1:1:1 ratio.

[0575]

[0576]

[0577]

[0578]

[0579]

[0580] The main objectives are:

[0581] To evaluate the efficacy of 2 mg, 5 mg, 15 mg or 30 mg of Compound 1 administered orally QD for 12 weeks in subjects with moderate to severe plaque psoriasis

[0582] Secondary objectives are:

[0583] To evaluate the safety and tolerability of 2 mg, 5 mg, 15 mg or 30 mg of Compound 1 administered orally QD for 12 weeks in subjects with moderate to severe plaque psoriasis

[0584] Evaluation of plasma concentrations of 2 mg, 5 mg, 15 mg or 30 mg of Compound 1 administered orally QD in subjects with moderate to severe plaque psoriasis

[0585] The exploratory objectives are:

[0586] To evaluate the effect of Compound 1 on joint pain in subjects with moderate to severe plaque psoriasis and concomitant psoriatic arthritis

[0587] To evaluate the effect of Compound 1 on cytokines and other inflammatory biomarkers in the blood of subjects with moderate to severe plaque psoriasis

[0588] end:

[0589] Primary efficacy endpoint:

[0590] Proportion of subjects achieving at least 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 12

[0591] Secondary efficacy endpoints:

[0592] Proportion of subjects achieving a Physician Global Assessment (PGA) of clear (0) or almost clear (1) at Week 12

[0593] Proportion of subjects achieving at least 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI-90) at Week 12

[0594] Proportion of subjects achieving 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI-100) at Week 12

[0595] Change from baseline in Dermatology Life Quality Index (DLQI) at Week 12 Exploratory efficacy endpoint:

[0596] Proportion of subjects achieving at least 50% improvement from baseline in the Psoriasis Area and Severity Index (PASI-50) at Weeks 2, 4, 8, and 12

[0597] Proportion of subjects achieving PASI-75 at Weeks 2, 4, and 8

[0598] Proportion of subjects achieving PASI-90 at Weeks 2, 4, and 8

[0599] Proportion of subjects achieving PASI-100 at Weeks 2, 4, and 8

[0600] Change from baseline in Psoriasis Area and Severity Index (PASI) at Weeks 2, 4, 8, and 12

[0601] Percent change from baseline in PASI at weeks 2, 4, 8, and 12

[0602] Change from baseline in PGA at weeks 2, 4, 8, and 12

[0603] Proportion of subjects achieving a PGA of clear (0) or almost clear (1) at Weeks 2, 4, and 8

[0604] Proportion of subjects with a PGA reduction of at least 2 grades from baseline at Weeks 2, 4, 8, and 12

[0605] Change from baseline in body surface area (BSA) at weeks 2, 4, 8, and 12

[0606] Change from baseline in the Itch Numerical Rating Scale (NRS) at Weeks 2, 4, 8, and 12

[0607] Proportion of subjects with a baseline pruritus NRS of 4 or greater who achieved a reduction of at least 4 points from baseline in the pruritus NRS at Weeks 2, 4, 8, and 12

[0608] Change from baseline in Dermatology Life Quality Index (DLQI) at Weeks 4 and 8

[0609] Change from baseline in pain NRS at Weeks 2, 4, 8, and 12 in subjects with concomitant psoriatic arthritis

[0610] Secondary safety endpoints:

[0611] The incidence of adverse events (AEs)

[0612] Changes in vital signs, clinical laboratory parameters, and electrocardiogram (ECG)

[0613] Secondary pharmacokinetic (PK) endpoints:

[0614] 1. Measure plasma concentrations of Compound 1 in subjects receiving active treatment Exploratory pharmacodynamic (PD) endpoints:

[0615] 2. Quantification of skin biomarkers (immune cell infiltration and mRNA expression levels) in lesional and non-lesional skin

[0616] 3. Quantification of circulating cytokines and other inflammatory biomarkers

[0617] Study Design: This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of Compound 1 in subjects with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentration of Compound 1 and explore the immune response (in the blood and skin) to Compound 1 in subjects with moderate to severe plaque psoriasis. Approximately 250 male and female subjects aged 18 to 70 years (including end values) with moderate to severe plaque psoriasis will be randomized in this study. To be eligible for the study, subjects will need to have a history of plaque psoriasis for at least 6 months prior to the screening visit. In addition, subjects will need to have the following characteristics at screening and on Day 1: PASI score of at least 12, PGA score of at least 3, and BSA involved in plaque psoriasis of at least 10%.

[0618] Before implementing any screening procedures, all subjects will read and sign the informed consent form (ICF). Subjects who meet all inclusion criteria and do not meet any exclusion criteria will be included in this study. During the screening period not exceeding the -30th day to the -1st day, subjects will be randomized (at the -7th day) to receive any one of four doses of compound 1 (2mg, 5mg, 15mg or 30mg) or placebo on the 1st day. The goal is to have about 50 subjects (1:1:1:1:1 ratio) randomized in each treatment group on the 1st day. During the treatment period, compound 1 (2mg, 5mg, 15mg or 30mg) or placebo will be administered orally QD for 12 weeks. After the 12-week treatment period, it will be a 4-week safety follow-up period. For planned research visits, subjects will come to the research site in 8 cases: screening, day 1 and week 1, week 2, week 4, week 8, week 12 (end of treatment [EOT]) and week 16 (end of study [EOS] / early termination visit [ET]). For subjects with concomitant psoriatic arthritis, efficacy will be assessed using the PASI, PGA, BSA of plaque psoriasis involvement, pruritus NRS, and pain NRS. Quality of life will be assessed using the DLQI. Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECG results.

[0619] Blood samples will be collected to measure plasma levels of Compound 1 as follows:

[0620] Before and 1 hour (± 5 minutes) after dosing on Day 1;

[0621] Before dosing, 1 hour (±5 minutes), and 4 hours (±10 minutes) after dosing in Week 4;

[0622] Before dosing at week 8;

[0623] - At any time during Week 12 (no study treatment was administered at this visit).

[0624] At any time during the ET Visit (if the ET Visit is scheduled before the Week 12 Visit).

[0625] Urine samples will be collected on day 1 and at weeks 4, 12, and 16 and can be used to evaluate the effect of compound 1 on exploratory biomarkers. Blood samples will be collected on day 1 and at weeks 4 and 12 to evaluate the effect of compound 1 on circulating inflammatory biomarkers. In the subject subgroup that agrees to the procedure, the effect of compound 1 on skin biomarkers will be evaluated by collecting three or four optional skin biopsies. Two 5-mm punch biopsies will be collected on day 1 (one from lesional skin and one from adjacent non-lesional skin), and one 5-mm punch biopsy will be collected from the same lesional skin at week 12 (outside the scar of the previous biopsy, at least 1 cm from the previous scar, even if the lesion has been cleared). In addition, at week 4, in subjects who agree to undergo four skin biopsies, a 5-mm punch biopsy will be collected from the same lesional skin (outside the scar of the previous biopsy, at least 1 cm from the previous scar). The biopsy area will be photographed.

[0626] In a subset of subjects who consent to the procedure, the effect of Compound 1 on skin biomarkers will be evaluated by collecting tape strips. Skin tape strips will be collected from lesional skin and from adjacent non-lesional skin at Day 1, and from the same lesional skin at Week 12. At certain study sites, in a subset of consenting subjects, full body, frontal and back medical photography will optionally be performed to illustrate the study results.

[0627] Inclusion / Exclusion Criteria: To be eligible for participation in this study, subjects must meet all of the following criteria at both the Screening and Day 1 visits or only at one of the designated visits (Screening or Day 1) as noted in the criteria:

[0628] Male or female subjects aged 18 to 70 years (inclusive) at the time of consent.

[0629] • Subjects had a history of plaque psoriasis for at least 6 months prior to the screening visit.

[0630] - Subjects had no significant flare-up of psoriasis for at least 3 months prior to screening (information obtained from medical records or the subject's physician, or directly from the subject).

[0631] - Subjects had moderate to severe plaque psoriasis at Screening and Day 1, defined as a PASI score of at least 12 and a PGA score of at least 3.

[0632] - Subjects had plaque psoriasis covering 10% of their total BSA at Screening and Day 1.

[0633] · Subjects must be candidates for phototherapy or systemic therapy.

[0634] For female subjects of childbearing potential who engage in any sexual intercourse that could result in pregnancy: Subjects must agree to use a highly effective method of contraception for at least 4 weeks prior to Day 1 and for at least 4 weeks after the last study product administration. Highly effective methods of contraception include hormonal contraceptives (e.g., combined oral contraceptives, patches, vaginal rings, injectables, or implants), intrauterine devices or intrauterine systems, partners with vasectomy (provided that vasectomy was performed at least 4 months prior to screening), bilateral tubal ligation or occlusion, or double barrier contraceptive methods combined with spermicide (e.g., male condoms with cervical caps, male condoms with diaphragms, and male condoms with contraceptive sponges). Note: Subjects must have been taking a stable dose of hormonal contraceptives for at least 4 weeks prior to Day 1. Note: The above list of contraceptive methods does not apply to subjects who have abstained from sexual intercourse for at least 4 weeks prior to Day 1 and will continue to abstain from penile-vaginal intercourse throughout the study. The reliability of abstinence needs to be evaluated for the duration of the clinical study and the subject's preferred and usual lifestyle. Periodic abstinence (calendar method, body temperature method, post-ovulation method) is unacceptable. Note: Female subjects of no childbearing potential are defined as follows:

[0635] - Female subjects who have undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy);

[0636] - Female subjects who have been amenorrhea for at least 12 months prior to the Screening Visit and have been shown to be non-fertile as determined by follicle stimulating hormone (FSH) testing (reference laboratory reference range for confirmed levels), in the absence of other medical reasons.

[0637] Female subjects of childbearing potential with a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1.

[0638] For male subjects who engage in any sexual intercourse that could result in pregnancy, the subject must agree to use one of the highly effective contraceptive methods listed in Inclusion Criteria 6 from Day 1 until at least 12 weeks after the last study product administration. If the female partner of the male subject uses any of the hormonal contraceptive methods listed above, the female partner should use this contraceptive method from at least 4 weeks before Day 1 until at least 12 weeks after the last study product administration.

[0639] NOTE: Male subjects must refrain from sperm donation from Day 1 until at least 12 weeks after the last dose of study product.

[0640] NOTE: No restrictions are required for male subjects who have undergone a vasectomy at least 4 months prior to screening and have the procedure documented. If the vasectomy procedure is not documented or was performed less than 4 months prior to screening, male subjects must follow the same contraception and sperm donation requirements as non-vasectomized subjects.

[0641] Subjects with a body mass index (BMI) between 18 and 38 kg / m 2 Within the range, including the end value, (BMI = weight [kg] / [height (m)] 2 ) and total body weight >50kg (110lb).

[0642] · The subject is willing to participate and able to give informed consent. Note: Consent must be obtained prior to any research-related procedures.

[0643] · Subjects must be willing to comply with all study procedures and must be available for the duration of the study.

[0644] Exclusion Criteria: Subjects meeting any of the following criteria (if applicable) at Screening and / or Day 1 Visit will be excluded from participation in this study:

[0645] 1. Female subjects who are breastfeeding, pregnant or planning to become pregnant during the study.

[0646] 2. Subjects with evidence of erythrodermic, pustular, guttate-dominant psoriasis or drug-induced psoriasis.

[0647] 3. Subjects with a history of skin disease or skin diseases that the investigator believes will interfere with the study assessment.

[0648] 4. Subjects with immune-mediated conditions commonly associated with psoriasis (such as psoriatic arthritis, uveitis, inflammatory bowel disease) that require systemic therapy including corticosteroids, immunosuppressants, or biologics.

[0649] NOTE: Subjects with immune-mediated disorders that do not require systemic therapy may be included in this study. Certain therapies (such as NSAIDs) may be permitted but should be discussed with the Medical Supervisor prior to determining subject eligibility.

[0650] 5. Subjects with any clinically significant medical illness, evidence of unstable clinical pathology (e.g., cardiovascular, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, immune, or locally active infection / infectious disease), psychiatric illness, or vital sign / physical / laboratory / ECG abnormalities that, in the opinion of the investigator, would place the subject at unnecessary risk or interfere with the interpretation of study results.

[0651] 6. Subjects who have undergone major surgery within 8 weeks prior to Day 1 or are scheduled to undergo major surgery during the study.

[0652] 7. Subjects with a history of Class III or IV congestive heart failure as defined by the New York Heart Association Criteria.

[0653] 8. Subjects who have been hospitalized for asthma in the past 3 months, have required intubation for asthma, currently require oral corticosteroids for asthma, or have required more than one short-term (≤2 weeks) course of oral corticosteroids for asthma in the 6 months prior to Day 1.

[0654] 9. Subjects with a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated non-metastatic squamous cell carcinoma or basal cell carcinoma of the skin and / or localized carcinoma in situ of the cervix are not excluded.

[0655] 10. Subjects with a history of fever, inflammation, or signs of systemic illness suggestive of systemic or invasive infection within the 4 weeks prior to Day 1.

[0656] 11. Subjects with active bacterial, viral, fungal, mycobacterial, or other infections (including TB or atypical mycobacterial disease), or any major infectious episode requiring hospitalization or treatment with intravenous antibiotics within the 12 weeks prior to Day 1, or requiring oral antibiotics within the 4 weeks prior to Day 1.

[0657] 12. Subjects with a history of chronic or recurrent infectious diseases, including but not limited to chronic kidney infection, chronic chest infection, recurrent urinary tract infection, fungal infection (except superficial fungal infection of the nail bed), or infected skin wounds or ulcers.

[0658] 13. Subjects with a history of prosthetic joint infection or receiving antibiotics for suspected prosthetic joint infection (if the prosthesis has not been removed or replaced).

[0659] 14. Subjects with active herpes infection, including herpes simplex type 1 and 2 and herpes zoster (as demonstrated on physical examination and / or medical history) within 8 weeks prior to Day 1.

[0660] 15. Subjects with a known or suspected history of congenital or acquired immunodeficiency states or conditions that, in the investigator's opinion, would compromise the subject's immune status (e.g., splenectomy, history of primary immunodeficiency).

[0661] 16. Subjects with positive results for hepatitis B surface antigen (HBsAg), antibodies against hepatitis B core antigen (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

[0662] 17. Subjects with clinical or laboratory evidence of active or latent tuberculosis (TB) infection at screening. Note: Subjects with a history of active or latent TB will not be included in this study unless a previous and complete record of anti-TB treatment is available, with appropriate duration and type of treatment according to current local national guidelines. Note: Subjects will be evaluated for latent TB infection using the QuantiFERON-TB Gold (QFT) test at screening. Latent TB is defined as a positive QFT test at screening or two consecutive indeterminate QFT tests.

[0663] 18. Subjects with any of the following laboratory values ​​at the Screening Visit:

[0664] Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values ​​≥ 3 times the upper limit of normal (ULN);

[0665] Hemoglobin <11.0 g / dL (<110.0 g / L);

[0666] White blood cell count <3.5 × 10 9 / L(<3500 / mm 3 );

[0667] Absolute neutrophil count <1.8 × 10 9 / L(<1800 / mm 3 );

[0668] Absolute lymphocyte count <1.0 × 10 9 / L(<1000 / mm 3 );

[0669] Platelet count <100 × 10 9 / L(<100,000 / mm 3 );

[0670] Total bilirubin > 2 times ULN.

[0671] 19. Subjects who donated >50 ml of blood or plasma within 30 days of screening or >500 mL of blood or plasma within 56 days of screening (during clinical studies or at a blood bank).

[0672] 20. Subjects who used any topical agents that may affect psoriasis (including corticosteroids, retinoids, vitamin D analogs [such as calcipotriol], JAK inhibitors, or tars) within 2 weeks prior to Day 1.

[0673] 21. Subjects who have used any systemic treatment that could affect psoriasis (including oral, intravenous, intramuscular, or intralesional corticosteroids; oral retinoids; immunosuppressive / immunomodulatory agents; methotrexate; cyclosporine; oral JAK inhibitors; or apremilast) within 4 weeks prior to Day 1. Note: Intranasal corticosteroids and inhaled corticosteroids are permitted. Eye drops and ear drops containing corticosteroids are also permitted.

[0674] 22. Subjects who received any ultraviolet (UV)-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.

[0675] 23. Subjects treated with psoralen and ultraviolet A (PUVA) within 4 weeks prior to Day 1.

[0676] 24. Subjects who have received any live attenuated vaccine within 4 weeks prior to Day 1 or plan to receive a live attenuated vaccine during the study and until 4 weeks after the last administration of the investigational product or 5 half-lives of the investigational product, whichever is longer. NOTE: Non-live attenuated vaccines for coronavirus disease 2019 (COVID-19) (e.g., RNA-based vaccines, inactivated adenovirus-based vaccines, protein-based vaccines) are permitted during the study. Study sites should follow local guidelines related to COVID-19.

[0677] 25. Subjects currently receiving a non-biologic investigational product or device or who have received one within the 4 weeks prior to Day 1.

[0678] 26. Subjects who have received any commercially available or investigational biologic within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1 (except those subjects listed in Exclusion Criteria 27 and 28, for whom the exclusion period is 6 months).

[0679] 27. Subjects previously enrolled in any study of Compound 1.

[0680] 28. Subjects with a history of lack of response to any therapeutic agent targeting interleukin (IL)-12, IL-17, and / or IL-23 (e.g., ustekinumab, secukinumab, ixekizumab, berdalumab, guselkumab, tetracycline, russezumab) after at least 12 weeks of treatment at the approved dose and / or received one of these therapies within 6 months prior to Day 1.

[0681] 29. Subjects who have received rituximab or other immune cell depleting therapies within 6 months.

[0682] 30. Subjects who are currently being treated with a strong or moderate cytochrome P450 3A (CYP3A4) inhibitor (such as itraconazole) or have received a moderate or strong CYP3A4 inhibitor within 4 weeks prior to Day 1.

[0683] 31. Subjects currently being treated with terbinafine or who have received terbinafine within 4 weeks prior to Day 1.

[0684] 32. Subjects who consumed grapefruit within 1 week prior to Day 1.

[0685] Note: Grapefruit must be avoided during the treatment period and for at least 1 week after the last dose.

[0686] 33. Subjects who have used a tanning room in the 4 weeks prior to Day 1, have been overexposed to the sun, or are unwilling to minimize exposure to natural and artificial sunlight during the study. Note: When sun exposure cannot be avoided, the use of sunscreen products and protective clothing is recommended.

[0687] 34. Subjects with known or suspected hypersensitivity to Compound 1 or any component of the investigational product, or with any other significant drug hypersensitivity (such as anaphylaxis or hepatotoxicity).

[0688] 35. Subjects with a known history of clinically significant drug or alcohol abuse within the previous year prior to Day 1.

[0689] 36. For subjects who consent only to biopsy collection:

[0690] Subjects with a history of allergic reaction or significant sensitivity to lidocaine or other local anesthetics.

[0691] Subjects with a history of hypertrophic scarring or keloid formation at scar or suture sites.

[0692] - Subjects who have taken anticoagulants (such as heparin, low molecular weight (LMW) heparin, warfarin, or antiplatelet agents) (except low-dose aspirin ≤ 81 mg, which will be permitted) within 2 weeks prior to Day 1 or have a contraindication to skin biopsy. Nonsteroidal anti-inflammatory drugs will not be considered antiplatelet agents and will be permitted.

[0693] Categorical variables will be presented in tables as frequencies and percentages. Continuous variables will be summarized in tables and will include the number of subjects, mean, standard deviation (SD), median, minimum and maximum values. Other details on efficacy and safety variable definitions, analysis strategies, statistical rationality and techniques for handling missing values ​​(if applicable) will be detailed in a separate statistical analysis plan (SAP), which will be formulated before the database is locked and any analysis is performed. Any deviation from the SAP will be appropriately described and justified in the final clinical study report.

[0694] Unless otherwise specified in the SAP, all statistical tests will be two-sided and will be performed at a significance level of 0.05. No adjustment will be made to account for multiple testing between treatment groups.

[0695] Efficacy Analysis: The primary endpoint can be interpreted as a responder analysis, where subjects are classified as responders if they achieve PASI-75 at Week 12. Intergroup comparisons of the primary endpoint will be performed using Cochran-Mantel-Haenszel (CMH), including prior treatment with biologics as a stratification factor. The primary efficacy analysis will be performed on the intent-to-treat (ITT) analysis set, while the per-protocol (PP) analysis set will be used as a sensitivity analysis.

[0696] At each time point and based on the ITT analysis, secondary endpoints involving the proportion of subjects will be analyzed using the same method as described for the primary efficacy analysis (CMH test). Continuous secondary endpoints involving absolute changes from baseline will be analyzed using a mixed effects model repeated measures method (MMRM) based only on the ITT analysis set. The model will include treatment, visit, communication during visit treatment, and previous biologic treatment as fixed effects, and baseline score as a covariate.

[0697] Safety Analysis: All safety analyses will be performed using the safety analysis set. No inferential statistics will be performed on safety variables. Adverse events and serious adverse events (SAEs) will be presented and tabulated by treatment group according to the Medical Dictionary for Regulatory Activities (MedDrA) classification. Description of the AE will include the start date, end date (if it resolves), the severity and severity of the AE, the causal relationship of the AE to the study product, actions taken with respect to the study product, and the outcome.

[0698] Reported AEs will be summarized by the number of subjects reporting the event and by system organ class, priority category, verbatim severity reported, severity, and investigator's assessment of relationship to investigational product. For AEs summarized by severity, each subject will be counted only once in a system organ class or priority category by using the AE with the highest intensity in each category for each analysis. For AEs summarized by relationship to investigational product, each subject will be counted only once in a system organ class or priority category by using the AE with the greatest reported relationship within each category. For AEs summarized by relationship to investigational product and severity, each subject will be counted only once in a system organ class or priority category by using (1) the greatest reported relationship, followed by (2) the highest reported intensity.

[0699] All information recorded during the study regarding AEs will be listed by treatment group, subject, verbatim description, system organ class, priority, start date, end date, intensity, outcome, actions taken regarding the study product, and relationship to the study product. AE onset will also be displayed relative to the day of study product administration (in days). Serious adverse events will be tabulated by treatment group, relationship to the test article, and reference to the relative dosing day on which the SAE occurred. Similar listings will be provided for SAEs and AEs that led to study discontinuation.

[0700] Results from vital signs, laboratory analyses, and ECGs will be tabulated by treatment group and visit using descriptive statistics. Observed values ​​at each visit will be presented, as well as changes from baseline. Conversion tables describing deviations from normal ranges will be provided for clinical laboratory results, and normal-abnormal conversion tables may be provided for vital signs.

[0701] Concomitant medications will be coded in the World Health Organization-Drug Dictionary (WHO-DD) and listed by subject. A summary of medications will also be tabulated.

[0702] Pharmacokinetic Analysis: Concentration data will be presented for each subject and summarized descriptively for each dose.

[0703] Pharmacodynamic Analysis: Analysis of urine, blood, and skin biomarker levels will be described in a separate analysis plan.

[0704] Other Analyses: A descriptive summary of subject disposition and baseline characteristics (including demographics and prior concomitant therapy) will be presented by treatment group. In addition, a list of subjects who discontinued the study will be provided along with the reasons for discontinuation. Protocol deviations will be summarized by treatment and category.

[0705] Sample size considerations: The sample size was determined based on a 2-sided test of the equality of two independent response rates using a significance level of α = 0.05 and a power of 85%. The formula used to calculate The formula used in is the same as that used in (i.e., the normal approximation using Fleiss's formula and continuity correction).

[0706] Assuming a 10% placebo response rate (proportion of subjects achieving PASI-75) at the end of Week 12, at least one Compound 1 dose treatment group will have a response rate of at least 40%, and after adjusting for a 15% withdrawal rate, a total of 250 subjects (50 per treatment group) will be randomized in this study. Fifty subjects per treatment group will provide at least about 90% power to detect at least a 30% difference in PASI-75 response rate between any two treatment groups under a 1-sided 2-sample Fisher's exact test at a significance level of 0.05.

[0707] Results: Baseline Characteristics. The demographics of the study subjects and the baseline disease characteristics of the subjects are presented in the following table:

[0708]

[0709]

[0710] BMI, body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; QD, once daily; SD, standard deviation

[0711] Results: Compound 1 at doses ≥5 mg achieved the primary endpoint (PASI 75 response at week 12). 68% of patients taking Compound 1 15 mg QD and 67% of patients taking 30 mg QD achieved PASI 75. Compound 1 at doses ≥5 mg also achieved secondary endpoints: at the highest dose of Compound 1, a greater proportion of patients achieved PASI 100 or PGA 0, and at 30 mg QD dosing, 33% of patients achieved clear skin. More detailed results for the primary endpoint (PASI 75 at week 12) in the modified intent to treat (mITT) analysis set are shown in the table below. The results are presented in graphical form at Fig.13 middle. Fig.14 A graph illustrating the percentage of patients achieving a PASI score of 75, 90, or 100 is shown in FIG.

[0712]

[0713] *Number of patients (percentage)

[0714] Adjusted odds ratio using Cochran-Mantel-Haenszel statistic

[0715] p values ​​from the Cochran-Mantel-Haenszel test comparing the proportion of patients in the treatment group to placebo, with prior biologic therapy included as a stratification factor.

[0716] Modified Intent-to-Treat (mITT) Analysis Set: All subjects who were randomized and received at least one dose of study treatment

[0717] CI, confidence interval; QD, once daily

[0718] exist Fig.15 , the fraction of patients achieving PGA 0 / 1 at week 12 is shown. The fractions of both PGA 1 and PGA 0 increased with increasing doses of Compound 1. Fig.16A showing the mean Dermatology Life Quality Index (DLQI) scores at baseline and 12 weeks for placebo and different dose levels of Compound 1; and Fig. 16B Shown is the change from baseline in DLQI at Week 12.

[0719] The safety results are summarized in the following tables.

[0720] Security Summary

[0721]

[0722] *Adverse events leading to drug interruption and premature discontinuation in 5 subjects included:

[0723] Increased CPK (30 mg)

[0724] Pericardial effusion and pleural effusion (15 mg)

[0725] Tachycardia and syncope (5 mg)

[0726] Decreased lymphocyte count (2 mg)

[0727] Atrial fibrillation (placebo)

[0728] One additional subject (30 mg) permanently discontinued study drug due to a hypertensive emergency AE but remained in the study.

[0729] Number of patients (percentage), data rounded up to the nearest integer

[0730] *No patients were discontinued due to COVID-19.

[0731] AEs were reported in ≥3 patients in any treatment group (events triggered by laboratory tests were not included).

[0732] Common Terminology Criteria for Grade ≥3 Adverse Events

[0733]

[0734] a For post hoc analysis, percentages are rounded up to the nearest whole number

[0735] b Occurred during treatment and increased by ≥1 grade from baseline

[0736] ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine kinase; CTCAE, Common Terminology Criteria for Adverse Events; QD, once daily; Wk, weekly

[0737] Figure 17A-17E Hematology parameters and CPK data collected during the study are shown. Data are mean ± standard deviation. Mean laboratory values ​​and changes from baseline do not disclose an adverse trend in cell counts. CPK showed some variability at 15 mg and 30 mg, with larger error bars.

[0738] Figure 18A-18E Liver and renal parameters collected during the study are shown. Data are mean ± standard deviation. Mean laboratory values ​​and changes from baseline did not reveal adverse trends in liver enzymes, creatinine, or eGFR.

[0739] Figure 19A-19E Lipid parameters collected during the study are shown. Data are mean ± standard deviation. Mean laboratory values ​​and changes from baseline did not reveal adverse trends in cholesterol, HDL or LDL. Triglyceride increases were minimal.

[0740] Example 5: A Phase 2b, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of Compound 1 in Subjects with Active Psoriatic Arthritis

[0741] Study Location:

[0742] Approximately 80 global research sites in North America and Europe will participate in this study.

[0743] Number of subjects (planned):

[0744] Approximately 260 subjects will be randomized in this study (approximately 65 subjects / group).

[0745] Duration of the study:

[0746] The maximum study duration for each subject was approximately 20 weeks, including a 30-day screening period, a 12-week treatment period, and a 4-week safety follow-up period.

[0747] Investigational Product, Dosage, and Mode of Administration:

[0748] Compound 1 or placebo will be administered orally once daily (QD) at doses of 5 mg, 15 mg, 30 mg for 12 weeks. Compound 1 will be available in 5 mg and 15 mg strength capsules. Matching placebo will be identical to Compound 1 but will not contain the active ingredient.

[0749] Subjects will be randomized in a 1:1:1:1 ratio.

[0750] Target:

[0751] The main objectives are:

[0752] • To evaluate the efficacy of Compound 1 administered orally at 5 mg, 15 mg or 30 mg QD for 12 weeks on rheumatological signs, symptoms and function in subjects with active psoriatic arthritis (PsA).

[0753] Secondary objectives are:

[0754] To evaluate the efficacy of 5 mg, 15 mg, or 30 mg of Compound 1 administered orally QD for 12 weeks in subjects with active PsA

[0755] To evaluate the safety and tolerability of 5 mg, 15 mg, or 30 mg of Compound 1 administered orally QD for 12 weeks in subjects with active PsA

[0756] To evaluate the plasma concentrations of 5 mg, 15 mg or 30 mg of Compound 1 administered orally QD in subjects with active PsA

[0757] The exploratory objectives are:

[0758] • Evaluate the effect of Compound 1 on cytokines and other inflammatory biomarkers in the blood of subjects with active PsA.

[0759] end:

[0760] Primary efficacy endpoint:

[0761] Proportion of subjects achieving at least an American College of Rheumatology (ACR) 20 response at Week 12

[0762] Secondary endpoints - efficacy:

[0763] Proportion of subjects achieving at least an ACR 50 or ACR 70 response at Week 12

[0764] Change in tender joint count from baseline (Day 1) at Week 12

[0765] Change in swollen joint count from baseline (Day 1) at Week 12

[0766] Change from baseline (Day 1) in Patient Global Assessment of Psoriatic Arthritis at Week 12

[0767] Change from baseline (Day 1) in patient global assessment of psoriatic arthritis pain at Week 12

[0768] Change from baseline (Day 1) in physician global assessment of psoriatic arthritis at Week 12

[0769] Change from baseline (Day 1) in Health Assessment Questionnaire-Disability Index (HAQ-DI) scores at Week 12

[0770] Change from baseline (Day 1) in dactylitis counts at Week 12 among subjects with dactylitis on Day 1

[0771] Change from baseline (Day 1) in the Lee Enthesitis Index at Week 12 in subjects with enthesitis on Day 1

[0772] Proportion of subjects with minimal disease activity at Week 12

[0773] Change from baseline (Day 1) in the Psoriatic Arthritis Disease Activity Index at Week 12

[0774] Proportion of subjects with psoriasis affecting ≥3% body surface area (BSA) at Day 1 who achieved a Psoriasis Area Severity Index (PASI)-75 at Week 12

[0775] Proportion of subjects achieving a static physician global assessment of 0 or 1 and at least a 2-point improvement from baseline at Week 12

[0776] Secondary endpoint - safety:

[0777] The incidence of adverse events (AEs), treatment-emergent AEs (TEAEs), treatment-emergent serious adverse events (TESAEs), and TESAEs leading to study drug discontinuation

[0778] To assess vital signs, clinical laboratory parameters, the proportion of subjects with clinically significant abnormal electrocardiograms (ECGs), and clinically relevant changes on physical examination

[0779] Secondary endpoints - pharmacokinetics:

[0780] Plasma concentrations of Compound 1 were measured in subjects who received 5 mg, 15 mg, or 30 mg of Compound 1

[0781] Exploratory endpoints:

[0782] Quantification of circulating cytokines and other inflammatory biomarkers

[0783] Change from baseline (Day 1) in the 36-item Short-Form Health Survey at Week 12

[0784] Change from baseline (Day 1) in Functional Assessment of Chronic Disease-Fatigue at Week 12

[0785] Change from baseline (Day 1) in the 28-joint disease activity score using high-sensitivity C-reactive protein (hsCRP) at Week 12

[0786] Change from baseline (Day 1) in Psoriasis Disease Activity Score at Week 12

[0787] Change from baseline (Day 1) in psoriatic arthritis response criteria at Week 12

[0788] Percent change from baseline (Day 1) in PASI at Week 12 in subjects with psoriasis involving ≥3% BSA at Day 1

[0789] Change from baseline (Day 1) in BSA affected by psoriasis at Week 12 in subjects with psoriasis affecting ≥3% of BSA at Day 1

[0790] Change from baseline (Day 1) in physician global assessment of psoriasis at Week 12

[0791] Study Design

[0792] This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of Compound 1 in subjects with active PsA. The plasma concentration of Compound 1 will also be evaluated in subjects with active PsA treated with Compound 1 and the pharmacodynamic changes in the levels of inflammatory cytokines in the blood will be explored.

[0793] Approximately 260 male and female subjects with active PsA and aged 18 to 70 years (inclusive) will be randomized in this study. To be eligible for the study, subjects must have a history of PsA diagnosis and symptoms persisting for ≥6 months prior to the screening visit and must meet all inclusion criteria, including Classification Criteria for Psoriatic Arthritis (CASPAR) criteria, ≥3 tender and ≥3 swollen joints at the screening and baseline (Day 1) visits, and active PsA despite prior therapy with nonsteroidal anti-inflammatory drugs (NSAIDs), traditional disease-modifying antirheumatic drugs (DMARDs), or a tumor necrosis factor inhibitor (TNFi).

[0794] Before implementing any screening procedure, all subjects will read and sign a written informed consent (ICF). Subjects who meet all inclusion criteria and do not meet any exclusion criteria will be included in this study. During the screening period of no more than 30 days, subjects will be randomized (at -7 days) to receive any one of three doses of compound 1 (5mg, 15mg or 30mg) or placebo on the 1st day. The goal is to have about 65 subjects (1:1:1:1 ratio) for each treatment group randomization. During the treatment period, QD oral administration of compound 1 (5mg, 15mg or 30mg) or placebo will continue for 12 weeks. After the 12-week treatment period, it will be a 4-week safety follow-up period.

[0795] For scheduled study visits, subjects will come to the study site on 8 occasions: Screening, Day 1, and Weeks 1, 2, 4, 8, 12 (End of Treatment / Early Termination Visit), and 16 (End of Study [EOS]).

[0796] Efficacy will be assessed using the ACR20 composite measure (including tender and swollen joint counts, subject assessment of PsA pain visual analog scale [VAS], subject global PsA assessment VAS, physician global assessment PsA VAS, HAQ-DI, and hsCRP) as well as individual components. Efficacy against psoriasis in subjects with ≥3% BSA accumulation on Day 1 will be measured using PASI, BSA, and physician global assessment.

[0797] Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECG results.

[0798] Blood samples will be collected to measure Compound 1 plasma concentrations.

[0799] Blood samples will also be collected to evaluate the effects of Compound 1 on circulating inflammatory biomarkers.

[0800] Before and 1 hour (±5 minutes) after dosing on Day 1 (Visit 2)

[0801] Before dosing, 1 hour (±5 minutes), and 4 hours (±10 minutes) after dosing at Week 4 (Visit 5)

[0802] Before dosing at Week 8 (Visit 6)

[0803] Any time after Week 12 (Visit 7) when study drug administration is completed, or after ET, whenever possible

[0804] Blood samples will also be collected on Day 1 and at Weeks 4 and 12 or at ET (whenever possible) to evaluate the effects of Compound 1 on circulating inflammatory biomarkers.

[0805] No interim analysis was planned for this study.

[0806] Inclusion criteria:

[0807] To be eligible for participation in this study, subjects must meet all of the following criteria at both the Screening and Day 1 visits or only at one of the designated visits (Screening or Day 1) as noted in the criteria:

[0808] 1. Subjects were male or female, aged 18 to 70 years (inclusive), at the time of consent.

[0809] 2. The subject has PsA based on CASPAR and peripheral symptoms at the screening visit as assessed by the investigator.

[0810] 3. Subjects had PsA symptoms for ≥ 6 months before screening as assessed by the investigator.

[0811] 4. Subjects had ≥3 tender joints and ≥3 swollen joints at Screening and Day 1 Visits as assessed by the Investigator.

[0812] 5. The subject has at least one plaque psoriasis lesion with a diameter ≥ 2 cm, nail changes specific to psoriasis, or a history of plaque psoriasis.

[0813] 6. Subjects still have active PsA as assessed by the investigator despite previous administration of standard doses of NSAIDs for ≥4 weeks, or traditional DMARDs (including methotrexate and sulfasalazine) for ≥3 months, or TNFi for ≥3 months, or the subject is intolerant to NSAIDs, DMARDs or TNFi.

[0814] 7. If subjects are taking concomitant PsA therapy, they must maintain a stable dose for the duration of the study as follows:

[0815] a. Methotrexate (MTX): Subjects must have been receiving treatment for ≥3 months prior to Day 1, with a stable dose and stable route of administration (not to exceed 25 mg MTX per week) for ≥4 weeks until Week 16 (EOS); subjects taking MTX should take folic acid supplements according to local standards of care to minimize the potential for MTX-related toxicity.

[0816] b. Sulfasalazine: Maximum dose is 3 gm / day. Minimum duration of therapy is 2 months with 4 weeks of stable dose prior to Day 1.

[0817] c. Other traditional DMARDs not listed may be considered on a case-by-case basis after discussion with the medical supervisor.

[0818] d. Oral corticosteroids: Subjects must be taking a stable dose, no more than 10 mg of prednisone equivalent per day, for ≥2 weeks prior to Day 1. If the subject is not currently using oral corticosteroids, they must not have received them for at least 2 weeks prior to Day 1.

[0819] e. NSAIDs or acetaminophen / acetaminophen as needed: Subjects must have been taking a stable dose for ≥2 weeks prior to Day 1. If not currently using an NSAID, they must not have received one for at least 2 weeks prior to Day 1.

[0820] 8. For female subjects of childbearing potential who engage in any sexual intercourse that could result in pregnancy: Subjects must agree to use highly effective contraceptive methods from screening until at least 4 weeks after the last study drug administration. Highly effective contraceptive methods include hormonal contraceptives (e.g., combined oral contraceptives, patches, vaginal rings, injectables, or implants), intrauterine devices or intrauterine systems, partners who have had vasectomy (prerequisite: vasectomy performed ≥ 4 months before screening), tubal ligation, or double barrier contraceptive methods combined with spermicide (e.g., male condoms with cervical caps, male con...

Claims

1. A method for treating psoriasis or psoriatic arthritis in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of Compound 1: or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

2. The method of claim 1, wherein the administering is performed daily for a period of between about 1 day to about 7 days, about 1 week to about 3 weeks, about 3 weeks to about 6 weeks, about 6 weeks to about 9 weeks, about 9 weeks to 12 weeks, about 12 weeks to about 15 weeks, or about 15 weeks to about 18 weeks.

3. The method of claim 1 or 2, wherein a mean reduction in the Psoriasis Area Severity Index (PASI) of about 50% to 75% is achieved.

4. The method of claim 1 or 2, wherein a mean reduction in the Psoriasis Area Severity Index (PASI) of about 75% to 100% is achieved.

5. The method of any one of claims 1-4, wherein a Physician Global Assessment (PGA) of 0 or 1 is achieved.

6. The method of any one of claims 1-4, wherein a Physician Global Assessment (PGA) of 0 is achieved.

7. The method of any one of claims 1-6, wherein the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 1 to about 3, about 3 to about 6, about 6 to about 9, about 9 to about 12, about 12 to about 15, about 15 to about 18, about 18 to about 21, about 21 to about 24, about 24 to about 27, or about 27 to about 30.

8. The method of any one of claims 1-7, wherein the Dermatology Life Quality Index (DLQI) score is reduced by an amount greater than about 5.

9. The method of any one of claims 1-7, wherein the Dermatology Life Quality Index (DLQI) score is reduced by an amount between about 6 to about 9.

10. The method of any one of claims 1-9, wherein the patient's body surface area (BSA) is reduced by multiple percentage points between about 1 to about 10, about 10 to about 20, about 20 to about 30, about 30 to about 40, about 40 to about 50, about 50 to about 60, about 60 to about 70, about 70 to about 80, about 80 to about 90, or about 90 to about 100.

11. The method of any one of claims 1-10, wherein a reduction of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Numerical Rating Scale (NRS) for pain is achieved.

12. The method of any one of claims 1-11, wherein a decrease of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 on the Itch Numeric Rating Scale (NRS) is achieved.

13. The method of any one of claims 1-12, wherein between about 1% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100% inhibition of IL-12 / 18 induced IFNγ production is achieved.

14. The method of any one of claims 1-13, wherein the patient has plaque psoriasis.

15. The method of claim 14, wherein the plaque psoriasis is moderate to severe plaque psoriasis.

16. The method of any one of claims 1-15, wherein the patient suffers from both psoriasis and psoriatic arthritis.

17. The method of any one of claims 1-15, wherein the patient has psoriatic arthritis.

18. The method of claim 17, wherein the method achieves at least an American College of Rheumatology (ACR) 20 response.

19. The method of claim 17, wherein the method achieves an improvement in tender joint count, swollen joint count, patient global assessment of psoriatic arthritis, patient global assessment of psoriatic arthritis pain, physician global assessment of psoriatic arthritis, Health Assessment Questionnaire-Disability Index (HAQ-DI) score, dactylitis count, Lee's Enthesitis Index, minimal disease activity, Disease Activity Index for Psoriatic Arthritis (DAPSA), or Psoriasis Area Severity Index (PASI)-75 at Week 12 in subjects with psoriasis involving ≥3% body surface area (BSA) on Day 1, or a static physician global assessment of 0 or 1 and an improvement of at least 2 points from baseline at Week 12.

20. The method of claim 17, wherein the method achieves improvements in circulating cytokines and / or inflammatory biomarkers, 36-Item Short Form Health Survey, Functional Assessment of Chronic Disease - Fatigue, 28-Joint Disease Activity Score using high-sensitivity C-reactive protein (hsCRP), Psoriasis Disease Activity Score at treatment week 12, Psoriatic Arthritis Response Criteria at treatment week 12; a mean reduction of 25% or greater in Psoriasis Area Severity Index (PASI); or an improvement in Psoriasis-involved BSA at week 12; or an improvement in Physician Global Assessment of Psoriasis at treatment week 12.

21. A method of inhibiting interferon gamma (IFNγ) production in a patient, the method comprising administering to the patient a therapeutically effective amount of Compound 1: or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

22. The method of claim 21, wherein the patient suffers from psoriasis.

23. The method of claim 21, wherein the patient has psoriatic arthritis.

24. The method of claim 22, wherein the psoriasis is moderate to severe.

25. The method of claim 23, wherein the psoriatic arthritis is moderate to severe.

26. The method of any one of claims 1 to 25, wherein the T of compound 1 in plasma is max This is achieved in about 3 hours to about 6 hours.

27. The method of any one of claims 1 to 26, wherein the t of Compound 1 in plasma is 1 / 2 Achieved in about 17 hours to about 37 hours.

28. The method of any one of claims 1-27, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient at a dose of up to about 200 mg.

29. The method of any one of claims 1-27, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient at a dose of about 20 mg to about 100 mg.

30. The method of any one of claims 1-27, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient at a dose of about 2 mg, about 5 mg, about 10 mg, about 15 mg, or about 30 mg.

31. The method of any one of claims 1-30, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient in a single daily dose.

32. The method of any one of claims 1-30, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient in multiple daily doses.

33. The method of any one of claims 1-32, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient daily for 2 weeks.

34. The method of any one of claims 1-32, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient daily for 4 weeks.

35. The method of any one of claims 1-34, wherein Compound 1 is administered orally to the patient.

36. The method of any one of claims 1-35, wherein the patient is a human.

37. The method of any one of claims 1-36, wherein the patient has a PASI of at least about 12 prior to said administering.

38. The method of any one of claims 1-37, wherein the patient has a PGA of at least about 3 prior to the administering.

39. The method of any one of claims 1-38, wherein the patient has a BSA of at least about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or about 90% to about 100% prior to the administration.

40. The method of any one of claims 1-39, wherein the psoriasis does not comprise erythrodermic, pustular, guttate predominant psoriasis, or drug-induced psoriasis.

41. The method of any one of claims 1-40, wherein a serum C between about 25 ng / ml to about 50 ng / ml, about 50 ng / ml to about 100 ng / ml, about 100 ng / ml to about 125 ng / ml, about 125 ng / ml to about 150 ng / ml, about 150 ng / ml to about 175 ng / ml, about 175 ng / ml to about 200 ng / ml, about 200 ng / ml to about 225 ng / ml, about 225 ng / ml to about 250 ng / ml, about 250 ng / ml to about 275 ng / ml, or about 275 ng / ml to about 300 ng / ml is achieved. max .

42. A method of treating moderate to severe plaque psoriasis in a patient in need thereof, the method comprising administering a therapeutically effective amount of Compound 1: The daily dosage is from about 5 mg to about 30 mg.

43. Use of Compound 1 or its pharmaceutically acceptable salt: It is used to treat psoriasis or psoriatic arthritis.